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Abstract 
 
Chitosan based nanoparticles prepared by ionic gelation with sodium tripolyphosphate 
(TPP) were developed and optimized. Chitosan and TPP were tested in different 
concentrations for the study of the chitosan:TPP best mass ratio until the final proportion 
of (7:1). The pH of nanoparticles formation medium was adjusted to 5.8, which was the pH 
value that best favors the interaction of rosmarinic acid and chitosan, thus reaching a 
maximum leading of rosmarinic acid entrapment. The encapsulation of rosmarinic acid, 
Salvia officinalis (sage) and Satureja montana (savory) was also tested in different 
theoretical loadings fairly to the initial concentration of chitosan. Nanoparticles were 
prepared and characterized freshly and lyophilized, and the theoretical loading was further 
fixed in 40% for rosmarinic acid and 50% for sage and savory nanoparticles. The particle 
size was observed to be dependent on both chitosan and TPP concentrations and 
minimum sizes were obtained for the lowest chitosan and TPP concentrations. The mean 
particle size was 244.0 ± 18.0, 278.4 ± 42.2 and 229.3 ± 29.6 for rosmarinic acid, sage 
and savory nanoparticles, respectively. No significant differences (P > 0.05) were 
observed between the different nanoformulations, which was expectable considering that 
the nanoparticulate system was optimized to encapsulate rosmarinic acid and since it is 
the major component of natural extracts. The obtained nanoparticles showed values of 
low dispersity index (< 0.25), corresponding to a narrow particle size distribution such as: 
0.193 ± 0.062, 0.268 ± 0.092 and 0.149 ± 0.121 for rosmarinic acid, sage and savory 
nanoparticles, respectively. Nanoparticles surface charge ranged from 29.5 ± 1.6, 24.9 ± 
0.1 and 26.5 ± 3.5 mV for rosmarinic acid, sage and savory nanoparticles, respectively. 
This indicates that the colloidal systems were stable in storage time. Scanning electron 
microscopy (SEM) and transmission electron microscopy (TEM) confirmed the particle 
size distribution, and individual, smooth, spherical and small sizing nanoparticles (ranged 
from 200-300 nm) containing the rosmarinic acid and extracts were observed. The loading 
capacity was 5.3 ± 0.4, 8.1 ± 0.6, and 7.8 ± 0.2% for rosmarinic acid, sage and savory 
nanoparticles, respectively. The higher values for extract nanoparticles were intimate 
correlated to the lower initial amount of rosmarinic acid in the nanocomplexes. In a similar 
way, the association efficiencies were higher for extracts than rosmarinic acid, with values 
of 51.2 ± 3.0, 96.1 ± 0.2 and 98.2 ± 0.1% for rosmarinic acid, sage and savory 
nanoparticles respectively, quantified by a previously validated high-performance liquid 
chromatography (HPLC) method. The higher extracts values may be also associated to 
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lower amount of rosmarinic acid in chitosan nanoparticles, since impair of association 
efficiency and the initial concentration is documented as a reverse. The rosmarinic acid in 
vitro release profile was evaluated in phosphate buffer saline (PBS), pH 7.4, for the 
different nanoparticles and a fast release was observed in all the formulations, reaching 
almost 100% up to 60 min, with no significant differences (P > 0.05). Therefore these 
nanoparticulate systems may provide a rational strategy for the development of ocular 
rapid release systems for rosmarinic acid delivery. Differential scanning calorimetry (DSC) 
and Fourier-transform infrared (FTIR) analysis set that no chemical interactions were 
found between antioxidants and chitosan, after encapsulation. Antioxidant activity was 
evaluated by 2,2-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) and oxygen 
radical absorbance capacity (ORAC) methods before and after lyophilization to assure 
that antioxidant activity was not compromised after the dried process. The best antioxidant 
activity results were obtained by ORAC method and after nanoparticles lyophilized, the 
values for rosmarinic acid, sage and savory nanoparticles were 3.6520 ± 0.1770, 0.4251 ± 
0.0069 and 0.4526 ± 0.0087 µmol/eq Trolox, respectively. Nonetheless, lower antioxidant 
activity was observed in the nanoparticles comparing to the free compounds due to the 
partial entrapment effect of the compounds. Considering the mucin particle method, 
nanoparticles indicate mucoadhesive proprieties, by the increase on nanosize and the 
consequent surface charge decrease, after mucin incubation, suggesting an increase 
retention time over the ocular mucosa after instillation. All nanoparticles demonstrate to be 
safe without relevant cytotoxicity (below 10%, for all the formulations and concentrations), 
by methylthiazolyldiphenyl-tetrazolium bromide conversion (MTT) and lactate 
dehydrogenase enzyme release (LDH) assays against retina pigment epithelium (ARPE-
19) and human cornea (HCE-T) cell lines. Nonetheless, the results in both cell lines were 
concentration dependent. Chorioallantoic membrane test (HET-CAM) also confirmed the 
absence of nanoparticles irritancy in the eye. The permeability study in HCE monolayer 
cell line showed apparent permeability coefficient (Papp) of 3.41 ± 0.99 x 10
-5 and 3.24 ± 
0.79 x 10-5 cm/s for rosmarinic acid loaded chitosan nanoparticles and free in solution, 
respectively. In ARPE-19 monolayer cell line the Papp  was 3.39 ± 0.18 x 10
-5 and 3.60 ± 
0.05 x 10-5 cm/s for rosmarinic acid loaded chitosan nanoparticles and free in solution, 
respectively. No significant differences (P > 0.05) were achieved neither between both cell 
lines nor between loaded and unloaded chitosan nanoparticles, probably due to the rapid 
release profile of nanoparticles described above. Preliminary ocular in vivo studies were 
implemented to evaluate the antioxidant effect of rosmarinic acid through intravitreally 
injection in Wistar rats using an Ischemia-reperfusion (I-R) model. Electroretinograms 
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(ERG) and immunohistochemistry showed that at 50 µM rosmarinic acid did not present a 
significant retina protective effect, suggesting acute pro-inflammatory damages in I-R 
model, difficult to revert with a single injection. Nonetheless and considering the good 
results achieved during this project, the rosmarinic acid nanoparticles were safe, 
mucoadhesive, with high ocular permeability, with good antioxidant activity performance 
and its therapeutical potential may be important to ocular diseases prophylaxis. It can be 
also concluded that these natural nanocarriers were promising ocular drug delivery 
systems and the study highlights the need to explore new drug delivery systems to be 
applied on ocular surface in order to overlap the limitations on topical drug effectiveness.   
Keywords: Chitosan, rosmarinic acid, extracts, ocular diseases 
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Resumo 
 
As nanopartículas de quitosano foram desenvolvidas e otimizadas por gelificação iónica 
com tripolifosfato de sódio (TPP). O quitosano e TPP foram testados em diferentes 
concentrações para o estudo da melhor relação quitosano:TPP até à proporção final de 
(7:1). O pH da solução das nanopartículas foi ajustado para 5,8, para favorecer a 
interação máxima entre o quitosano e o ácido rosmarínico. A encapsulação de ácido 
rosmarínico, e dos extractos naturais de Salvia officinalis (salva) e Satureja montana 
(segurelha) também foram testados, considerando diferentes cargas teóricas 
relativamente à concentração inicial de quitosano. As nanopartículas foram preparadas e 
caracterizadas diretamente após a sua formulação e após liofilização, e foram 
posteriormente fixados os valores de carga teórica de 40% para o ácido rosmarínico e 
50% para a salva e segurelha. O tamanho das partículas demonstrou ser dependente de 
ambas as concentrações de quitosano e TPP e os tamanhos mínimos foram obtidos para 
a menor concentração de quitosano e TPP. O tamanho médio das partículas foi 244,0 ± 
18,0, 278,4 ± 42,2 e 229,3 ± 29,6 nm para as nanoparticulas de ácido rosmarínico, salva 
e segurelha, respetivamente. Não houve diferenças significativas (P > 0,05) observadas 
entre as diferentes nanoformulações o que seria expectável, considerando que o sistema 
de nanopartículas foi otimizado para encapsular o ácido rosmarínico, e este é o principal 
componente dos extratos naturais. As nanopartículas obtidas apresentaram valores de 
baixo índice de polidispersão (< 0,25), o que corresponde a uma reduzida distribuição do 
tamanho das partículas, sendo os valores: 0,193 ± 0,062, 0,268 ± 0,092 and 0,149 ± 
0,121 para as nanoparticulas de ácido rosmarínico, salva e de segurelha, respetivamente. 
A carga da superfície das nanopartículas foi: 29,5 ± 1,6, 24,9 ± 0,1 and 26,5 ± 3,5 mV 
para as nanopartículas de ácido rosmarínico, salva e de segurelha, respetivamente. Isto 
sugere que os sistemas coloidais são estáveis ao longo do tempo. A microscopia 
eletrónica de varrimento (SEM) e a microscopia eletrónica de transmissão (TEM) 
confirmaram os resultados anteriores e demonstraram nanoparticulas individualizadas, 
lisas, esféricas e pequenas (variando entre 200-300 nm). A capacidade de carga das 
partículas foi de 5,3 ± 0,4, 8,1 ± 0,6 e 7,8 ± 0,2% para as nanoparticulas de ácido 
rosmarínico, salva e de segurelha, respetivamente. Os valores mais elevados para as 
nanopartículas com extrato foram intimamente correlacionados com a menor quantidade 
inicial de ácido rosmarínico nos nanosistemas. De um modo semelhante, as 
percentagens de eficiência de associação dos extratos nas nanopartículas foram mais 
elevadas, em comparação com as do ácido rosmarínico. Os valores foram: 51,2 ± 3,0, 
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96,1 ± 0,2 e 98,2 ± 0,1% para as nanopartículas de ácido rosmarínico, salva e segurelha, 
respetivamente. Estes valores mais elevados associados à nanoencapsulação dos 
extratos também podem ser associados à menor quantidade de ácido rosmarínico nas 
nanopartículas de quitosano, uma vez que a concentração inicial é documentada como 
inversamente proporcional à própria eficiência de associação. O perfil de liberação in vitro 
do ácido rosmarínico foi avaliado em tampão fosfato (PBS), a pH 7,4 nas diferentes 
formulações, por um período de 60 min, e não se observaram diferenças significativas (P 
> 0,05). A rápida libertação do ácido rosmarínico dá indicações que estes sistemas de 
nanopartículas podem fornecer uma estratégia racional para o desenvolvimento de 
formulações de libertação imediata para administração ocular do ácido rosmarínico. A 
eficiência de associação e de liberação in vitro foram realizadas utilizando um método de 
cromatografia líquida de alta eficiência (HPLC), especialmente desenvolvido e otimizado 
para garantir a obtenção de resultados precisos e exatos. As análises de calorimetria 
diferencial de varrimento (DSC) e a espetrofotometria de infravermelho por transformada 
de Fourier (FTIR) permitiram concluir que não foram encontradas interações químicas 
entre os antioxidantes e o quitosano, depois do processo de encapsulação. A atividade 
antioxidante dos nanosistemas foi avaliada pelos métodos de 2,2-azinobis-(3-etil-
benzotiazolin-6-ácido sulfónico) (ABTS) e de capacidade de absorção radical (ORAC), 
antes e depois do processo de liofilização, para garantir que a atividade antioxidante não 
é comprometida durante o processo de secagem das partículas. Os melhores resultados 
de atividade antioxidante foram obtidos pelo método de ORAC após liofilização das 
partículas, os resultados para as nanoparticulas de ácido rosmarinico, salva e segurelha 
foram: 3,6520 ± 0,1770, 0,4251 ± 0,0069 e 0,4526 ± 0,0087 µmol/eq Trolox, 
respetivamente. Todavia foi observada uma atividade antioxidante mais baixa nas 
nanopartículas do que nos compostos livres, devido ao efeito da nanoencapsulação. As 
partículas demonstraram propriedades mucoadesivas após incubação com mucina, pelo 
aumento em tamanho e consequente diminuição da carga de superfície. Os resultados 
indicam que pode ser expectável um aumento do tempo de retenção sobre a mucosa 
ocular após a instilação. Todas as formulações demonstraram ser seguras para o teste 
de citotoxicidade 3-(4,5-dimetiltiazol-2yl)-2,5-difenil brometo de tetrazolina (MTT) e para o 
teste da libertação da enzima lactato desidrogenase (LDH), sem citotoxicidade relevante 
(abaixo de 10%, para todas as formulações e concentrações), em linhas oculares da 
retina (epitélio pigmentar da retina - ARPE-19) e da córnea (linha de células da córnea 
humana - HCE-T). O teste da membrana corioalantóide (HET-CAM Teste) foi utilizado 
como alternativa aos testes biológicos em coelhos (teste de Draize) e também sugere a 
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ausência de irritação das partículas no olho. Os estudos de permeabilidade em 
monocamada de células da córnea (HCE) revelou um coeficiente de permeabilidade 
aparente (Papp) de 3,41 ± 0,99 x 10
-5 e 3,24 ± 0,79 x 10-5 cm / s para as nanopartículas de 
ácido rosmarínico e para o ácido rosmarínico livre, respectivamente. O estudo de 
permeabilidade em monocamada de células da retina (ARPE-19) revelou valores de Papp 
de 3,39 ± 0,18 x 10-5 e 3,60 ± 0,05 x 10-5 cm/s para as nanopartículas de ácido 
rosmarínico e para o ácido rosmarínico livre, respectivamente. Não houve diferença 
significativas (P > 0,05) entre os valores de permeabilidade das nanoparticulas, composto 
livre e entre ambas as linhas celulares, provavelmente devido ao perfil de liberação 
rápido das nanopartículas acima descrito. Foram feitos testes preliminares in vivo, em 
que o ácido rosmarínico foi injetado na cavidade intravítrea de ratos Wistar, num modelo 
animal isquemia-reperfusão (I-R). Eletrorretinogramas (ERG) e ensaios imuno-
histoquímicos revelaram que o ácido rosmarínico (a uma concentração de: 50 µM), por 
injeção intravítrea, não teve um efeito protector na retina. O que poderá ser devido danos 
pró-inflamatórias severos no modelo I-R, difíceis de reverter com o estudo de uma única 
injeção. No entanto, e considerando os bons resultados obtidos neste trabalho, as 
partículas de quitosano contendo ácido rosmarínico demonstraram ser seguras, 
mucoadesivas, com elevado potencial de permeabilidade ocular e com um bom perfil de 
atividade antioxidante, o que permite concluir que estes nanosistemas podem ser 
importantes para a prevenção de doenças degenerativas oculares. Os resultados desta 
tese, permitem também concluir que estes nanosistemas naturais são promissores na 
administração tópica de antioxidantes no olho e ressalta a necessidade de se explorar 
novos sistemas para ultrapassar as limitações na eficiência da administração tópica de 
fármacos no olho. 
Palavras-chave: Quitosano, ácido rosmarinico, extratos, doenças oculares  
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Scope and outline 
  
This thesis was organized in 9 chapters, thus closely reflecting the development of my 
research work. All chapters were related to each other and the aims and methodology 
chosen in each chapter were indeed dependent on the conclusions brought about in 
previous one(s).  
Overall, the work described in this thesis encompasses development and characterization 
of chitosan nanoparticles for the rosmarinic acid, sage and savory encapsulation - to 
prevent and control degenerative eye diseases.  
Part I include Chapter 1, and entail a bibliographic review regarding chitosan biological 
proprieties, biomedical potential as well as chitosan-based delivery systems. A particular 
emphasis was put on the key factor of antioxidants in the degenerative eye diseases 
prophylaxis, as well as in the nanocarriers as a way to improve antioxidant activity 
performace and efficacy. In Part II - Chapter 2, the project aims and goals were detailed 
to be a guideline of the work major core. In Part III - Chapter 3 a high-performance liquid 
chromatography (HPLC) method was developed and optimized to be used throughout the 
experimental work of this thesis and to allow the best precise quantification of antioxidant 
content in the natural extracts, the nanoparticles association efficiency and either release 
and permeability profiles, developed in the following chapters. In Part IV - Chapter 4 a 
comprehensive development, optimization and physical-chemical characterization of 
antioxidant-chitosan nanoparticles was presented. The effect of rosmarinic acid content, 
mass correlation and pH of nanoparticle preparation were evaluated for the ionic gelation 
optimization process. Complementary methodologies were employed to provide a more 
rational understanding of the interactions between components and the success of the 
encapsulation, such as the particle size and zeta potential. In Chapter 5 the nanocarriers 
were evaluated and characterized regarding the in vitro antioxidant activity potential. In 
Part V - Chapter 6 the nanocarriers were then tested to guarantee their safety 
performance, mucoadhesion proprieties and in vitro ocular cell permeability. In Chapter 7, 
it was performed the first attempting efforts to prove rosmarinic acid therapeutical potential 
in an ischemia-reperfusion (I-R) animal model. Finally, in Part VI, the overall conclusions 
were presented in Chapter 8 - and future prospects, based on critical questions arising 
from this dissertation, were put forward in Chapter 9. 
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1. Introduction 
 
In pharmaceutical science there is a continuous blockbuster drug development, and 
nowadays biomolecules as active agents, are widely explored to develop new 
therapeutics. Nevertheless, most of these new active compounds are unstable and must 
be protected from degradation in the physiological environment, due to the poor 
absorption that constrains the transport across biological barriers. Thus, the efficacy of 
most drugs clearly depends on the design of appropriate carriers for their physical 
protection, delivery and controlled release (1). Among the different approaches explored 
so far, colloidal carriers are particularly interesting, especially those made of 
mucoadhesive polymers to assure their epithelium permanence (2, 3). For this application, 
chitosan has had quite impact in the association and delivery of labile macromolecular 
compounds (4). Chitosan carriers have an exceptional potential for drug delivery, 
especially for mucosal, since these systems are stable in contact with physiological fluids 
and barriers. They are also able to control drug release and protect against adverse 
conditions like mucosal enzymes and biological protective fluids. Due to its 
mucoadhesion, particle size, particle surface chemistries, charge and the unique 
absorption enhancing properties, the chitosan potential in the medical field is widely 
promising. Different formulations such as films, tablets, hydrogels, micro and 
nanosystems are expected to optimize, characterize and select the drug performance, 
improved properties and increase stability for great specific applications. 
Pharmacokinetics and toxicological relevance of chitosan systems are guaranteed by in 
vitro model systems in molecular, subcellular and cellular levels, as well as their 
therapeutic efficacy and safety performance should also be proven in vivo. One category 
of compounds in which these chitosan carriers may be a key for success, are the 
antioxidants. Considering the biology definition, antioxidants are chemical compounds or a 
substance that inhibits oxidation, counteracting the damage of free radicals effects in a 
living organism, and for this reason are reactive species (5). Antioxidants are widespread 
virtually in plant foods, often at high levels, and include phenols, phenolic acids and 
flavonoids (6). Rosmarinic acid (a-O-caffeoyl-3,4-dihydroxyphenillactic acid) (7) is a 
phenolic compound, which can provide protection against cancer (7) and have other 
multitude biological activities, namely adstringent, anti-inflammatory, anti-mutagen, 
antibacterial and antiviral (7, 8). The latter activity has been tested in the therapy of 
Herpes simplex infections with rosmarinic acid-containing extracts of Melissa officinalis 
(7). It is also one of the efficient natural antioxidants (9) since rosmarinic acid displays a 
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huge potential radical scavenging activity, higher than trolox (a derivative of a-tocopherol) 
(10-12). Rosmarinic acid has also an anti-angiogenic activity to retinal neovascularization 
in a mouse model of retinopathy (13). Significantly inhibited the proliferation of retinal 
endothelial cells in a dose-dependent manner, and inhibited in vitro angiogenesis of tube 
formation. Moreover, rosmarinic acid showed no retinal toxicity. These data suggest 
rosmarinic acid could be a potent inhibitor of retinal neovascularization and may be 
applied in the treatment of vasoproliferative retinopathies (13). It is the major component 
of Salvia officinalis (sage) and Satureja montana (savory) natural extracts. These are 
plants often used in traditional medicine, and which grow in the poor soils of the 
Mediterranean basin (14). Besides application as condiment, sage and savory have been 
used as an anti-diarrhea vector, digestion adjuvant, contribute to heal wounds, play an 
anti-inflammatory role, disinfectant, fight insomnia and decrease blood pressure. Some of 
these biological activities have been associated with its high contents of rosmarinic acid 
and the presence of other relevant phenolic compounds such as quercetin and rutin (9, 
14). Beyond the biological huge benefits, antioxidants are extremely sensitive to light, 
oxygen, are highly reactive with other compounds, in some cases possess poor solubility, 
inefficient permeability, and are extremely unstable (15-17). For all these reasons their 
delivery using the conventional dosage forms is a challenge (18). In this context, 
alternative carriers are being considered, regarding the optimization of pharmacokinetics 
and pharmacodynamics of antioxidant molecules. Chitosan nanoparticles, due to their 
proper properties, are on the raw. For this concern the nanotechnology is expected to 
increase the ability, to retain the antioxidant activity during the preparation process, to 
optimize the release of the compound from the carrier system, and to ensure a good 
control of their physical-chemical properties increasing their stability. If these nanocarriers 
may improve the efficacy performance of the antioxidants, several diseases like cancer, 
diabetes, hypertension, arterio-sclerosis, cardiovascular disease or ocular anomalous 
conditions that have a clinical impairment with oxidation processes, may be prevented or 
better controlled (19). Considering the eye disorders, there are many types of 
retinopathies conditions that may have an oxidative etiology (20, 21), like retinitis 
pigmentosa, glaucoma,  macular degeneration, retinoblastoma and diabetic retinopathy 
(19, 21). Multiple factors have been also proposed to explain retinopathies, including 
genetic disorders, infections by microbial agents, sorbitol pathway hyperactivity, 
accumulation of advanced glycation end products (AGEs) (22) and protein kinase C 
activation (23). Nevertheless the precise pathological mechanism remains to be 
elucidated. Which is clear is the collateral damage of these disorders, that may result on 
  
7 
 
reflectivity changes, bifurcations, tortuosity neovascularization as well as other patterns of 
blood vessels and even blindness (19, 21). In the case of ocular pathologies the oxidative 
stress (OS) clinical impairment has a significant impact, since the ocular globe is the 
organ most affected by OS. Its constantly expose to light and oxygen and its high 
polyunsaturated fatty acid (PUFA) content that is prone to lipid peroxidation, may be some 
prominent reasons (24). OS is also associated with increased vascular permeability, 
disruption of blood-retinal barrier, apoptotic loss of retinal capillary cells, microvascular 
abnormalities and neovascularization (25). High levels of OS are also usually associated 
with increased levels of oxidative modified desoxyribonucleic acid (DNA) and nitrosylated 
proteins, and antioxidant defense enzymes impair (26). When such damages are 
presented, without effective medical treatment, cells and tissues of the retina become 
malnourished and progressively degenerate, which leads to damage in cells responsible 
for vision, leading to its inevitable loss (21). Due to this intimate relationship between OS 
and the pathogenesis of retinopathies, the use of appropriate antioxidants may have 
potential on the metabolic and functional abnormalities in retinopathies (27). Nevertheless, 
for antioxidants assure these conditions they need the nanocarrier support to take them to 
the right place without losing their functional activity.  
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2. Chitosan proprieties and biomedical application 
 
Chitosan is an alkaline-deacetylated chitin biodegradable polysaccharide commonly 
derived from the exoskeletons shells of crustaceans and  insects (28). Its extraction is a 
cost-effective way to valorise seafood wastes and it is produced with different 
deacetylation degrees (DD) (29, 30), and molecular weights (MW) (31). Chitin is 
synthesized by an enormous number of living organisms and considering the amount of 
chitin produced annually in the world, it is the most abundant polymer after cellulose (29). 
Chitin is obtained on an industrial scale from shrimp and crustaceans in general. The 
pupae of silkworms are also an alternative source of chitin and, consequently, of chitosan 
(32). Another sources include the production of chitosan from fungi by fermentation (33), 
from chrysalides (a by-product from the silk industry) (32), or from sources of chitin (e.g. 
β-chitin) obtained from squid pens (4). However, the most commonly obtained form of 
chitosan is the α-chitosan from crustacean, which represents approximately 70% of the 
organic compounds in such shells (4). 
For the chitin isolation from the raw materials and subsequent chitosan production, the 
original sources in solid form are washed with water, desiccated at room temperature and 
cut into small pieces. Demineralization is carried out at room temperature using 
hydrochloric acid and the de-proteinization should also be performed (32). 
There are small difference in the chemical structure of chitin and chitosan, but these 
differences are extremely important when drug delivery is thought (34). Considering the 
similar structures of chitin and chitosan with cellulose, both are made by linear β-(1-4)-
linked monosaccharides. However, the functional groups connected to the second carbon 
in the repeating units differ from one to another (35). Chitin is a linear homopolymer 
composed of β-(1,4)-linked N-acetyl-glucosamine units (34), while chitosan is a linear co-
polymer polysaccharide consisting of β-(1–4)-linked 2-amino-2-deoxy-D-glucose (D-
glucosamine) and 2-acetamido-2-deoxy-D-glucose (N-acetyl-D-glucosamine) units, as 
depicted in Figure 1.1 (4). Chitin is insoluble in water and most common organic solvents 
used in pharmaceutical technology and consequently not useful in the development of 
drug delivery systems (36). In contrast, chitosan is a rather insoluble in water and organic 
solvents, but soluble in dilute aqueous acidic solution (pH < 6.5), which can convert the 
glucosamine units into a soluble protonated amine form (34). It is readily soluble in dilute 
organic acids such as acetic, citric and malic acid as well as hydrochloric acid (37). This 
positive charge of chitosan is very useful since enables negative interaction with 
polyanions (36). Chitosan is usually characterize in terms of MW, which commonly ranges 
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from ca. 10 to 1000 kDa, and DD, in the range of 50 to 95% (38). The biodegradability and 
biological properties of chitosan are frequently dependent on the relative proportions of N-
acetyl-D-glucosamine and D-glucosamine residues (4) as well as on the MW. 
 
 
 
Figure 1. 1. Structure and molecular formula of chitosan. 
. 
Chitosan has biological properties (28, 39), unique and exceptional, that promote its use 
as a drug carrier (1, 3, 40), particularly to enhance transiently the permeability of mucosal 
barriers (36), increasing the effect on cell permeability (41), biocompatibility and 
biodegradability (42), being simultaneously non-toxic, non-antigenic (43) and 
mucoadhesive (2, 42). Previous reports also indicated that chitosan possess various 
biological activities, such as antitumor effects (44), anti-hypercholesterolemia (45) and 
antimicrobial activity against several pathogen and spoilage bacteria that has already 
been widely demonstrated (46). Currently, chitosan is widely used as a supporting 
material for tissue engineering applications, cell culture and nerve regeneration (47). 
Table 1.1, summarizes the main potential biomedical properties of chitosan and 
associated characteristics. The better understanding of this unique cationic polymer 
invites new and several applications. 
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Table 1. 1. Principal properties of chitosan in relation to its use in biomedical applications. 
Potential biomedical applications Principal characteristics 
Surgical sutures Biocompatible 
Dental implants Biodegradable 
Artificial skin Nontoxic, biological tolerance 
Bone rebuilding  Non-antigenic  
Corneal contact lenses Mucoadhesiveness 
Time-control release drugs for animals and 
humans 
Renewable 
Encapsulating material Film forming 
Tissue engineering  Hydrating agent 
Cell culture Hydrolyzed by lysozyme 
Nerve regeneration  
Efficient against bacteria, viruses, 
fungi 
 
Anti-tumor 
 
Anti-hypercholesterolemia 
 
 
2.1. Chitosan-based drug delivery systems  
 
Controlled release technology emerged during the 1980s with a remarkable and 
increasing importance. This pharmaceutical technology that allows the predictable and 
reproducible release of a drug into a specific environment over an extended period of 
time, creating an optimal response, with minimum side-effects and prolonged efficacy, is a 
borderline of science (48).  
The cationic nature of chitosan has been conveniently exploited for the development of 
new drug delivery systems and actually, a variety of chitosan-based delivery carriers have 
been described for pharmaceutical field as well as for other medical applications (1). In 
addition, the further chemical modification of chitosan is a powerful tool to control the 
interaction of the polymer with drugs, to enhance the load capability and to tailor the 
release profile of the particles (1). Hence, chemically modified chitosan improves its bulk 
properties for the preparation of sustained drug release systems (1), which enhance its 
versatility in the biomedical and biotechnological fields (49). 
Chitosan can be employed to formulate a variety of pharmaceutical dosage forms, namely 
solutions, hydrogels, films, tablets, micro and nanoparticles. It is also a protagonist in 
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other advanced fields, like non-viral vector for DNA and gene delivery (49, 50). Drug 
delivery applications include oral, nasal, parenteral and transdermal administration, 
implants and gene delivery. The transmucosal administration of drugs is being largely 
exploited by chitosan-based systems (30). 
 
2.1.1. Chitosan solutions 
 
The study of chitosan solutions and related properties has much merit considering the 
multi-potential of the polymer and its many applications in the biomedical field. The 
preparation of the aqueous solution is also a mandatory step before obtaining any type of 
secondary materials such as films, gels, sponges, fibers, or particles. Despite this, most of 
the properties such as flocculation, adsorption and biological activities are accomplished 
in aqueous solution, the interactions between molecules of chitosan and metal ions, 
proteins, cells and bacteria have been widely studied in solutions (51). The gross 
conformation of chitosan in solution may be spherical shape, random coil and rod shape, 
which is manipulated by two sets of parameters: structure parameters such as MW and 
DD, and solution parameters such as ionic strength, solvent, temperature and pH. 
Molecular weight can induce a conformation transitions — the conformations of small MW 
chitosans are stiffer and more extended than those of higher MW. In general, an increase 
of ionic strength makes the molecule contract (51). These parameters are obtained from 
the plots of log intrinsic viscosity, sedimentation coefficient, diffusion coefficient, radius of 
gyration and log MW of the polymer (51). The most widely used methods to characterize 
the conformation transition are capillary viscosity, analytical ultracentrifugation, static and 
dynamic light scattering (51). Commonly, chitosan solutions are easily prepared dissolving 
chitosan in organic acid like acetic or lactic acid.  
Chitosan solutions have demonstrated most of their applications in the mucosal 
absorption, mainly due to the transiently ability of chitosan molecules to open tight junction 
of epithelial cells. Globally, it can be concluded that chitosan is able to enhance the 
paracellular route of absorption by tight junction disruption, inducing the translocation of 
tight junction proteins from the membrane to the cytoskeleton (52). Regarding the effect of 
chitosan salts on drug intestinal permeability in vitro, there is general agreement that 
these polymers are potent absorption enhancers for poorly absorbed drugs such as 
atenolol and peptides (52). Studies with buserelin, 9-deglycinamide, 8-arginine 
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vasopressin and insulin have evidenced a strong increase in the transport of these drugs 
in the presence of chitosan glutamate and chitosan hydrochloride (acidic environment) 
(52). Studies using chitosan glutamate and western blotting of Caco-2 cells fractions, 
observed translocation of tight junction proteins (ZO-1 protein) from the membrane to the 
cytoskeleton in response to treatment with chitosan (53).  
Yu and his collaborators (54) developed a chitosan solution for nasal insulin delivery. 
They reported that chitosan concentration, osmolarity, medium and absorption enhancing 
ability of chitosan solution have significant effect on nasal insulin absorption. This may 
represent a new administration of insulin, safer, convenient for diabetic patients and with 
good applicability. 
Recent research has also exploited the ability of chitosan solutions to control the spread 
of cytokine and improve the immunoadjuvant properties in vaccine applications (55). 
Sustained, local delivery of immunomodulatory cytokines in chitosan solution is under 
investigation for its ability to enhance vaccine and anti-tumor responses, both pre-clinically 
and clinically. In short, the study concluded that the chitosan solution maintained a deposit 
of bioactive antigen and cytokines, induced a cell expansion of the lymph nodes, including 
an increase in dendritic cells and antigen presenting cells. The resulting increase in the 
capacity of antigen presentation was exploited to improve both the humoral and cellular 
responses to the vaccine. The ability of chitosan to form deposits of antigens and 
cytokines, in addition to its safety profile and inherent versatility makes it a promising 
platform for the delivery of vaccines and cytokines (55). 
 
2.1.2. Films 
 
Use of porous biomaterials in the film development attracts scientists in particular 
concerning the biomedicine applications (47). In the field of tissue engineering, porous 
polymer scaffolds can provide a framework for the seeded cells until they are well 
organized into a functioning tissue, especially in bone regenerative therapy (47). In the 
field of surgical, the porous biomaterial is usually used as wound dressing to absorb 
wound fluid and promote healing (47). On the other side, films, erodible and non-erodible 
inserts, rods and shields are the most logical delivery systems aimed at remaining for a 
long resident time in contact with physiologic surfaces like skin and the mucosal (56). 
Films by themselves or acting as drug carriers have been particularly considered 
worldwide (31). Porous membrane materials based on chitosan, add advantages of 
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biocompatibility, barrier properties, non-toxicity, non-polluting and low cost (31, 47). 
Besides biological activities, chitosan has attracted notable interest due to its good 
mechanical and oxygen barrier properties, becoming a promising edible film component 
(44) applicable to pharmaceutical and food industries. The functional properties of 
chitosan-based films can be improved by combining them with other hydrocolloids (57). 
The cationic properties of chitosan offer good opportunities to take advantages of electron 
interactions with numerous compounds (mainly macromolecules) and incorporate specific 
properties into the material (44). Examples are chitosan blends with hyaluronic acid, 
alginate, rice, collagen and oleic acid (35). Several aspects of the chitosan film-forming 
properties have been described, including the effect of solvent, concentration, storage 
effects and the influence of important structural characteristics such as the MW of 
chitosan and its DD (58).  
To produce chitosan films, usually chitosan is dissolved in acetic acid or hydrochloric acid 
and then the solvent is removed by drying and final dry film is collected. Another 
methodologies involves the precipitation of chitosan by common coagulating agents (e.g., 
sodium hydroxide) and finally made into film (35). Other preparation techniques (e.g. 
casting and extrusion) and drying conditions may have influence on film properties. 
Mechanical film properties can be modified by controlling chain polymer orientation (44). 
The relevant applications of these chitosan films include bone cell adhesion and growth, 
blood compatibility and cell adhesion (35).  
Since chitosan was reported to have intragastric floating characteristics and prolonged 
retention of the dosage form in the stomach, novel citrate cross-linked chitosan film was 
prepared by dipping chitosan film into citrate solution in order to  improve it for site-specific 
drug delivery in the stomach (59). The results indicated that the citrate-chitosan film was 
useful in drug delivery such as for the site-specific drug controlled release in stomach. 
Another study demonstrated the use and potential of chitosan films for production of mono 
and bilayer chitosan films containing corticosteroids as a drug carrier and controlled 
release in the eye (56). Corticosteroids are most common use in eye drops for 
inflammation following eye surgery, such as after cataract surgery and corneal operations 
and others. Mono and bilayer corticosteroids chitosan films were successfully obtained 
and results suggested that these films are potential sustained release carriers for 
corticosteroids. The monolayer corticosteroids chitosan film might be a promising ocular 
delivery carrier for corticosteroids in few hours and bilayer corticosteroids-chitosan film in 
weeks. The importance and application of chitosan films also cover the local drug delivery 
system of antibiotics (60). Local antibiotic delivery is another area of study designed to 
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provide alternative methods of treatment to clinicians for compromised wound sites where 
avascular zones can prevent the delivery of antibiotics to the infected tissue. A recent 
study demonstrated that incorporating antibiotics in chitosan films could provide 
alternative methods of treating musculoskeletal infections (60). 
Novel chitosan based polyelectrolyte complexes were developed and optimized in order to 
obtain films possessing the optimal functional properties (flexibility, resistance, water 
vapor transmission rate and bioadhesion) to be applied on skin (61). The development 
was based on the combination of chitosan and two polyacrylic acid polymers with different 
cross-linkers and crosslinking densities. The optimized film, including adhesive property, 
has shown very good properties for application in the skin and represents a very 
promising formulation for further incorporation of drugs for topical and transdermal 
administration. 
 
2.1.3. Tablets 
 
Various studies with chitosan regarding controlled release delivery systems have been 
conducted for oral dosage forms, from film coated pellets, tablets or capsules to more 
sophisticated and complicated delivery systems such as osmotically driven systems, 
systems controlled by ion exchange mechanism, systems using three dimensional printing 
technology and systems using electrostatic deposition technology (62). The most common 
controlled delivery system have been tablets and granules because of its effectiveness, 
low cost, ease of manufacturing and prolonged delivery time period, where the drug is 
uniformly dissolved or dispersed throughout the polymer (62). The tableting process is 
associated with relatively high pressure in order to form suitable compacts. However, not 
only the tableting excipients are deformed during the process of tablet formation, but also 
the tablet itself. This can lead to total or partial damage to such materials, namely loss of 
biological activity of proteins and enzymes, polymorphic transformation of excipients or 
damage of the coating material. Most recently, different excipients were tested in order to 
prevent such damages. Amongst others, polysaccharides like chitosan and carrageenan 
have shown to be advantageous because of their elastic tableting behavior (63). Several 
reports have been published on the use of chitosan as tablet excipients. It was applied as 
a carrier for sustained release tablets, a direct compressible diluent, a tablet disintegrate 
and a tablet binder (37). As a diluent, chitosan was used for preparation of direct 
compressed tablets (64, 65) where drug release was controlled. Studies using chitosan as 
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directly compressible tablet excipient showed its potential for use in modified release drug 
delivery systems without the need for additional adjuvants (64). Chitosan also showed 
higher binder efficiency than other tablet binders such as methylcellulose and sodium 
carboxymethylcellulose (66) and used as a binder for colon specific drug delivery tablets 
with slow drug release compared with other polysaccharides or synthetic polymers (67). 
Chitosan was utilized as tablets disintegrate (66) and showed bioadhesive properties in 
mixture with sodium alginate and in the form of thiolated chitosan derivative with slow drug 
release for intra-oral drug delivery tablets (68). Furthermore, the solubilizing and 
amorphizing properties of low MW chitosan toward naproxin made it an optimal carrier for 
developing fast release oral tablet (69). Depending mainly on ionic interaction, chitosan 
was also used for the preparation of tablets matrix to control drug release (70, 71).  
When used in a matrix-type tablet formulation, chitosan forms a gel-barrier in an acid 
environment that can modulate or constrain drug release. Furthermore, at acidic pH 
amines of chitosan are protonated and can therefore interact with oppositely charged drug 
ions, serving as excipient for modified release of drug delivery systems (65).  
Chitosan was studied as excipient in the preparation of prolonged theophylline tablets. 
These tablets showed higher drug bioavailability than of the commercial ones, which 
becomes a new potential formulation to respiratory problems (66). 
The biological potential of chitosan adds also clear benefits to the tablet formulation and 
process. In a recent research five different polysaccharides with potential antioxidant 
activity for extended-release matrix tablets were compared (72). The results suggest that 
chitosan would be potentially useful in an extended-release tablet with the higher 
antioxidant activity, able to catch the most diverse and natural oxidative species, usually 
involved in different pathologies. 
A new study concerning vaginal infections and inflammations were evaluated using 
chitosan tablets (73). Topical administration of the antibacterial metronidazole represents 
the most common therapy in the treatment of bacterial vaginosis caused by Trychomonas 
vaginalis. The formulations generally available for such therapy are creams, gels, vaginal 
lavages and vaginal suppositories. In this study, a new dosage form, containing 
metronidazole was developed with the aim to realize vaginal mucoadhesive tablets by 
including bioadhesive polymers as chitosan. This kind of delivery systems suitable for 
formulating metronidazole for topical application represents a good alternative to 
traditional dosage forms for vaginal topical administration in the treatment of infections or 
inflammations. These solutions overlap the limitations of conventional therapies that are 
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not suitable to assure drug permanence on the vaginal mucosa surface for adequate time 
assuring the complete elimination of bacteria and pathology eradication. 
Nonetheless, all applications of chitosan as tablet excipient were not in its derivative 
forms. However, attempts have been made to improve chitosan property by developing 
derivative salts. Chitosan derivatives such as glutamate, aspartate and hydrochloride salts 
have been used for colon-specific drug delivery and to enhance the delivery of therapeutic 
peptide across intestinal epithelia (37). 
 
2.1.4. Hydrogels 
 
Hydrogels are networks of hydrophilic polymers that can absorb large quantities of water 
without dissolution. Due to their physical properties resembling human tissue and its 
excellent tissue compatibility, hydrogels have been extensively studied for biomedical 
applications. They can be used as soft contact lenses (74), tissue engineering scaffolds 
(75), drugs carriers and controlled-release systems (76). In addition, hydrogels have the 
potential for further healing (77). They can absorb excess wound exudates, protect the 
wound from secondary infection and effectively promote the healing process by providing 
an environment for moist wound healing (78). Even can also be removed without causing 
trauma to the wound (78). 
Several models of hydrogels have been studied, including chitosan, poly (vinyl alcohol) 
(PVA) that is a water-soluble polyhydroxy polymer and alginate. However, chitosan has 
been widely exploited in hydrogel formulation and in practical applications because of its 
easy manipulation, excellent chemical resistance, physical properties, biodegradability 
and low price (78). This polymer is used to produce hydrogels with well-known properties 
that are used for delivery of proteins and synthetic drugs. Since this compound is also 
polyelectrolyte, its ionic form produces complexes through hydrogen bonding or 
electrostatic interactions. Besides this, another interesting property of chitosan is its ability 
to gel in contact with specific polyanions. This gelation process is due to the formation of 
inter- and intramolecular bonding mediated by these polyanions (1). In the last decade, 
different chitosan hydrogels were produced for drug delivery in micro or nano-scale using 
the polyelectrolyte complexation technique. There are many factors that affect the relevant 
properties of the capsules of chitosan, in particular the composition, MW and DD of 
chitosan. Several methods have been developed in which the particle size of chitosan 
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hydrogel and its related properties are quite distinct, according to the method of 
preparation and the reaction conditions that are employed. One of the major factors that 
may influence the final properties is the method of preparing hydrogel. Moreover, few 
attempts were made to correlate statistically the reaction conditions with the final 
properties of chitosan hydrogel. Liu and his collaborators (79) evaluated the influence of 
chitosan MW and its concentration, along with pH, upon the swelling behavior of 
microcapsules of chitosan-alginate, and postulated that all factors have an effect on the 
behavior of the hydrogel swelling. The alginate-chitosan hydrogels are commonly 
prepared by ionic complexation using alginate as a gel core (80) and then characterized 
by the vibration modes of their main groups using FTIR. Other hydrogels formulation 
procedures can be performed by UV crosslinking. In this method, lactose moieties are 
introduced into chitosan to obtain much better water-soluble chitosan at neutral pH, and 
photoreactive azide groups are added to provide the ability to form a gel through 
crosslinking azide groups with amino groups (81). This photocrosslinkable chitosan is then 
exposed to UV irradiation to form an insoluble and adhesive hydrogel within 60 s. 
Hydrogel has the consistency of transparent and soft rubber (81). 
The crosslinking can also be performed by high temperature. It is based on the 
neutralization of a chitosan solution with a polyol counterionic dibase salt such as β-
glycerophosphate. Chitosan/glycerophosphate is a thermosensitive solution, which is 
liquid at room temperature and solidifies into a white hydrogel at body temperature (81). 
In addition, crosslinking can be achieved by high pH, employing the pH-sensitive property 
of chitosan solutions at low pH. Once injected into the body, these polymer solutions face 
different environmental pH conditions and form gels (81).  
The chitosan hydrogel formulation can also be made by, freezing, thawing or chemical 
methods. Irradiation has the advantages of easy control of processing, without adding 
initiators or cross-linkers that can be harmful and difficult to remove and also has the 
option of combining the hydrogel formation and sterilization in one technological step. The 
main disadvantage of hydrogels prepared by irradiation is its poor mechanical strength. 
However, hydrogels prepared by freeze-thaw for example, of aqueous solutions of PVA 
has good mechanical strength, are stable at room temperature and does not require 
initiators or cross-linkers. The main disadvantage of this type of hydrogel is its opaque 
appearance and limited expansion capability (78). 
The hydrogel yields are evaluated through the weight difference, placing the washed 
hydrogels into pre-weighed flasks and then into a stove at 50 ºC until dryness. The 
chitosan hydrogel particles can then be visualized and characterized by particle size and 
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size distribution using an inverted optical microscope (80) as well as, by solubility, X-ray 
diffraction, thermal analysis, and solvent uptake (82). 
An ophthalmic delivery system with improved mechanical and mucoadhesive properties 
that could provide prolonged retention time for the treatment of ocular diseases were 
evaluated considering chitosan hydrogel formulation. For this, an in situ forming gel was 
developed by the combination of a thermosetting polymer, poly (ethylene oxide)–poly 
(propylene oxide)–poly (ethylene oxide) with chitosan. Therefore, the final formulation 
presented adequate mechanical and sensory properties and remained in contact with the 
eye surface for a prolonged time. In conclusion, the in situ forming gel comprised of 
poloxamer/chitosan is a promising tool for the topical treatment of ocular diseases (83). 
To overlap the limitation of topical delivery of antimicrobial agents and to prolong active 
drug concentrations in the oral cavity, it was designed a hydrogel formulation containing 
chitosan for delivery of chlorhexidine gluconate to the oral cavity (84). Chitosan prolongs 
the adhesion time of oral gels and drug release also inhibiting the adhesion of Candida 
albicans to human buccal cells since it has antifungal activity (84). The antifungal agent, 
chlorhexidine gluconate also induces the reduction of Candida albicans adhesion to oral 
mucosal cells.  
The preparation and characterization of thiol-modified chitosan, which formed crosslinked 
hydrogels, was also described to characterize in vitro release kinetics of insulin 
encapsulated in different chitosan MW hydrogels and evaluated for their potential use as a 
scaffold for the culture of NIH 3T3 cells (85). The results demonstrated that insulin is not 
immobilized locally within the gel network. Since the incorporation into the gel has no 
impact on insulin stability it may be assumed that the chitosan thermogelling system is an 
attractive delivery system for peptides and proteins. 
The main goal of other study was to developed a chitosan bioadhesive gel for nasal 
delivery of insulin (86). The proposed gel formulation could be useful preparation for 
controlled delivery of insulin through the nasal route and may represent an alternative 
treatment to diabetes.  
Mucoadhesive chitosan lactate gels were developed intended for the controlled release of 
lactic acid onto vaginal mucosa (87). The conclusions finding makes it reasonable to 
envisage a complete release of lactate from the tested formulations in vaginal 
environment. A recent research reports an in situ gelling chitosan-based hydrogel system 
that sustains the release of a potential anti-cancer gene (pigment epithelium-derived 
factor) to the tumor site. A significant reduction of the primary osteosarcoma in a clinically 
relevant orthotopic model was measured. The combination of plasmid treatment and 
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chemotherapy together with the use of this delivery system led to the highest suppression 
of tumor growth without side effects. The results obtained from this study demonstrate the 
potential application of a hydrogel system as an anti-cancer drug delivery for successful 
chemo-gene therapy (88). 
Another notorious study focuses on the current use of injectable to form in situ chitosan 
hydrogels in cancer treatment (81). Formulation protocols for in situ hydrogel systems, 
their cytotoxic properties, loading and in vitro release of drugs, their in vitro effect on cell 
growth, the inhibition of tumor growth in vivo using mouse models, and future directions to 
enhance this technology were discussed. In conclusion, chitosan gelling systems due to 
their antibacterial, biocompatible, biodegradable and mucoadhesive properties are a 
potential carrier for various cancer treatments.  
These hydrogels may also be useful to detect the localized growth of cells (81), which can 
also be directed to innovative methods of diagnosis. 
 
2.1.5. Microparticles 
 
Microparticles are defined as multiparticulate delivery systems, usually spherical with size 
varying from 1 to 1000 µm, containing a core active substance (48). The terms 
microcapsules and microspheres are often used synonymously. Spheres and spherical 
particles are also used for a large size and rigid morphology (48). 
The use of microparticles-based therapy allows drug release to be carefully tailored to the 
specific treatment site through the choice and formulation of various drug–polymer 
combinations. The total dose of medication and the kinetics of release are the variables, 
which can be manipulated to achieve the desired result. Using innovative 
microencapsulation technologies, and by varying the copolymer ratio, MW of the polymer 
among other parameters, microparticles can be developed into an optimal drug delivery 
system, which will provide the desired release profile (34). 
Chitosan with different MW and concentration, degradation rate of chitosan particles and 
drug concentration interfere on microparticle properties (1). Chitosan microparticles are 
used to provide controlled release of many drugs and to improve the bioavailability of 
degradable substances such as protein or enhance the uptake of hydrophilic substances 
across the epithelial layers (34). Having in mind bio/mucoadhesive properties of natural 
biopolymers, chitosan microparticles have potential for colon targeting. In order to achieve 
localization and prolonged residence time in the colon, matrices should have optimal 
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particle size, between 4 and 15 µm (89). Carrier systems in that size range are able to 
attach more efficiently to the mucus layer and accumulate in the affected region without 
the need for macrophage uptake. This novel formulation will offer efficient treatment of 
colon inflammatory diseases like ulcerative colitis and Chron’s disease (89), increasing 
therapeutic concentration (at the site of inflammation) and activity and minimizing side 
effects that occur by conventional systemic absorption. Chitosan microparticulate carrier 
systems are also efficient in the treatment of inflammatory bowel diseases (89). 
Budesonide is one of the most used drug substances in the treatment of active 
inflammatory bowel diseases. Chitosan microparticles loaded with budesonide were 
produced using novel one step spray-drying procedure. Coated microparticles were 
suitable candidates for oral delivery of budesonide with controlled release properties for 
local treatment of inflammatory bowel diseases.  
Chitosan microparticles also represents a promising polymer in nasal peptide delivery (90) 
prolonging the residence time of nasal drug delivery systems at the site of drug 
absorption. Additionally, chitosan improves the absorption of peptides by opening 
transiently the tight junctions.  
Oral administration of the nonsteroidal anti-estrogen tamoxifen is the treatment of choice 
for metastatic estrogen receptor-positive breast cancer. Chitosan microparticles were 
developed for tamoxifen delivery into the lymphatic system (91), improving tamoxifen oral 
bioavailability and decreasing its side effects. These data underline other potential 
therapies to this serious cancer condition. 
It was also reported the importance of chitosan microparticles in the purification of 
immunoglobulin G from human plasma by affinity chromatography using linoleic acid 
attached chitosan microparticles (92). It was concluded that the microparticles allowed just 
one-step purification of immunoglobulin G from human plasma. 
Chitosan and its derivative N-trimethyl chitosan chloride, given as microparticles 
associated to the non-toxic mucosal adjuvant LTK63, were evaluated for intranasal 
immunization with the group C meningococcal conjugated vaccine. The bactericidal 
activity measured in serum of mice immunized intranasally with the conjugated vaccine 
formulated with this delivery system and the LT mutant was superior to the activity in 
serum of mice immunized sub-cutaneous. Importantly, intranasal but not parenteral 
immunization, induced bactericidal antibodies at the nasal level, when formulated with 
both delivery system and adjuvant (93). 
In another study, it was evaluated the ability of chitosan microparticles to enhance both 
the systemic and local immune responses against diphtheria toxoid after oral and nasal 
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administration in mice. Significant systemic humoral immune responses were also found 
after nasal vaccination with diphtheria toxoid associated to chitosan microparticles. 
Diphtheria toxoid associated to chitosan microparticles results in protective systemic and 
local immune response against this toxoid after oral vaccination and in significant 
enhancement of immunoglobulin G production after nasal administration. Hence, these in 
vivo experiments demonstrate that chitosan microparticles are very promising mucosal 
vaccine delivery system (94). Other similar studies considered the chitosan microparticles 
as encapsulating agent of large amounts of antigens such as ovalbumin, or tetanus toxoid 
(95). Besides chitosan particles are a promising candidate for mucosal vaccine delivery, 
mucosal vaccination not only reduces costs and increases patient compliance, but also 
limits the invasion of pathogens through mucosal sites. 
 
2.1.6. Nanoparticles 
 
Nanoparticles are defined as a microscopic particle whose size is in the nanoscale, 
varying from 1 to 1000 nm, able to deliver drugs (2) to the right place, at appropriate times 
and at the right dosage, also improving their bioavailability, efficiency and reducing 
cytotoxicity associated to other systemic drugs carriers, actually becomes one of the most 
attractive areas of research in drug delivery (2). These submicron particles containing 
entrapped drugs are intended for enteral or parenteral administration, which may prevent 
or minimize the drug degradation and metabolism as well as cellular efflux, extending the 
shelf-life (50). Some researchers have also observed that the number of nanoparticles, 
which cross the intestinal epithelium is greater than that of the microparticles and 
hydrophilic nanoparticles generally have longer resident time in blood then microspheres 
(96). With their easy accessibility in the body, nanoparticles can also be transported via 
the circulation to different body sites. These particulate delivery systems have been 
shown to enhance the immune response following mucosal application. Nanoparticles 
have been made of safe materials, including synthetic biodegradable polymers, natural 
biopolymers, lipids and polysaccharides and have the potential for overcoming important 
mucosal barriers, such as the intestinal, nasal and ocular barriers (50). Chitosan based 
nanoparticles show great potential for delivering macromolecular therapeutics (in 
particular drugs and genes) and control the complete release of the drugs in their native 
forms across biological barriers (41). Important advantages of these nanoparticles include 
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their rapid preparation under extremely mild conditions and also their ability to incorporate 
bioactive compounds (45). Chitosan nanoparticles topically applied into the eye has been 
proven to increase the residence time of drugs in the precorneal area due to their 
adhesive properties and, therefore, could prolong the penetration of drugs into the 
intraocular structures (2). An important research shows that a chitosan derivative can be 
used to prepare norcantharidin-associated nanoparticles by taking advantage of the ionic 
cross-linkage between the drug molecule and of the chitosan carrier for anti-
hepatocarcinoma medicine (97). 
The potential of nanoparticles as a vaccine delivery has also been demonstrated in 
several studies (98-100). Nanoparticle-mediated gene delivery is an alternative to viral 
gene delivery. Nanoparticles offer the potential for safe, targeted and efficient gene 
delivery in a variety of organs (101).  
Borges et al. (102), recently described a delivery system that is composed of a 
nanoparticulate chitosan core to which the hepatitis B surface antigen (AgHBs) was 
adsorbed and subsequently coated with sodium alginate. The enhancement of the 
immune response observed with the antigen-loaded nanoparticles demonstrated that 
chitosan is a promising platform for parenteral delivery of this antigen, since it resulted in a 
mixed Th1/Th2 type immune response. 
Chitosan nanoparticles have been also produced as a carrier system for the nasal delivery 
of a monovalent influenza subunit vaccine (103). The intranasal administered antigen-
chitosan nanoparticles induced higher immune responses compared to the other 
intranasal antigen formulations, and these responses were enhanced by intranasal 
booster vaccinations. Moreover, among the tested formulations only intranasal 
administered antigen-containing chitosan nanoparticles induced significant 
immunoglobulin A levels in nasal washes of all mice tested, demonstrating that chitosan 
nanoparticles are a potent new delivery system for intranasal administered influenza 
antigens. 
Another study indicate that chitosan nanoparticles are a good carrier for DNA vaccines 
against tuberculosis by pulmonary delivery, which may provide an advantageous delivery 
route compared to intramuscular immunization, due increasing higher immunogenicity 
(104). 
Chitosan nanoparticles have been also introduced as a useful carrier for peptide oral 
delivery, because they can protect these compounds from degradation. Insulin, like other 
peptides, has low therapeutic activity when administered orally due to degradation by 
proteolytic enzymes (105). 
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Sarmento et al. (106) developed chitosan nanoparticles as drug carrier of insulin. Insulin 
was entrapped in different polyanion/chitosan nanoparticulate systems with high 
efficiency, to study morphologic and physical properties of resulting nanoparticulate 
complexes and to investigate insulin release behavior under gastrointestinal conditions 
(106). These nanoparticulate complexes appear to possess good properties for oral 
protein delivery, particularly those containing dextran sulfate/chitosan polyelectrolytes, 
which provided highest insulin association efficiency and retention of insulin in gastric 
simulated conditions. However alginate/chitosan nanoparticles also appear as promising 
in oral delivery system for insulin and potentially for other therapeutical proteins (107). 
Moreover, it was demonstrated that blood glucose levels of diabetic rats can be effectively 
controlled by insulin-loaded chitosan nanoparticle administration, following either single or 
multiple oral administration. In addition, the hypoglycemic effect was observed for more 
than 24 h (108). 
 
2.2. Clinical trial - Safety and tolerability of chitosa-n-acetylcysteine eye 
drops in healthy young volunteers  
 
There are many definitions of clinical trials, generally are studies of biomedical and health 
research related to human beings following a pre-defined protocol (109). These tests can 
only take place when quality and safety of the test are guaranteed by the Health Authority 
or the Ethics Committee recognized by the country, which will run the clinical trial. The 
randomized controlled trial is commonly accepted as the gold standard research method 
for evaluating health care interventions (110). In any clinical trial it is desirable not only to 
achieve similar numbers of patients in each treatment group, but also to ensure that 
patient groups are similar with respect to prognostic factors such as age or stage of 
disease (110). Nowadays, many studies have come and explore the multi-potential of 
chitosan as a carrier for drug delivery and release (109).  
The "dry eye syndrome" DES is a highly prevalent ocular disease, particularly in the 
elderly population and that current therapy is the use of topically administered lubricants, 
no "ideal" formulation has yet been found. Recently, Croma Pharma has introduced 
chitosan-n-acetylcysteine eye drops (111), designed for treatment of symptoms related to 
“dry eye syndrome". The new formulation comprises n-acetylcysteine, which has been 
used in ophthalmology because of its mucolytic properties for several years. Based on 
theoretical considerations, one can hypothesize that the new chitosan derivative may 
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prove an increased adhesion to mucins of the ocular surface and may therefore be 
particularly beneficial in reducing the symptoms associated with DES. 
Men and women aged between 18 and 45 years healthy with normal physical 
examination/laboratory values, medical history and with normal ophthalmic findings, were 
considered. Exclusion criteria were: patients who participated in a clinical trial in the 3 
weeks preceding the study; abuse of alcoholic beverages; symptoms of a clinically 
relevant illness in the 3 weeks before the first study day; ametropia and pregnancy. The 
study was completely and successful based on the differences found between the treated 
and the non-treated eye with chitosan-n-acetylcysteine eye drops. 
The study resulted in two subsequent studies in similar collaboration with Croma-Pharma: 
Evaluation of the corneal residence time of chitosan-n-acetylcysteine eye drops in patients 
with dry eye syndrome after single and multiple instillation; and the assessment of safety 
and tolerability of chitosan-n-acetylcysteine eye drops in subjects while wearing contact 
lenses before and insertion of contact lenses. The studies were successfully completed in 
Phase II and Phase I, respectively. 
The emergence of innovative medicines demands effective strategies to enhance drug 
permeation and bioavailability. A better understanding of the mechanisms of action of 
these novel drugs carriers will provide their further optimization, opening exciting 
opportunities to improve the administration of macromolecules, such as proteins, 
peptides, genes, vaccines, antigens and synthetic compounds, which allows the treatment 
of several diseases.  
Therefore, useful knowledge for future adaptation is provided for pharmaceutical industry, 
medical assistance and human health care. 
 
3. Oxidative products and the clinical importance of antioxidants 
 
The reactive oxygen species (ROS) like superoxide anion radical (•O2−), hydrogen 
peroxide (H2O2) and hydroxyl radical (•OH), are also ubiquitous, highly reactive, diffusible 
molecules that are generated within the cell as by-products of aerobic respiration and 
metabolism resulting in a very reactive unpaired electron state, within and out of the cell 
(112). Indeed, (•O2−) radical is the precursor of most ROS and could be a mediator in 
oxidative chain reactions (112). 
Cellular damage or oxidative injury arising from free radicals or ROS now appears the 
fundamental mechanism underlying a number of human neurodegenerative disorders, 
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diabetes, inflammation, viral infections, autoimmune pathologies, atherosclerosis, 
coronary heart disease, digestive system disorders and cancer (113). Free radicals are 
constantly generated through normal metabolism, degradation of drugs, environmental 
chemicals and other xenobiotics as well as endogenous chemicals, especially stress 
hormones (adrenalin and noradrenalin) (113). 
Antioxidants may control this OS imbalance by acting at different levels: scavenge free 
radicals, inhibiting their formation or otherwise preventing the damage caused by them 
and increasing antioxidant defense (15-17).  
The global market of antioxidants is increasing rapidly, because of the increased health 
risk in a constantly polluting environment. However, there are not many antioxidants listed 
in pharmacopoeias and extensive research is being carried out globally on these agents, 
most of them demonstrating their pharmacological effect (18). For instance, the role of 
several active infusions in the prevention and cure of disease has been attributed, at least 
in part, to antioxidant properties and to its constituents that are widely known as 
polyphenols. These phenolic compounds are commonly found in both edible and inedible 
plants, and display a variety of biological effects, including anti-inflammatory properties 
(114), regulation of cholesterol, vascular problems healing, promotes blood circulation, 
relieves blood stasis and have huge antioxidant activity (14, 115, 116). In this regard, 
antioxidants are seen as compounds that protect cells against OS, which could lead to cell 
damage, cancer, neurodegenerative diseases and vision problems (115). 
However, all these antioxidant compounds are labile macromolecules that are light and 
oxygen sensitive, with a high index of reactivity with other compounds and in some cases 
with poor solubility and low mucosa permeability (15-17). 
 
3.1.1. Types of antioxidants agents 
 
Antioxidant is any substance which when present at low concentrations compared with 
those of an oxidizable substrate, significantly decreases in oxidation of substrate, 
preventing oxidative complications (113). The term ‘oxidizable substrate’ includes almost 
everything found in the living cells including proteins, lipids, DNA and carbohydrates 
(113). Antioxidants may interact and eliminate ROS before they react with biologic targets, 
preventing chain reactions or preventing the activation of oxygen to highly reactive 
products (117). Antioxidants can be classified into enzymatic and non-enzymatic 
antioxidants, since they are endogenously produced or exogenously obtained (118). 
Antioxidants that are endogenously produced include enzymes, low molecular weight 
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molecules and enzyme cofactors (119). Enzymes are known to afford more effective 
protection against acute massive oxidative damage, such as hyperoxia or inflammation 
(18). The enzymatic antioxidant systems, such as Copper (Cu), Zinc (Zn), manganese 
superoxide dismutase (MnSOD), glutathione peroxidase (GPx), glutathione reductase 
(GR) and catalase may remove the ROS directly or sequentially, preventing their 
excessive accumulation and consequent adverse effects (113). Non-enzymatic 
antioxidants are obtained exogenously, mainly from dietary sources such as vitamins, 
carotenoids, organosulfural compounds, minerals, lipoic acid, and polyphenols (120). 
Polyphenols are the major and most important class which includes phenolic acids and 
flavonoids (121). A polyphenol is any compound that contains more than two (–OH) 
groups attached to a benzene ring (119). Naturally occurring in vegetables, fruits and 
plant derived beverages such as tea, red wine, and extra virgin olive oil, are a wide variety 
of organic molecules (122). Commonly flavonoids are catechins, resveratrol, quercetin, 
anthocyanins and hesperitin derivatives, and phenolic acids such as phytic, caffeic and 
chlorogenic acids (112). 
Vitamin E, fat-soluble antioxidants, is a family of four tocotrienols (α-β-δ-γ-tocopherols) 
(123). Vitamin E is generally thought to be the most important inhibitor of lipid 
peroxidation. There are some reports showing that vitamin E intake prevents the 
generation of free radicals (119). The most active form of vitamin C (ascorbic acid), a 
water soluble antioxidant, interacts with the tocopheroxyl radical and regenerates the 
reduced tocopherol, scavenging ROS and protects the DNA damage (119).  
Carotenoids are fat-soluble antioxidants, including β-carotene, lutein, α-carotene, 
zeaxanthin, cryptoxanthin and lycopene (112). 
Trace elements also have indirect antioxidant and detoxifying properties and are therefore 
essential in the defense systems against ROS-induced cellular damage. Indeed, copper 
(Cu), zinc (Zn), manganese (Mn), selenium (Se) are particularly of utmost importance as 
they are essential constituents of enzymatic antioxidant systems (112). 
Plant extracts and their constituents are a natural source of antioxidants. There are 
several different plant organs such as seeds (soybean, peanut, cottonseed, mustard, 
rapeseed, rice and sesame seed), fruits (grape, citrus, black, pepper and olive), leaves 
(tea, rosemary, thyme and oregano) and others (sweet potato, onion and oat seedling) 
(113). 
Numerous naturally compounds are useful as antioxidants in plant extracts, namely α-
tocopherol and β-carotene, phenolic compounds (tannins, flavonoids, anthocyanins, 
chalcones, xanthones, liganans, depsides, and depsidones), terpenes (sesquiterpens and 
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diterpines), alkaloids, and organic sulfur compounds (124). Rosmarinic acid, (a-O-
caffeoyl-3,4-dihydroxyphenillactic acid ), is a phenolic compound generally admitted as a 
free radical scavenger (125). The high biological activity is related to its chemical 
structure, in particular the two catechol moieties. Catechol is an important sub-structure 
for the potent antioxidant activity of phenolic antioxidants (125). The general antioxidant 
mechanism of phenolic compounds is thought to be divided into two stages: radical 
catching stage and radical conclusion stage (126). The structure of the final product would 
afford important information about the antioxidant mechanism of the phenolics (126). 
Rosmarinic acid can have many beneficial functionalities like its potent antioxidant activity 
associated to its huge potential radical scavenging activity, higher than trolox (a derivative 
of α-tocopherol), commonly used as control (10-12). It is also well documented its 
antibacterial and antiviral activity (7, 8), anti-inflammatory activity (127), anti-mutagenicity 
character (128), capability to reduce atopic dermatitis symptoms (129), prevention of 
Alzheimer’s disease (130) and apoptosis induction of colorectal cancer cells (131). 
Rosmarinic acid has also an anti-angiogenic activity to retinal neovascularization in a 
mouse model of retinopathy. Rosmarinic acid is suggested as potent inhibitor of retinal 
neovascularization and that may be applied in the treatment of vasoproliferative 
retinopathies (13). It is reported that rosmarinic acid may inhibit the proliferation of retinal 
endothelial cells and inhibited in vitro angiogenesis of tube formation. It also has showed 
no retinal toxicity. 
 
3.1.2. Physiology and pathobiology of reactive oxygen species in retinopathies 
 
The retina is a thin, transparent, highly organized structure of neurons, glial cells, and 
blood vessels (118) (Figure 1.2). Of all structures within the eye, the neurosensory retina 
has been the most widely studied. Retina is organized into neural retina and retinal 
pigment epithelium (RPE) (132), being the first involved in signal transduction, leading to 
vision. Light enters through the retinal ganglion cell layer and penetrates all the deeper 
layers where the transduced signal is taken by several retinal neurons to the optic nerve 
and forward to the brain, where it is registered and formed an image. RPE, on the other 
hand, is a single cell layer that separates the outer surface of the choroid and neural 
retina and appears as a uniform, continuous layer that extends through the retina and a 
have an essential role in the viability of the neural retina (132).  
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There are two barriers that form the blood–ocular barrier which limit the permeation into 
the retina, the blood–aqueous barrier (BAB) and blood–retina barrier (BRB) (Figure 1.3) 
(132). 
 
 
Figure 1. 2. Schematic illustration of eye structure and subsequent critical biological 
barriers that drugs need to overcome after topical administration onto the eye surface, in: 
(118). 
 
In addition to the physical barriers, ocular tissues contain metabolic enzymes, such as 
esterases, aldehyde and ketone reductases (133, 134), which may degrade drugs or 
infectious agents that reach the eye, reducing their efficacy, pathogenicity or even 
eliminating them. As a result of these anatomical and physiological constraints after 
topical or local application, a major fraction of the administered drug is lost by different 
mechanisms, resulting in very low ocular bioavailability (Figure 1.3) (135). This justifies 
the poor effectiveness of topical administrations in ocular globe, and the need to treat 
several diseases by invasive methods as the intra-vitreous injections or surgeries. 
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Figure 1. 3. Schematic view of the ocular permeability, physiological barriers, and 
transport pathways of a drug applied topically onto the eye, in: (27). 
 
Nevertheless, human antioxidant defense is set with enzymatic scavengers like 
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx), 
hydrophilic scavengers like urate, ascorbate, glutathione (GSH) and flavonoids, lipophilic 
radical scavengers such as tocopherols, carotenoids and ubiquinol (18). In addition, 
defense also comprises enzymes responsible for the reduction of oxidized forms of 
molecular antioxidants like glutathione reductase and dehydroascorbate reductase.  
In eye pathologies, the defense against ROS is weakened or damaged and the oxidant 
load increases. In such conditions, external supply of antioxidants is essential to 
countervail the deleterious consequences of OS (136). The OS imbalance, potentially 
leads to retinal cell damage, and degenerates lipids, proteins, enzymes, carbohydrates 
and DNA in cells and tissues, resulting in membrane damage (25). These consequences 
of OS construct the molecular basis in the development of degenerative eye diseases.  
 
3.1.3. Oxidative stress imbalance and retinal affected diseases 
 
The clinical impair of OS and ocular diseases are particularly due to some factors, 
namely: the retina natural high content of PUFA, the oxygen uptake and glucose oxidation 
higher than any other tissue (15), the eye structurally subjected to light, atmospheric 
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oxygen, environmental chemicals and physical abrasion (137, 138). Protective 
components like water-soluble antioxidants, lipid-soluble antioxidants and highly 
specialized enzymes are thought to serve as a frontline defense for the ocular surface tear 
film and underlying tissues (118). If the antioxidants are depleted or acting inefficiently, an 
imbalance between the high increased production of ROS and the sharp reduction in 
antioxidant defenses will alter cellular redox status (136). In retinopathy, OS has been 
widely involved in decreased retinal blood flow (139), increased vascular permeability, 
disruption of BRB (140) and the appearance of cellular capillaries from the apoptotic loss 
of retinal capillary cells (141). OS has also been linked to microvascular abnormalities in 
retinopathies, degenerative process of retinal neovascularization and the suppression of 
antioxidants systems (25).  
 
4. Nanotechnology applied to antioxidants protection 
 
Nanoparticles have been made of safe materials, including synthetic bio-degradable 
polymers, natural biopolymers, lipids and polysaccharides and have the potential for 
overcoming important mucosal barriers, such as ocular barriers (50). Nanoparticles may 
be obtained via different preparation protocols and have been widely studied in recent 
years as carriers for therapeutic agents with varying degree of effectiveness (142). 
Different preparation of micro/nanoparticles can be considered, mainly physical methods, 
chemical crosslinking methods and miscellaneous. Physical methodologies involve 
ionotropic gelation, emulsification and ionotropic gelation, modified emulsification and 
ionotropic gelation, floating hollow chitosan microspheres obtained by ionic interaction 
with sodium dioctyl sulfosuccinate, coacervation and complex-coacervation (34). 
Crosslinking with other chemicals are used for emulsion crosslinking method, multiple 
emulsion method, precipitation–chemical crosslinking and crosslinking with a naturally 
occurring agent (34). Miscellaneous methods include thermal crosslinking, solvent 
evaporation method, spray drying and interfacial acylation (34). Nanocarriers can be 
applied to improve the solubility, permeability, stability of the compounds and some can 
even surpass the first pass metabolism (Figure 1.4). These delivery systems have been 
beneficial to the pharmaceutical industries as it is a strategic tool for expanding drug 
market and patent life. Novel drug delivery systems would make antioxidant reach site of 
action and improve the efficacy of therapy, generally by improving the bioavailability, 
which are of prime importance when antioxidants intended for prophylactic purpose (116). 
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Implication of novel delivery systems for antioxidants is ruled by physical-chemical 
characteristics, biopharmaceutics and pharmacokinetic parameters of the antioxidant to 
be formulated (116). Recently, chemical modifications, coupling agents, liposomes, 
microparticles, nanoparticles and gel-based systems have been explored to overcome 
difficulties in the development of new products for the improvement of human healthcare 
(18). 
 
 
Figure 1. 4. Classification of antioxidants and characterization of some nanostructures. 
Highlights to real benefits of antioxidants encapsulation considering its liberation, 
absorption, distribution, metabolism, elimination and response, adapted from (18). 
 
Nevertheless, it may be highlighted the huge importance of nanotechnology and 
nanocarriers to be applied in common delivery systems, like immunoglobulin’s deliver to 
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the retina. In particular, the injecting vascular endothelial growth factor (VEGF) to 
neutralize the antibodies into the vitreous. Silicate nanoparticles (SiNPs) have been 
demonstrated efficiency in inhibition of VEGF-induced angiogenesis. Via suppression of 
VEGF receptor-2 phosphorylation induced by VEGF, SiNPs blocked ERK 1/2 activation 
(143). Intravitreal injection of gold nanoparticle (GNP) also has shown an inhibition of 
retinal neovascularization in a mouse model of retinopathy of prematurity. GNP not 
affected the cellular viability of retinal microvascular endothelial cells and not induced 
retinal toxicity. GNP can be used in a variable vaso-proliferative retinopathies mediated by 
VEGF (144).  
A molecule with ideal solubility and permeability profile can be administered with a 
minimum effective dose and with no presystemic loss due to mucosas, physical barriers or 
enzymatic degradation (18). For antioxidants assure these conditions they need 
nanocarriers to take them to the right place without losing their functional activity. 
Therefore, considering the therapeutic potential of the antioxidants, there is every need to 
implicate novel drug delivery technologies to improve their performance. Nanoparticles 
are expected to develop and improve protection, stability, bioavailability and therefore the 
therapeutic efficacy of antioxidants, without compromising the safety performance of the 
drug. The Age-Related Eye Disease Study (AREDS) (145), an National Eye Institute–
sponsored, multicenter, controlled, randomized clinical trial, demonstrated that the 
combination of oral supplements consisting of antioxidant vitamins C (500 mg), E (400 
international units), and β-carotene (15 mg), and minerals, ZN (80 mg of zinc oxide) with 
Cu (2 mg cupric oxide). This reduced the 5-year risk of developing advanced age macular 
degeneration (AMD) in eyes with intermediate AMD by 25% (estimated probability of 
progression was 28% for placebo vs 20% for antioxidants plus zinc). The primary purpose 
of the Age-Related Eye Disease Study 2 (AREDS2) (145) was to evaluate the efficacy 
and safety of lutein plus zeaxanthin and/or ω-3 long-chain polyunsaturated fatty acid 
(LCPUFA) supplementation, reducing the risk of developing advanced AMD. Nevertheless 
and besides the promising effect of this huge antioxidant supplementary, it would be 
expectable that this effect could be also potentiated by the protection of these antioxidants 
using the nanotechnology. The protection may be crucial in order to guarantee the safe 
antioxidant performance, bioavailability and absorption, over the several barriers of the 
digestive system (such as the biological fluids and enzymatic pathways). Other studies 
have been performed to maintain or even increase the activity and stability of antioxidants 
using nanotechnology (Table 1.2). These are evidences that antioxidant nanoparticles 
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may be used for therapy of several diseases, however further studies are needed to prove 
their efficacy in the prevention and treatment of retinopathies. 
 
 
 
Table 1. 2. Recent published data of antioxidants nanoencapsulation for several 
applications. 
Antioxidant Method Results Application References 
3,5-di-tert-
butyl-4-
hydroxycinna
mic acid 
A nanosilica-
immobilized 
antioxidant was 
prepared and 
incorporated into 
polypropylene (PP) 
by melt 
compounding 
The antioxidant efficiency of the nanosilica-
immobilized antioxidant was superior to the 
corresponding low molecular counterpart 
(AO). The thermal oxidative stability of 
PP/nanosilica-immobilized antioxidant was 
much higher than that of PP/AO compound 
during the long-term accelerated thermal 
aging  
Application not 
described 
 
(146) 
 
Antioxidant 
enzymes 
(catalase and 
superoxide 
dismutase) 
Magnetically 
responsive 
nanoparticles (MNP) 
formed by 
precipitation of 
calcium oleate in the 
presence of 
magnetite-based 
ferrofluid (controlled 
aggregation/ 
precipitation) 
Catalase stably associated with MNP was 
protected from proteolysis and retained 20% 
of its initial enzymatic activity after 24 h of 
exposure to pronase. Under magnetic 
guidance catalase-loaded MNP were rapidly 
taken up by cultured endothelial cells 
providing increased resistance to OS (62 ± 
12%) cells rescued from hydrogen 
peroxide induced cell death vs. 10 ± 4% 
under non-magnetic conditions 
Can be highly 
relevant for the 
treatment of 
vascular 
disease 
 
(147) 
Antioxidants of 
Salvia 
miltiorrhiza 
(salvianolic 
acid B, 
cryptotanshino
ne, tanshinone 
I and 
tanshinone 
IIA) 
 
The dried roots 
of S. miltiorrhiza 
were ground by the 
atomizer and 
further sprayed 
granulating with the 
aid of floating bed. 
The resulting 
materials were dried 
to form the 
nanoparticles 
under the dry 
processes 
Stronger antioxidant bioactivities were 
observed for the extracts prepared using 
nanotechnology in all tested assays. The 
polar active constituent in the nanoparticles 
samples was released faster compared to the 
traditionally powdered samples 
Application not 
described 
 
(116) 
Idebenone 
Co-drying with 
chitosan (Ch) or N-
carboxymethylchitos
an (N-CMCh) cross-
linked with 
tripolyphosphate 
(TPP) 
Nanoparticles showed a 10-fold increase of 
drug stability in comparison with free drug 
and preserved antioxidant activity in vitro. 
Compared with the severely irritative free 
form of idebenone, the nanoparticle 
formulation showed decreased mucous 
membrane irritation 
These  
nanoparticles 
have potential 
roles a carriers 
for hydrophobic 
and irritative 
drugs such as 
the antioxidant 
idebenone for 
topical or nasal 
use 
(148) 
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Natural 
antioxidants 
extracted from 
Ilex 
paraguariensis 
(ILE) 
Nanoparticles were 
prepared by ionic 
gelation of chitosan 
hydrochloride and 
sodium 
tripolyphosphate. 
The active 
components were 
added to the sodium 
tripolyphosphate 
solution and this was 
added dropwise to 
the chitosan 
hydrochloride 
solution while stirring 
Chitosan hydrochloride–TPP nanoparticles 
maintain the antioxidant activity of ILE-
polyphenols. Nanoparticles released 100% of 
ILE-polyphenols loaded after 15 min in two 
buffers with different pH values (pH 5.7 and 
6.5) 
This method is  
a promising 
technique for 
nutraceutical 
and cosmetic 
applications 
(149) 
p-
Hydroxybenzyl 
alcohol (HBA) 
HBA-incorporated 
copolyoxalate 
(HPOX) 
HBA released from HPOX demonstrated 
excellent antioxidant activity, such as 
inhibition of nitric oxide (NO) production by 
suppressing iNOS (inducible nitric oxide 
synthases) expression in lipopolysaccharide 
(LPS)-activated RAW 264.7 cells. HPOX 
nanoparticles delivered intranasally 
significantly reduced pulmonary inflammation 
and suppressed the iNOS expression 
HPOX 
nanoparticles 
are highly potent 
for the treatment 
of oxidative 
damage-related 
diseases, such 
as asthma 
(150) 
Quercetin 
Nanoprecipitation 
technique with 
Eudragit® E (EE) 
and PVA as carriers 
Particle distribution with polydispersity index 
<0.3, and its yield and encapsulation 
efficiency were over 99%. The release of the 
drug from the quercetin-loaded nanoparticles 
(QUEN) was 74-fold higher compared with 
the pure drug. The antioxidant activity of the 
QUEN was more effective than pure 
quercetin on diphenyl-1-picrylhydrazyl 
(DPPH) scavenging, anti-superoxide 
formation, superoxide anion scavenging, and 
anti-lipid peroxidation 
These 
nanoparticles 
may be applied 
in clinical setting 
 
(151) 
Quercitrin 
(Albizia 
chinensis 
isolated 
antioxidant) 
Quercitrin has been 
encapsulated on PLA 
nanoparticles 
by solvent 
evaporation method 
The encapsulation efficiency of 
nanoencapsulated quercitrin evaluated by 
HPLC and antioxidant assay is 40%. The in 
vitro release kinetics of quercitrin under 
physiological condition reveals initial burst 
release followed by sustained release. Less 
fluorescence quenching is observed with 
equimolar concentration of PLA encapsulated 
quercitrin than free quercitrin. The presence 
of quercitrin specific peaks on FTIR of five 
times washed quercitrin loaded PLA 
nanoparticles provides an extra evidence for 
the encapsulation of 
quercitrin into PLA nanoparticles 
Potential use for 
therapeutic of 
intestinal anti-
inflammatory 
effect and 
nutraceutical 
compounds 
(152) 
α-tocopherol 
(vitamin E) 
Gold nanoparticles 
prepared with 
2,2-DPPH 
Chromanol groups on gold nanoparticles 
could efficiently enhance the activity of the 
vitamin E-derived antioxidant 
Potential  
strategy for 
antioxidant 
design with 
several 
applications 
(153) 
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4.1. Nanoantioxidants pharmacotherapy 
 
Drugs topically administered in the eye have low probability of reaching the posterior 
segment in significant amounts, as they have to pass through several metabolic and 
physical barriers to reach the retina, namely the corneal and conjunctival epithelium, then 
aqueous humor, and lens (132). One of the main problems encountered with the topical 
administration of liquid forms is the rapid and extensive loss of drugs to the limited 
capacity of drug retention in the ocular surface and also as a result of the blinking 
process, which normally is stimulated after instillation (118). The BRB and the extra ocular 
epithelia represent the obstacle in the drug delivery to the choroid, retina and vitreous. 
Only a fraction of the drug administered orally or by subcutaneous or intramuscular routes 
reaches the retina, requiring large doses to be therapeutically effective (118). Presently, 
there are several antioxidant products on market which have been formulated into these 
conventional dosage forms, with vitamins leading the group. Vitamins have been 
formulated mainly into tablets and capsules. Generally, these agents were found in 
combinations rather than individual products (18). A possible approach to improve retinal 
drug delivery is to facilitate localized delivery to the posterior segment of the eye by using 
Anopore™ nanoporous filter. Catalase and vitamin C were delivered using these inorganic 
nanoporous filter, which is made up of aluminum oxide filter with pores of 20 nm size, as a 
semipermeable membrane to separate two compartments in vitro. The data shown 
represented the possibility of biocompatible capsules based on nanoporous filters, which 
are able to provide controlled delivery of antioxidant molecules (154). Several 
nanocarriers may be consider as nanoantioxidants transporters as self-emulsifying drug 
delivery systems, which offer the potential for enhancing the absorption of poorly soluble 
and/or poorly permeable compounds. For drugs that are poorly soluble and/or poorly 
permeable, a significant improvement in reproducibility in performance and bioavailability 
might be achieved with these nanocarriers. Lutein is a well-known antioxidant and anti-
free radical used in cosmetic, nutraceutical industry with potential application in 
pharmaceutics as supportive antioxidant in treatments. However, lutein is a lipophilic 
molecule which is poorly soluble in water and has a low bioavailability. The lutein 
nanosuspension was converted into pellets and filled into hard gelatin capsules for 
nutraceutical use, yielding a superior in vitro release (155). However, there are some 
limitations associated with these formulations, including stability, manufacturing methods, 
interaction of the fill with the gelatin shell and limited solubility of some drugs in lipid 
solvents (18). Liposomes are potential systems for drug delivery because of their size, 
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hydrophilic and hydrophobic character and biocompatibility (156). The term liposomes 
with antioxidants could be liposomes containing lipid-soluble, water-soluble or enzymatic 
antioxidants. Antioxidant liposomes hold great promise in the treatment of many diseases 
in which OS plays a significant role (157). A major problem associated with conventional 
liposomes is that they are recognized by the immune system as foreign substances and 
rapidly removed by phagocytic cells of the reticuloendothelial system (18). Nanoparticles 
have been explored as drug delivery systems for encapsulation of different drugs or 
incorporation either into lipid or polymeric particles. The nanoencapsulation can help 
deliver drugs with poor aqueous solubility and permeability. In biodegradable polymeric 
nanoparticles the drug is dissolved, adsorbed, attached or encapsulated in the polymeric 
matrix of nanometer size. Depending upon the method of preparation, nanospheres or 
nanocapsules are obtained with different release and surface properties (158). 
Nanoparticles are also being explored for targeted drug delivery (159). Polymeric 
nanocarriers are attractive vehicles for vascular drug delivery as well, but remained a waif 
technology for antioxidant enzymes due to poor loading and inactivation of proteins during 
formulation (159). Microparticles have also been designed and evaluated as delivery 
systems for antioxidants produced endogenously and exogenously. The matrix is 
generally a polymer which sustains the release of drug. These particles are either matrix 
type entrapping the active moiety or capsule type encapsulating the drugs (18). The need 
to improve the ocular drug bioavailability, effectiveness and higher retention time becomes 
an emerging field in medicine, considering ocular conditions. Although there are not any 
antioxidant nanoparticles agent approved by European Medicines Agency (EMA) and 
Food and Drug Administration (FDA) there are at least 60 agents in the clinic touted as 
anti-angiogenic, many more potential anti-angiogenic candidates are currently in 
preclinical development, with the distinct possibility of moving into ocular clinical studies 
(160, 161). Recent data from very important multicenter clinical trials have emphasized 
the importance of new and evolutional therapies.  
 
4.2. Safety issues of antioxidant nanoparticles 
 
Despite of nanoparticles with antioxidants are known to be from natural sources, then 
safe, biocompatible and biodegradable with no toxicity effects or collateral damages, 
pharmacokinetics and toxicological analyses should not be dispensable. This safety 
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performance should guarantee the molecular, subcellular and cellular behavior of 
nanoparticles in ocular tissues and in the systemic circulation. The development of in vitro 
cell culture models for studying ocular barriers undoubtedly provides a platform to 
investigate the impact of pharmaceutical trafficking on ophthalmic diseases (162). The 
human corneal epithelium HCE-T model, formed by transfection of human corneal 
epithelial cells from a 47-year-old female donor with a recombinant SV40-adenovirus, 
represents a standard tool for drug permeation, bioavailability prescreening, and toxicity 
assessment (163), should be used to simulate the corneal absorption of antioxidants. The 
cell line has good growth characteristics and shows a cobblestone-like appearance. The 
IOBA-NHC cell line, a nontransfected, spontaneously immortalized epithelial cell line 
derived from human conjunctiva (164), should be used for predicting the conjunctival 
absorption of antioxidants. The IOBA-NHC cells demonstrated high proliferative ability in 
vitro and typical epithelial morphology. Furthermore, cytokeratins, mannose, and sialic 
acid residues are immunologically detected, therefore appears that this cell line can be a 
useful experimental tool in the field of ocular surface cell biology. Immortalized human 
cells ARPE-19 cells are particularly important in the retinopathies studies, since they 
simulate the retinal behavior and may indicate the absorption of antioxidants. These cells 
are fully characterized regarding their morphology, the expression of retina specific 
marker, and their barrier properties (162, 165). Monolayers of ARPE-19 cells have 
become a well-established in vitro model of the outer BRB. Moreover, monolayers of 
ARPE-19 cells are used by researchers for a variety of other in vitro experiments, 
including studies of the regulation of gene expression, polarized distribution and secretion 
of proteins, delivery of genes and antisense oligonucleotides, for toxicity studies, and as 
models of retinal diseases (162, 166, 167). The fate of nanoparticles loaded with natural 
antioxidants must be followed with a minimum required amount of in vivo experiments 
using topical routes of administration. The therapeutic efficacy and safety in vivo in rabbits 
should be monitored by means of physiological and behavioral parameters, 
complemented by toxicological and monitoring of conjunctival tissue. 
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5. Summary 
 
The physical-chemical properties of chitosan, such as inter- and intramolecular hydrogen 
bonding and the cationic charge in acidic medium in addition with its several bioactivities 
such as nontoxicity, biocompatibility, biodegradability and transmucosal absorption allows 
chitosan to become an excellent candidate for drug carrier and excipient for controlled 
release systems. A number of chitosan-based colloidal systems have been explored for 
bioactive molecules carriers, like films, tablets, hydrogel, micro and nanoparticle. In these 
formulations chitosan can reach the target sites with low collateral damages, toxicity and 
higher efficiency. The antioxidant therapy major problem in ocular treatments is the 
difficult to maintain an effective drug concentration at the site of action for an appropriate 
period of time, in order to achieve the expected pharmacological response. This 
suboptimal delivery can be overcome by different novel delivery strategies. Innovative 
nanomedicines with antioxidants pharmacotherapy could be seen as the key factor for eye 
diseases, since the use of topical nano-antioxidants to treat or delaying OS-related ocular 
manifestations is still unexplored, while current retinopathies therapy includes invasive 
method like laser photocoagulation or surgery, which may also increase risk of 
endophthalmitis, cataract formation and retinal detachment. Besides the development of 
laser for retinopathy, there have been no major advances in treatment for the disease, 
despite numerous clinical trials. Drugs applied directly to the eye represent a non-invasive 
and safe methodology, increasing the effectiveness of treatment and reducing toxicity 
associated with systemic administration. An ideal anti-angiogenic agent should be 
developed for neovascularization control and regression. It may inhibit and stabilize the 
disease, to prevent the vision loss, retinal scarring and detachment with no toxicity as well 
as the formulation should be for long term drug delivery. Agents should also be classified 
into early and late acting, specific and non-specific, and reversible and irreversible. The 
understanding of where a drug falls into these classes may help in the comprehension of 
the potential and/or limitation of the drug when used in the clinic, as well as how to predict 
potential serious adverse events. The nano-antioxidants are expected to be early acting, 
especially for prophylaxis. Considering this, there are a number of challenges associated 
to the treatment of ocular diseases. Thus, successful alternatives for ocular therapies are 
needed and they should provide non-invasive and a cost effective treatment reaching 
every economic status. Therefore, useful knowledge for future adaptation is provided for 
pharmaceutical industry, medical assistance and human health care. 
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PART II - Aims and goals 
 
 
“There is a world of advantages of nanotechnology application in different fields ... 
are all a part of its own disadvantages!” 
Jacques de la Palice 
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CHAPTER 2 - Aims and organization of the 
Thesis 
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2. Aims and organization of the Thesis  
 
Considering the antioxidants biological potential, there is every need to implicate novel 
drug delivery technologies to improve their performance. Chitosan drug delivery systems 
would achieve this goal by making antioxidants reach the site of action and improve the 
efficacy, generally by enhancing their bioavailability, which is of prime importance when 
antioxidants are intended for prophylactic purpose (116). 
Implication of novel delivery systems for antioxidants is ruled by physical-chemical 
characteristics, biopharmaceutics and pharmacokinetic parameters of the antioxidant to 
be formulated (116). Chitosan-based nanosystems are expected to increase the ability, to 
retain the drug activity during the preparation process, to optimize the release of the 
compound from the carrier system, and to ensure good control of their physical-chemical 
properties, their stability and the crucial ocular mucoadhesion (168). 
Presently, the pharmaceutical research in the field of antioxidants is not going so fast as 
the research concerning the role of free radicals ocular diseases, despite the fact that 
there are various antioxidants in conventional products on the pharmaceutical market 
(18).  
Chitosan nanoparticles are known to be new natural drug delivery systems that may 
incorporate antioxidants, being safe, biocompatible and biodegradable systems with no 
toxicity effects or collateral damages. Moreover pharmacokinetics and toxicological 
analyses should not be dispensable. The safety performance should guarantee the 
molecular and cellular behavior of nanoparticles in ocular tissues and in the systemic 
circulation. The development of in vitro cell culture models for studying ocular barriers 
undoubtedly provides a platform to investigate the impact of pharmaceutical trafficking on 
ophthalmic diseases (162).  
 
Throughout this thesis, it was expected to:  
Characterize, quantify and compare the antioxidant potential of Salvia officinalis and 
Satureja montana extracts and their major pure antioxidant compound: rosmarinic acid; 
Encapsulate antioxidant compounds into chitosan-based nanoparticles, optimize 
nanoparticulate systems after deep physical-chemical characterization;  
Evaluate the potential absence of cytotoxicity of the developed and optimized 
aforementioned nanoparticles; 
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Evaluate the mucoadhesion, permeability, and stability of rosmarinic acid into chitosan-
based nanoparticles on the ocular surface by in vitro cell cultures, human cornea (HCE-T) 
and retina pigment epithelium (ARPE-19) (162, 165); 
To study the actual effects of the antioxidant power in the elimination of free radicals and 
decreased vascularity in the retinal, as well as, to evaluate the toxicity, bioavailability and 
effectiveness (e.g. HCE-T and ARPE-19)  (162, 166, 167); 
Measure the neuroprotection effect of rosmarinic acid after intravitreal injection in an I-R 
animal model by monitoring retina morphology and biological parameters. 
 
Pharmacokinetics and toxicological relevance of nanoparticles were guaranteed by in vitro 
model systems to mimic as close as possible the biological conditions. The development 
of in vitro cell culture models (e.g. HCE-T and ARPE-19) for studying ocular barriers 
undoubtedly provided a platform to investigate the impact of pharmaceutical handling on 
ophthalmic diseases (162). Nevertheless a number of in vivo tests were required in order 
to validate the antioxidant biological potential; in this way the I-R animal model was 
chosen to monitor the rosmarinic acid therapeutical potential due to its intimate 
relationship with glaucoma, and other ocular diseases. Moreover the I-R model allows the 
control of the magnitude and duration of ischemia, as well as the duration of reperfusion, 
which are very important parameters concerning retinal ganglion cell death (169). Even 
though it does not directly track the exact pathophysiology that occurs in human 
glaucoma, but it induces a specific insult to retinal cells, which is fundamental for the study 
(169). 
The project casts light on the improved therapeutic utilization of the antioxidants loaded in 
novel, pharmaceutically acceptable nanoparticles. Therefore, useful knowledge for future 
adaptation is provided for pharmaceutical industry. The development of this project 
provided a further insight on ocular delivery, benefiting from the advantages of the eye for 
drug delivery and, additionally, offered new potential applications of chitosan as drug 
carrier and of natural antioxidants for ocular diseases prevention.  
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PART III  
 
 
“A journey of a thousand miles begins with a single step!” 
Confucius 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
46 
 
 
  
  
47 
 
Abstract 
 
Introduction: Salvia officinalis and Satureja montana (sage and savory, respectively) are 
plants used in traditional medicine. The quality control of their herbal formulations is of 
paramount concern to guarantee the expected biological activity of their antioxidant 
compounds. 
Objectives: To establish a simple and effective HPLC method to evaluate simultaneously 
quercetin and rosmarinic acid, in a pure form, in natural extracts (sage and savory), and 
encapsulated into chitosan-based nanoparticles (in the next sections).  
Methodology: Chromatography was performed on a RP C18 column, in a gradient mode 
with a mobile phase comprising methanol:formic acid:water 92.5:2.5:5 (v/v) at a flow rate 
of 0.75 mL/min and at detection wavelength of 280 nm.  
Results: The method was specific, linear in the range of 0.05-1.0 mg/mL (R2 = 1.00), 
precise at the intra-day and inter-day levels, accurate (recovery rate percentage of 90.5 ± 
0.6), and robust to changes in equipment conditions.  
Conclusion: The established method was effective for quercetin and rosmarinic acid 
characterization in natural extracts and in chitosan nanoparticles, allowing the loading 
capacity determination, the association efficiency as well as its in vitro release. 
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CHAPTER 3 - High-performance liquid 
chromatography method validation 
 
 
  
  
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
51 
 
3. Introduction 
 
During the last decade, scientific evidences have proved that plant phenolics are an 
important class of defense antioxidants. These compounds are virtually widespread in all 
plant foods, often at high levels, and include phenols, phenolic acids, flavonoids, tannins, 
and lignans (6). Sage and savory are plants used in traditional medicine, and grow in the 
poor soils of the Mediterranean basin (14). Besides application as condiments, sage and 
savory have been used in folk medicine for their anti-diarrheal, digestive, wound healing, 
anti-inflammatory, disinfectant, anti-hypertensive and sedative properties. Some of these 
activities have been associated with their high contents of rosmarinic acid and the 
presence of other relevant phenolic compounds such as, quercetin, rutin and rosmarinic 
acid (9, 14). Rosmarinic acid (α-O-caffeoyl-3,4-dihydroxyphenillactic acid) is a phenolic 
compound that has been claimed to provide protection against cancer (7), among other 
biological activities, namely astringent, anti-inflammatory, antimutagen, antibacterial and 
antiviral (7, 8). It is also an efficient natural antioxidant (9). Quercetin (3,3’,4’,5,7-
pentahydroxyflavone) is a major representative of the flavonol subclass (170). In its 
natural sources it exists mainly in the form of glycosides and can be found in vegetables, 
fruits, herbs, or red wine (151, 171). It has been demonstrated a variety of quercetin 
biological activities and pharmacological actions, such as dilating coronary arteries, 
decreasing blood lipid, anti-platelet aggregation, anti-cancer, antioxidant, anti-anemia, 
anti-inflammation, anti-anaphylaxis and hepatoprotective effects (151). Several studies 
have also reported that quercetin can inhibit the proliferation of multiple cancer cell types 
(lung, colon, prostate, pancreatic carcinoma cells) (171-173). Accurate identification and 
quantification in final formulations or plant extracts is essential to guarantee the expected 
biological activity. The aim of this study was to validate a HPLC method for simultaneous 
quantification of rosmarinic acid and quercetin in natural extracts and in polymeric 
nanoparticles to assess the content, the association efficiency, the in vitro release and 
permeability profile further evaluated in the next chapters.  
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3.1. Experimental 
 
3.1.1. Materials 
 
Two plants were selected as extract source namely sage and savory, both provided by 
ERVITAL (Castro Daire, Portugal), from a previous study involving 48 medicinal plants 
made by our research group (115). These plants had been cultivated as organic products, 
and were supplied in their commercial form of dried leaves: ca. 4 g was then crushed 
(using a coffee mill) for 1 min, so as to obtain the corresponding powder. A fraction (ca. 1 
g) was contacted, under uniform stirring, with 100 mL of boiling distilled water. After the 
powder deposition, samples were filtered, frozen at -80 ºC and lyophilized for further 
procedures (Heto Holten A/S Drywinner). Then solutions (1%) of lyophilized powder were 
prepared in methanol for chromatographic analyses. Before injections, samples were 
filtered through a 0.45 µm filter. Rosmarinic acid (96.5 w/w, HPLC), quercetin dehydrate 
(99.0% w/w, HPLC), methanol CHROMASOLV® (HPLC ≥ 99.9%) and formic acid (HPLC 
≥ 98.0%) were purchased from Sigma-Aldrich (Missouri, USA).  
 
3.1.2. Equipment and chromatographic conditions 
 
All HPLC runs were performed using a Waters Series 600 HPLC and results were 
acquired and processed with Empower® Software 2002 for data acquisition (Mildford MA, 
USA). HPLC analysis was conducted by using a Nova-Pack® RP C18 column (250 x 4.6 
mm i.d., 5 µm particle size and 125 Å pore size) from Waters. Chromatographic analysis 
was performed in gradient mode. The mobile phase consisted of methanol: formic 
acid:ultra-pure water in the ratio of 92.5:2.5:5 (v/v). Stationary phase was made with the 
same components in the ratio of 5:2.5:92.5, respectively. The phases were filtered 
through 0.22 µm filter and degassed. Eluent was pumped at a flow rate of 0.75 mL/min, 
the injection volume was 20 μL and detection wavelength was set to 280 nm. All 
experiments occurred at room temperature and the total area of peak was used to 
quantify the rosmarinic acid and quercetin compounds. The conditions were investigated 
to provide a simple procedure with the best peak resolution regarding symmetry and 
tailing, reduced run time and cost-effective analysis.  
  
53 
 
3.1.3. Preparation of standard and sample solutions 
 
Stock standard solutions of 2 mg/mL of rosmarinic acid and quercetin were prepared with 
methanol. The calibration curve was made from the dilution of stock solutions in methanol 
of seven standards: 0.05, 0.1, 0.2, 0.3, 0.5, 0.8 and 1.0 mg/mL. 
 
3.1.4. Method validation 
 
The HPLC method was validated according to the International Conference on 
Harmonization (ICH) guidelines (174), using the following analytical parameters: linearity, 
precision, accuracy, specificity, range, robustness, detection and quantification limits. 
Linearity was evaluated by calculation of a regression line using least squares method. 
Calibration curves were obtained from seven different concentrations analyzed three 
times. Precision was assessed by testing the repeatability of three different standard 
solutions ten times (intra-day) and by intermediate precision analyzing the same three 
standard solutions, three times on different days (inter-day). Accuracy was tested by 
percentage recovery of mean of three determinations of rosmarinic acid and quercetin at 
three different concentrations precisely prepared and by determination of the relative 
standard deviation (RSD). Specificity was determined by comparing rosmarinic acid and 
quercetin samples under different stress conditions that may common affect natural 
extracts and antioxidant activity as the temperatures of (60, 20 and 1 ºC) for 24 and 72 h. 
The solutions were also subjected to the effect of light and air in the same period of time. 
Range was derived from linearity, accuracy, and precision studies. Robustness was 
evaluated by testing the same chromatography conditions in different HPLC equipment 
(Merck-Hitachi Interface D-7000). Detection limit (DL) and quantification limit (QL) were 
determined based on the standard deviation of the response and on the slope of the 
calibration curve, using the following expressions: 
𝐷𝐿 =  
3.3𝜎
𝑆
 
𝑄𝐿 =
10𝜎
𝑆
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where σ is the standard deviation of the response and S is the slope of the calibration 
curve.  
 
3.1.5. Method applicability 
 
Applicability of the method was governed with the simultaneous determination of two 
antioxidant compounds with great impact on health. The determination could be made for 
each independent compound or combined, since the presence of both does not affect 
their quantification, also it could be made in natural extracts or even in the nanoparticulate 
systems. This HPLC method was also developed, optimized and validated for the best 
precise results regarding, rosmarinic acid association efficiency in chitosan-based 
nanoparticles, rosmarinic acid in vitro release from the aformentioned nanoparticles and it 
permeability profile in cell monolayers, assays developed and characterized in the next 
chapters.  
 
3.2. Results and discussion 
 
3.2.1. Application of the chromatographic method  
 
An HPLC method for the assessment of rosmarinic acid and quercetin has been 
proposed. Previous experiences were exploited to provide a simple procedure with the 
best chromatographic peak resolution, reduced run time and cost-effective analysis. All 
these factors contribute to the establishment of an analytical method which permits the 
analysis of a large series of samples. A typical chromatogram for the proposed method 
was depicted in Figure 3.1. The rosmarinic acid and quercetin peak retention time was 
48.9 ± 0.1 min (i) and 57.9 ± 0.6 min (ii), respectively. These retention times were not 
completely straight, but this method may also be useful for the identification and detection 
of other compounds in natural extracts, which were complexes matrixes with different 
compounds (latest retention time compound at 90 min). However, retention factor 
parameter (k’) was measured in order to evaluate the chromatographic performance 
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(175). This retention factor was often used to describe the migration rate of an analyte on 
a column. The retention factor for analyte A was defined as: 
𝐾′𝐴 =
𝑡𝑅 − 𝑡𝑀
𝑡𝑀
 
where retention time of the analyte (tR) and retention time of the eluent (tM) were easily 
obtained from the chromatogram. When the analytic retention factor was less than one, 
elution was so fast that accurate determination of the retention time was very difficult. 
High retention factors (greater than twenty) mean that elution takes a very long time. 
Ideally, the retention factor for an analyte was between two and ten (175). The retention 
factors of both compounds were 0.918 and 0.930, for rosmarinic acid and quercetin, 
respectively. Both compound parameters were in the optimal range (k’ < 10), which 
means that the migration rate of the analytes were adequate and so was the method. A 
good experimental design is crucial, and this seems particular important in herbal 
medicines in order to obtain an optimal separation, since these natural matrixes may 
entail hundreds of natural compounds (176). 
 
3.2.2. Linearity 
 
Linearity was studied in the concentration range of 0.05-1.0 mg/mL by visual inspection of 
a calibration curve plotting (n = 21) and by calculating the regression equation and the 
correlation coefficient (R2) by the method of least squares. A primary stock solution was 
accurately prepared followed by rigorous dilution to give secondary standard solutions. 
Each sample was analyzed three times. A good linearity was obtained in the range of 
study. The calibration curve for rosmarinic acid was: 
𝐴 = 5.44 × 107 (±2.66 ×  105 )  × 𝐶 − 6.21 × 105 (±1.43 × 105)(𝑛 = 21) 𝑅2 = 1.00 
and the calibration curve for quercetin was: 
𝐴 = 4.48 × 107 (±2.73 ×  105 )  × 𝐶 − 9.75 × 105 (±1.47 × 105)(𝑛 = 21) 𝑅2 = 1.00 
where A is the peak area, C is the standard solution concentration in mg/mL, and 
standard deviation values for A and C are indicated in brackets. The R2 obtained was 
higher than 0.999 as frequently recommended (177), indicating a good linearity in the 
proposed range.  
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3.2.3. Precision 
 
Precision may be considered at three levels: repeatability, intermediate precision and 
reproducibility (174). The precision of an analytical procedure is usually expressed as the 
variance, standard deviation or coefficient of variation of a series of measurements. 
Repeatability was termed intra-day and expresses the precision under the same operating 
conditions over a short interval of time. Intermediate precision expresses within-
laboratories variations like different days, different analysts or different equipment. 
Reproducibility expresses the precision between laboratories (standardization of 
methodology) (174). For this validated method the relative standard variation for system 
repeatability and analysis repeatability was ≤ 1.476 and ≤ 1.456%, respectively since RSD 
≤ 2%. Such results indicate that the proposed method presents good precision (Table 3.1) 
(178). 
 
Table 3. 1. Results of precision tests for the determination of rosmarinic acid and 
quercetin in standard solutions. 
Standard solution (mg/mL) Day 
Measured 
concentration 
SD (%) RSD (%) 
System repeatability 
(n = 10)      
Rosmarinic acid 
0.800 0 0.776 0.183 0.235 
 
5 0.776 
  
 
10 0.779 
  
0.400 0 0.405 0.030 1.097 
 
5 0.404 
  
 
10 0.404 
  
0.200 0 0.169 0.065 1.476 
 
5 0.168 
  
 
10 0.168 
  
Quercetin 
0.800 0 0.735 0.444 0.602 
 
5 0.733 
  
 
10 0.741 
  
0.400 0 0.408 0.248 0.610 
 
5 0.409 
  
 
10 0.404 
  
0.200 0 0.213 0.176 0.835 
 
5 0.209 
  
 
10 0.210 
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System repeatability 
(n = 3)      
Rosmarinic acid 
0.800 0 0.775 0.415 0.533 
 
5 0.782 
  
 
10 0.776 
  
0.400 0 0.389 0.394 1.003 
 
5 0.393 
  
 
10 0.397 
  
0.200 0 0.166 0.244 1.456 
 
5 0.165 
  
 
10 0.170 
  
Quercetin 
0.800 0 0.807 0.320 0.398 
 
5 0.804 
  
 
10 0.801 
  
0.400 0 0.406 0.389 0.950 
 
5 0.409 
  
 
10 0.413 
  
0.200 0 0.207 0.059 0.352 
 
5 0.208 
  
 
10 0.207 
  
System repeatability 
(n = 3)      
Rosmarinic acid 
0.800 0 0.776 0.882 1.128 
 
5 0.778 
  
 
10 0.792 
  
0.400 0 0.405 0.030 0.075 
 
5 0.404 
  
 
10 0.404 
  
0.200 0 0.212 0.578 2.813 
 
5 0.203 
  
 
10 0.201 
  
Quercetin 
0.800 0 0.821 0.968 1.195 
 
5 0.809 
  
 
10 0.802 
  
0.400 0 0.408 0.248 0.610 
 
5 0.409 
  
 
10 0.404 
  
0.200 0 0.206 0.407 1.983 
 
5 0.209 
  
 
10 0.201 
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3.2.4. Accuracy 
 
Three standard solutions (0.05, 0.30 and 0.50 mg/mL) were carefully prepared in triplicate 
and analyzed by the proposed method. The overall recovery percentage was found to be 
90.5 ± 0.6, thus showing strong agreement between experimental and theoretical values. 
Detailed results for the three tested concentration levels were presented in Table 3.2. 
 
Table 3. 2. Accuracy results for different levels of rosmarinic acid and quercetin in 
standard solutions. 
Standard solution  (mg/mL) Recovery (%) RSD (%) 
System repeatability 
(n = 3)    
Rosmarinic acid 0.05 87.06 0.16 
 
0.30 90.76 0.87 
 
0.50 91.98 1.16 
Quercetin 0.05 89.02 0.92 
 
0.30 95.21 0.38 
 
0.50 98.70 0.06 
 
  
3.2.5. Specificity 
 
Specificity of method was verified by analyzing four stress conditions (temperature, UV 
light, pH and oxidation), in accordance with other publish works (175), in order to detect 
the occurrence of possible interfering peaks at 280 nm, resulting from the degradation of 
antioxidants. The stress conditions were the most compromising of antioxidant activity 
were for that helpful tools in establishing degradation pathways and also help validating 
the power of the proposed method for studying the stability of the compounds (175). It 
was tested the effect of solutions of rosmarinic acid and quercetin in methanol for the 
temperatures of (60, 20 and 1 ºC) for 24 and 72 h. The solutions were also subjected to 
the effect of light and air in the same period of time. Overall, obtained data provides 
evidence that the method can be regarded as specific, since no potential interfering peak 
was observed in the antioxidants retention times and the recovery percentage for stress 
condition was 76.0 ± 1.4%. The compounds used as matrix for encapsulation (chitosan 
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and TPP), could also be seen as interfering. However, the method, once more, 
demonstrates to be specific for the presence of these compounds, since no potential 
interfering peak was observed in the antioxidants retention times in the association 
efficiency tests. 
 
3.2.6. Range 
 
The method working range was defined as to fulfill the required versatility, proving to be 
linear, accurate and precise between 0.05 and 1.0 mg/mL. Therefore, samples presenting 
these concentration levels may be suitably assayed by the proposed HPLC method. 
 
3.2.7. Robustness 
 
A method is said to be robust when these alterations produce no significant changes in 
obtained results. The robustness of this HPLC method was verified by the experimental 
under the same conditions in totally different equipment (Merck-Hitachi Interface D-7000). 
This was a robust method since no significant changes were observed in recovery 
percentage and in the retention time of the compounds. 
 
3.2.8. Detection limit and quantitation limit 
 
Several alternatives were described to determine DL and QL (177). In the present work, 
these parameters were established from the SD of the response and the slope of the 
calibration curve. Values of SD were calculated from standard deviation of the free terms 
taken from regression equations of calibration curves obtained using reference samples in 
the region of DL. DL and QL were found to be 0.02 and 0.08 mg/mL for rosmarinic acid, 
respectively. For quercetin were found to be 0.03 and 0.09 mg/mL for DL and QL, 
respectively.  
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3.2.9. Method applicability 
 
The developed method was applied to ensure the analytical identification, quantification 
and limit control in both, savory and sage extracts, as well as their antioxidant association 
efficiency and in vitro release from chitosan-based nanoparticles in the next chapters. The 
peaks of rosmarinic acid and quercetin has a retention time of 48.9 ± 0.1 and 57.9 ± 0.6 
min, respectively, and for the present study the quantification of both antioxidants were 
clear and easily performed (Figure 3.1). For natural extracts quantification of the both 
antioxidants, three independent experiments were made, with different lyophilized powder 
dissolved in methanol, in a concentration of 10 mg/mL and in triplicate injections. Savory 
was founded to contain rosmarinic acid and quercetin in a concentration of 0.52 ± 0.02 
mg/mL and 0.50 ± 0.04 mg/mL, respectively and sage has only rosmarinic acid, in a 
concentration of 1.10 ± 0.09 mg/mL. The method can be extended to other applications, 
namely, dissolution testing, drug products or different drug release from nanoparticulate 
systems, testing for impurities or interferences and to analyze changes in the synthesis of 
the drug substance, in the composition of the finished product and in the analytical 
procedure.  
 
Figure 3. 1. Representative chromatogram of: (i). rosmarinic acid (retention time: 48.9 ± 
0.1 min) and (ii). quercetin (retention time: 57.9 ± 0.6 min); (a). in standard solutions; (b). 
in sage extracts; (c). and savory extracts. 
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3.3. Conclusion 
 
In summary, this was the first study to describe a validated HPLC method with UV 
detection for rosmarinic acid and quercetin determination according to ICH guidelines, in 
natural extracts and in nanoparticulate systems. All parameters were within the limits 
proposed by those guidelines for pharmaceutical formulations, indicating that this method 
was specific, precise, accurate and robust with low detection and quantification limits. 
Furthermore, suitable application for rosmarinic acid in vitro analysis was assumed during 
formulation development and characterization. The proposed method was used to predict 
the association efficiency and the release profile of rosmarinic acid from chitosan-based 
nanoparticles containing sage and savory extracts in the further chapters. Rosmarinic acid 
and extracts entrapment occurs essentially by reversible ionic interactions, which permits 
an absence of interaction of polymers on compound determination in the different steps of 
formulation development. 
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PART IV 
 
 
“Science is a way of thinking much more than it’s a body of knowledge” 
Carl Sagan 
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Abstract  
 
Introduction: Nanotechnology can be applied to deliver and protect antioxidants in order to 
control the OS phenomena in several chronic pathologies. Chitosan nanoparticles are 
biodegradable carriers that may protect antioxidants with potent biological activity such as 
rosmarinic acid in Salvia officinalis (sage) and Satureja montana (savory) extracts for safe 
and innovative therapies.  
Objective: Development, optimization and characterization of chitosan-based 
nanoparticles as stable and protective vehicle to deliver rosmarinic acid for medical 
applications using natural extracts as sage and savory.  
Methodology: Antioxidant-chitosan based nanoparticles were prepared by ionic gelation 
with sodium tripolyphosphate (TPP), at pH 5.8 with mass ratio of 7:1 (chitosan:TPP), with 
a theoretical antioxidant-chitosan loading of 40 to 50%. The size and shape of 
nanoparticles were then characterized by different methods such as: photon correlation 
spectroscopy, laser Doppler anemometry, scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM). Chemical interactions between antioxidants and 
chitosan were assessed by differential scanning calorimetry (DSC) and Fourier-transform 
infrared (FTIR). HPLC allowed the association efficiency and in vitro released 
measurements. Antioxidant activity was evaluated by 2,2-azinobis (3-
ethylbenzothiazoline-6-sulphonic) (ABTS) and oxygen radical absorbance capacity 
(ORAC) methods before and after lyophilization to assure that antioxidant activity was not 
compromised after the dried process. 
Results: Small sizing nanoparticles, around 300 nm, were obtained. SEM and TEM 
confirmed smooth and spherical nanoparticles. No chemical interactions were found 
between antioxidants and chitosan, after encapsulation, by DSC and FTIR. The 
association efficiency was 51.2% for rosmarinic acid (with 40% loading), 96.1 and 98.2%, 
for sage and savory nanoparticles, respectively (both with 50% loading). The best 
antioxidant activity results were obtained after nanoparticles lyophilization and by ORAC 
method, the values for rosmarinic acid, sage and savory nanoparticles were: 3.6520 ± 
0.1770, 0.4251 ± 0.0069 and 0.4526 ± 0.0087 µmol/eq Trolox, respectively. 
Conclusion: The extracts under study were promising vehicles for rosmarinic acid drug 
delivery in chitosan nanocarriers.  
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CHAPTER 4 - Development, optimization and 
physical-chemical characterization of chitosan-
based nanoparticles 
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4. Introduction 
 
Sage and savory, are plants often used in traditional medicine to improve digestion  (179), 
as disinfectant (180), to decrease blood pressure (7), to prevent premature ejaculation 
(181), to treat neuropathy (182), urinary and pulmonary infections (183), and other 
diseases such as Alzheimer’s disease (184) and cancer (183). Some of these biological 
activities have been associated with its high contents in rosmarinic acid (9, 179, 185). 
Rosmarinic acid, (a-O-caffeoyl-3,4-dihydroxyphenillactic acid), is a phenolic compound 
generally admitted as a free radical scavenger (125). Besides its huge antioxidant activity 
rosmarinic acid can have many beneficial functionalities like antibacterial and antiviral 
activity,  anti-inflammatory activity (127), anti-mutagenicity character (128), capability to 
reduce atopic dermatitis symptoms (129), prevention of Alzheimer’s disease (130) and 
apoptosis induction of colorectal cancer cells (131). Nevertheless, besides the poor 
absorption that constrain the transport across biological barriers, most of the natural 
antioxidants or other active compounds are unstable and must be protected from 
degradation in the physiological environment (186). Thus, the efficacy of these drugs 
clearly depends on the design of appropriate carriers for their delivery, protection and 
release (1). Among the different approaches explored so far, colloidal carriers have 
particular interest, especially those made of mucoadhesive polymers to assure drug time 
retention at the absorption site (2). For this application, chitosan has become of 
particularly interesting for the association and delivery of labile macromolecular 
compounds, due to its exceptional potential for drug delivery, especially for mucosal, 
control drug release and protect against adverse conditions like mucosal enzymes and 
biological protective fluids (187). The smart symbiosis of these chitosan nanoparticles with 
a high potent antioxidant could be a hope for future therapies, considering the important 
effect of OS in several chronic pathologies. In this study chitosan nanoparticles were 
used, to incorporate natural extracts of sage and savory as a stable and protective vehicle 
to deliver rosmarinic acid for medical applications. There were no reports in the literature 
that have demonstrated the good performance of chitosan nanoparticles to incorporate 
these extracts in order to bring the huge benefits of rosmarinic acid antioxidant, as well as, 
other compounds that may act synergistically. 
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4.1. Experimental 
 
4.1.1. Materials 
 
The two selected plants sage and savory were provided by ERVITAL (Castro Daire, 
Portugal). The plants had been cultivated as organic products, and were supplied in their 
commercial form of dried leaves. The dried leaves were then kept in the dark at 20 ºC. 
Rosmarinic acid (purity 96.5%), methanol CHROMASOLV® (HPLC ≥ 99.9%) and formic 
acid (HPLC ≥ 98.0%) were purchased from Sigma-Aldrich (Missouri, USA). Chitosan low 
molecular weight and sodium tripolyphosphate (TPP) were also purchased from Sigma-
Aldrich (Lisbon, Portugal). The degree of deacetylation for the low molecular weight 
(LMW) chitosan was 85%, with a purity grade of 85%. Pure acetic acid was purchased 
from Pornalab (Lisbon, Portugal). Sodium hydroxide (NaOH) and hydrochloric acid (HCl) 
were from Merck (Darmstadt, Germany). Ultra-pure water was obtained in the laboratory 
using a MilliporeTM water purification equipment (Massachusetts, USA).  
 
4.1.2. Preparation of chitosan-based nanoparticles 
 
Optimized conditions to obtain chitosan nanoparticles were based on previously studies 
(188), and was schematically described in Figure 4.1. The chitosan nanoparticles were 
obtained by inducing the gelation of a chitosan solution with TPP. Chitosan was dissolved 
in acetic acid aqueous solutions at various chitosan concentrations: 0.05, 0.5, 1, 2, 3 and 
5% (w/v), the pH value was adjusted to 5.8 with 1M NaOH. The concentration of acetic 
acid was, in all cases, 1.75 higher than chitosan. Then, TPP was dissolved in purified 
water at 0.05, 0.1, 0.2, 0.5, 1 and 2% (w/v). For the study of the best ratio chitosan:TPP, a 
volume of the TPP solution of 2 was added to 5 mL of the chitosan solution under 
magnetic stirring at room temperature, thus achieving a final concentration of 2 mg/mL 
and 0.28 mg/mL of chitosan and TPP respectively (7:1). Stock solution of chitosan (1%) 
and TPP (0.1%) were maintained at 4 ºC for a period of 1 month. 
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Figure 4. 1. Schematic illustration of ionic gelation process of antioxidant-chitosan based 
nanoparticles. 
 
4.1.3. Encapsulation of sage, savory and rosmarinic acid into chitosan-based 
nanoparticles 
 
The addition of 1% extracts aqueous solution and a 1% of aqueous rosmarinic acid 
solution was added to chitosan previously dissolved in acetic acid at a pH value adjusted 
to 5.8, in different volumes in order to guarantee the best concentration ratio between 
chitosan and the different compounds. The encapsulation of rosmarinic acid, sage and 
savory were tested in different theoretical loadings (5, 10, 15, 20, 30, 40 and 50%) fairly to 
the initial concentration of chitosan (2 mg/mL). All the tests were made for the 7 batches, 
considering the two plants and the antioxidant pure. Some of the final batches were then 
lyophilized (Heto Holten A/S Drywinner) and maintained at -20 ºC for 1-2 months for 
further analysis.  
 
4.1.4. Size and surface charge 
 
Size and polydispersity (size distribution) of freshly loaded nanoparticles were determined 
by photon correlation spectroscopy using ZetaPALS (Brookheaven, New York, USA). A 
sample of 1.6 mL was gently homogenized, placed into analyzer chamber and measured. 
Collective 6 readings were performed three times on a sample of particles at 25 ºC with a 
detection angle of 90º. The zeta potential was determined by laser Doppler anemometry, 
Rosmarinic 
acid/ 
Sage/Savory 
TPP Chitosan Antioxidant-
chitosan based 
nanoparticles 
stirring 
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at 25 ºC. Triplicate samples were also analyzed, each sample being measured 6 times, 
and the arithmetic mean was adopted. 
 
4.1.5. Morphology 
 
In order to characterize the nanoparticles morphology and confirm their size distribution, 
nanoparticles were also observed by transmission electron microscopy (TEM, Joel JEM 
1400) using an acceleration voltage of 120 kV. For sample preparation, fresh 
nanoparticles were diluted in MilliQ-water, placed on copper coated grids, and contrasted 
with uranyl acetate. In each step, the excess of water was removed using a filter paper, 
and finally, grids were left at room temperature for a few minutes to dry before the 
imaging. Lyophilized nanoparticles morphology such as shape and occurrence of 
aggregation phenomena was studied by scanning electron microscopy (SEM). Samples of 
nanoparticles were mounted on metal stubs, gold coated under vacuum and then 
examined on a JEOL-5600 Lv microscope (Japan). SEM was operated at the low vacuum 
mode, using a spot size of 27-28 and a potential of 30 kV. All analyses were performed at 
room temperature (20 ºC). 
  
4.1.6. Association efficiency 
 
Association efficiency (AE) was evaluated considering the amount of rosmarinic acid 
associated with the particles. For this purpose the particles were centrifuged (20.000 × 
g/45 min) and suspended in 7 mL of ultra-pure water. The AE was then calculated by the 
difference between the total rosmarinic acid used to prepare the particles, and the amount 
of residual rosmarinic acid in the supernatant. AE of rosmarinic acid in rosmarinic acid 
nanoparticles sage and savory nanoparticles were obtained according to the following 
equation:  
𝐴𝐸% =
Total amount of rosmarinic acid −  Free amount of rosmarinic acid in supernatant 
Total amount of rosmarinic acid
× 100 
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4.1.7. In vitro release of rosmarinic acid from chitosan nanoparticles 
 
The release of rosmarinic acid from chitosan nanoparticles was tracked to predict the 
diffusion and kinetic behavior of the nanosystems in simulated physiological conditions. 
The osmolarity was correct to these release tests, to better simulate the topical ocular 
administration and to study the release profile of rosmarinic acid from chitosan-based 
nanoparticles in biological settings. The loaded nanoparticles obtained after centrifugation 
were suspended in 10 mL of a phosphate-buffered saline (PBS) solution, pH 7.4 to also 
best simulate tear physiological conditions. The PBS ionic strength was 0.075 M which is 
in the optimal range (e.g. 0.025 to 0.15 M) for physiological environment proof-of-concept 
testing and characterization (189). Osmolarity of nanoparticles dispersions in PBS, was 
determined at room temperature using a Micro-Osmometer Type 15 (Löser Messtechnik, 
Berlin, Germany). Plastic eppendorfs containing 200 µL of nanoparticles dispersions were 
placed in the osmometer and osmolarity values read directly from the equipment. 
Osmolarity was adjusted 300 mOsm / L, which is the tear film normal osmolarity, with 
NaCl solution (Merck - Darmstadt, Germany). The nanoparticle suspension was 
transferred to clean eppendorfs and placed in a water bath at 37 °C under stirring, to fake 
the blinking process. After 0.5, 1 and 2 h, samples were collected from the bath and 
centrifuged at 14.000 rpm for 5 min (BOECO, Hamburg, Germany). Supernatants were 
analyzed by HPLC and used to calculate the amount of rosmarinic acid released from the 
nanoparticles over the specified time. Triplicate samples were analyzed at each time. It 
must be highlighted regarging this in vitro assays and taking into account the ionic nature 
of the particles that it would be expected a rapid release of rosmarinic acid, and thus the 
trial was designed for last only 1 h. However, due to the nanoparticles trapped proprieties 
it would not be predictable such a rapid release profile, so more sampling times could be 
considered (preferably before 15 min). Nonetheless, this test was planned to best 
simulate the physiological ocular conditions and to study the consequente chitosan-based 
nanoparticles behavior over a spaced period of time.  
 
4.1.8. High performance liquid chromatography analysis and rosmarinic acid 
quantification 
 
Chromatographic analysis were performed as previously described (190), using the 
Waters Series 600 HPLC and results acquired and processed with Empower® Software 
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2002 for data acquisition (Mildford MA, USA), on a Nova-Pack® RP C18 column (250 x 
4.6 mm i.d., 5 µm particle size and 125 Å pore size) from Waters, in a gradient mode with 
a mobile phase comprising methanol:formic acid:water 92.5:2.5:5 (v/v) at a flow rate of 
0.75 mL/min. The injection volume was 20 μL and detection wavelength was 280 nm. For 
analysis and quantification of rosmarinic acid content in the extracts, stock standard 
solutions of 2 mg/mL of rosmarinic acid were prepared with methanol. The calibration 
curve was made from the dilution of stock solutions in methanol of seven standard (0.05; 
0.1; 0.2; 0.3; 0.5; 0.8; 1.0) mg/mL. The HPLC method was validated in chapter 3, 
according to the International Conference on Harmonization (ICH) guidelines (174). 
 
4.1.9. Differential scanning calorimetry analysis 
 
Thermograms were obtained using a DSC (DSC-60, Shimadzu, Columbia, USA). 
Samples were lyophilized, and 2.0 mg of the lyophilized powder were crimped in a 
standard aluminum pan and heated from 20 to 350 ºC at a heating constant rate of 10 
ºC/min under constant purging of nitrogen at 20 mL/min. All samples were run in triplicate 
and data presented were the average of the three measurements. 
 
4.1.10. Fourier-transform infrared analysis 
 
Infrared spectroscopy analysis were performed in a ABB MB3000 FTIR spectrometer 
(ABB, Switzerland) equipped with a horizontal attenuated total reflectance (ATR) sampling 
accessory (PIKE Technologies, USA), the Horizon MBTM FTIR software and a 
diamond/ZnSe crystal. All spectra were acquired using 200 scans and a 4 cm-1 resolution 
in the region of 4000-700 cm-1. In order to perform the spectra comparison, spectra were 
truncated at 1800 and 700 cm-1, since this region displays typical absorption bands for the 
used compounds. In addition, baseline - point adjustment and spectra normalization was 
performed. All samples used were previously lyophilized and run in triplicate, and the data 
presented were the average of the three measurements. 
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4.1.11. Statistical analysis 
 
Statistical analysis was performed using IBM SPSS Statistics v 19.0.0 (Illinois, USA). The 
one-way analysis of variance (ANOVA) was used with Scheffé post hoc test comparison 
of groups with normal distribution, and Mann-Whitney test for groups with non-normal 
distribution. Differences were considered to be significant at a level of P < 0.05. 
 
4.2. Results and discussion 
 
4.2.1. Particle size, polydispersity and zeta potential  
 
Particle size and size distribution are important parameters towards development of 
suitable nanomedicines for therapeutic purposes, they influence in vivo distribution, 
biological fate, toxicity and the targeting ability of nanoparticle systems (191). In addition, 
they can also influence the drug loading, drug release and stability of drug inside 
nanoparticles (192). Considering the nanoparticles charge it is known that the highest 
value of zeta potential represents the greater electrostatic repulsive interactions among 
the particles, the stability will increase as well as the size distribution will be more 
homogenous. Zeta potential values of ± 30 mV indicates that the colloidal system are 
stable in time and that amino groups of chitosan are on the surface, which was also 
documented in some similar studies of antioxidants encapsulation in chitosan 
nanoparticles (193). The loaded nanoparticles under study, ranging from 200-300 nm, and 
with zeta potential from 20-30 (Table 4.1) showed no significant differences (P > 0.05) 
between the different theoretical loadings for each formulation and between the two crude 
extracts, which was in accordance with previously reports (190). Rosmarinic acid-
nanoparticles at 50% theoretical loading were the only exception, since their higher size 
(1218.0 ± 136.2 nm) was not in the range of nanoscale, and as consequence not 
considered for the following tests. The extracts do not seem to interfere in the size or zeta 
potential of the nanoparticles being a good vehicle for rosmarinic acid incorporation. The 
obtained nanoparticles also showed values of polydispersity between 0.1 and 0.2 (Table 
4.1) corresponding to a narrow particle size distribution, and to monodispersed particles. 
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These results similar with other research works using similar antioxidant nanoparticles 
(194). 
 
Table 4. 1. Average hydrodynamic diameter (Z), polydispersity index (PdI), zeta potential 
and the association efficiency considering the different loading (%) of rosmarinic acid, 
sage and savory nanoparticles (n = 3). 
Nano 
Loading  
Z-average  PdI Zeta potential  
Free 
amount 
Total 
amount  AE (%) 
(%) (nm) (mV) (µg/mL) (µg/mL) 
R
o
s
m
a
ri
n
ic
 a
c
id
 
5 230.0 ± 48.8 a 0.155 ± 0.043 23.9 ± 5.5 b 56.6 ± 3.6 100 43.4 ± 3.5 c 
10 242.4 ± 112.3 a 0.215 ± 0.126 18.7 ± 2.3 b 94.8 ± 6.1 200 52.6 ± 3.1 c 
15 229.5 ± 40.1 a 0.142 ± 0.076 29.9 ± 9.9 b 147.9 ± 54.8 300 50.7 ± 18.3 c 
20 231.1 ± 68.3 a 0.149 ± 0.044 32.7 ± 6.4 b 186.4 ± 52.0 400 53.4 ± 2.0 c 
30 261.8 ± 50.4 a 0.171 ± 0.027 34.5 ± 4.5 b 306.0 ± 39.2 600 49.0 ± 6.5 c 
40 244.0 ± 18.0 a 0.193 ± 0.062 29.5 ± 1.6 b 390.4 ± 41.0 800 51.2 ± 3.0 c 
50 1218.0 ± 136.2 a 0.294 ± 0.132 35.0 ± 7.9 b 422.0 ± 65.0 1000 57.8 ± 1.3 c 
S
a
g
e
 
5 330.9 ± 78.9 a 0.137 ± 0.012 20.8 ± 0.6 b 15.1 ± 0.4 100 84.9 ± 0.4 d 
10 224.3 ± 82.1 a 0.182 ± 0.061 24.3 ± 0.2 b 17.6 ± 0.6 200 91.2 ± 0.3 d 
15 200.0 ± 15.3 a 0.145 ± 0.018 21.4 ± 1.1 b 22.5 ± 1.1 300 92.5 ± 0.4 d 
20 243.0 ± 66.2 a 0.170 ± 0.123 21.7 ± 0.1 b 26.0 ± 4.0 400 93.5 ± 1.0 d 
30 271.5 ± 22.3 a 0.180 ± 0.056 27.8 ± 0.6 b 29.4 ± 3.0 600 95.1 ± 0.5 d 
40 272.9 ± 58.1 a 0.254 ± 0.099 25.1 ± 0.0 b 39.2 ± 2.1 800 95.1 ± 0.3 d 
50 278.4 ± 42.2 a 0.268 ± 0.092 24.9 ± 0.1 b 39.0 ± 2.6 1000 96.1 ± 0.2 d 
S
a
v
o
ry
 
5 233.1 ± 40.8 a 0.171 ± 0.083 23.8 ± 1.5 b 11.9 ± 0.0 100 88.1 ± 0.0 d 
10 230.7 ± 21.2 a 0.136 ± 0.094 27.8 ± 4.2 b 12.0 ± 0.1 200 94.0 ± 0.1 d 
15 182.7 ± 24.1 a 0.087 ± 0.075 28.0 ± 5.8 b 12.6 ± 0.1 300 95.8 ± 0.0 d 
20 220.8 ± 52.7 a 0.092 ± 0.024 26.7 ± 1.3 b 13.2 ± 0.2 400 96.7 ± 0.0 d 
30 188.0 ± 50.6 a 0.098 ± 0.006 28.9 ± 4.5 b 14.4 ± 0.6 600 97.6 ± 0.1 d 
40 139.4 ± 16.2 a 0.135 ± 0.088 28.4 ± 1.6 b 15.2 ± 0.4 800 98.1 ± 1.1 d 
50 229.3 ± 29.6 a 0.149 ± 0.121 26.5 ± 3.5 b 18.0 ± 0.2 1000 98.2 ± 0.1 d 
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4.2.2. Morphology 
 
TEM images can directly provide information on the particle size and morphology, also 
allowing an easy confirmation of photon correlation spectroscopy measurements. The 
micrograph - Figure 4.2 (a, b and c), showed TEM images of rosmarinic acid, sage and 
savory nanoparticles respectively (prepared freshly). The microstructural analysis 
confirmed a mono-disperse population of isolated, smooth and spherical particles with 
well-defined sizes, which were at all times lower than 500 nm, corroborating the previously 
obtained results of chitosan nanoparticles characterization. Moreover, in the micrograph it 
can be also observed a black ‘corona’ type of structure surrounding the nanoparticle 
surface which may indicate the presence of rosmarinic acid either adsorbed or covalently 
linked to the surface of the nanoparticle. Thus it is possible that at this pH rosmarinic acid 
may be partially adsorbed or covalently linked to the surface of the nanoparticle, and not 
completely incorporated into chitosan polymeric network. The effect of pH in chitosan ionic 
nanoparticles incorporation of iron oxide was reported to be crucial to its encapsulation or 
partial adsorption (195).  
 
 
Figure 4. 2. TEM micrographs of fresh chitosan-based nanoparticles loaded: (a). 
commercial rosmarinic acid; (b). sage; and (c). savory. 
 
The size and morphology results were aligned with SEM analyze (Figure 4.3) for the same 
nanoparticles (196). In this study SEM images were analyzed to prove that the size was 
500nm 500nm 500nm 
(a) (b) (c) 
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maintained after freeze dried (dehydration process). In the SEM analysis the particles 
after lyophilization also confirmed smooth and spherical shape with size below 500 nm, 
even with some aggregation due to the dry process (196). It can be therefore affirmed that 
rosmarinic acid and extracts encapsulation (either fresh or lyophilized), did not 
considerably affect particle shape and overall size as it was described above. Figure 4.3 
shows the SEM images of lyophilized chitosan nanoparticles prepared by ionic gelation 
under the same pH conditions, for the encapsulation of rosmarinic acid in a pure form, 
sage and savory. The lyophilized samples even with some aggregation of the 
nanoparticles formed by dispersion during freeze drying guarantee the nanoscale particles 
with the diameters, which was in accordance with other previous studies (197). The 
microstructural analysis confirmed the morphology and size of the nanoparticles. Other 
studies reported an increase in the particle size after lyophilization with the unmodified 
chitosan particles (198). This was resulted from aggregation from the strong inter- and 
intra-molecular hydrogen bonding, which was not possible to breakdown even by vortex 
homogenization (198). This particles size increase after lyophilization process was also 
reported in essentials oils encapsulation (197). 
 
 
 
 
 
 
 
 
 
 
Figure 4. 3. SEM micrographs of lyophilized chitosan-based nanoparticles loaded: (a). 
commercial rosmarinic acid; (b). sage; and (c). savory. 
 
1µm 1µm 1µm 
1µm 1µm 1µm 
(a) (b) (c) 
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4.2.3. Association efficiency and drug loading 
 
It is known that chitosan in acidic media (pKa 6.5) can interact with the negatively charged 
TPP, forming inter- and intra-molecular cross-linkages, yielding ionically crosslinked 
chitosan nanoparticles (36). This is a spontaneous method for smaller nanoparticles 
formation with positive charge, without using any organic solvent or surfactants (198). It is 
also known that the inter- and intra-molecular linkages created between TPP and the 
positively charged amino groups of chitosan are responsible for the success of the 
gelation process (188). In the present study it was described a nanoparticulate system 
able to encapsulate natural extracts. The particle size was observed to be dependent on 
both chitosan and TPP concentrations as described in previously studies (188), being the 
minimum sizes obtained for the lowest chitosan and TPP concentrations. Further 
experiments were conducted using the mass ratio chitosan:TPP of (7:1), where TPP final 
concentration was 0.28 mg/mL and chitosan final concentration was 2 mg/mL. Rosmarinic 
acid was selected as a model antioxidant in order to investigate the feasibility of using 
chitosan and chitosan nanoparticles for natural extract carriers. Association efficiency and 
theoretical antioxidant loading of these nanoparticles were displayed in Table 4.2.  
The pH of the nanoparticles formation medium was between 5.8 and 6.0, a pH value that 
favors the interaction of rosmarinic acid and chitosan, thus reaching a maximum leading 
to the entrapment of high amounts of rosmarinic acid. Among the different samples 
considering the encapsulation of rosmarinic acid into chitosan nanoparticles, it was 
observed similar association efficiency around 50% (Table 4.2), for all the different 
loadings no significant differences were observed (P > 0.05). Higher association efficiency 
was found for rosmarinic acid entrapment in extracts of sage and savory, 96 and 98% 
respectively with no significant differences observed (P > 0.05). This was in accordance 
with previous reports (190).The higher association efficiency in extracts nanoparticles may 
be due to the different amount of rosmarinic acid in chitosan nanoparticles and inside the 
extracts in chitosan nanoparticles (Table 4.2). Since competitive interaction may be 
happen between phenolic (OH−) of rosmarinic acid and (P3O10
5−) groups of TPP for 
protonated amino groups of chitosan resulting in low levels of particle formation compared 
to the chitosan nanoparticles, this may be intensified with the highest amount of 
rosmarinic acid and phenolic groups (198). This was in accordance with other studies that 
encapsulate other phenolic compound, such as cathechin, in chitosan nanoparticles (198) 
and in other nanoparticles (199).  
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Table 4. 2. Association efficiency, theoretical loading, and final rosmarinic acid content in 
chitosan nanoparticles. 
Nano 
AE 
 (%) 
Theoretical 
Loading 
(%) 
Final content 
in the chitosan 
nanoparticles 
(µg/mL) 
Final rosmarinic 
acid content 
in chitosan 
nanoparticles 
(mg/mL) 
Rosmarinic acid 51.2 ± 3.0 40 800 400 
Sage 96.1 ± 0.2 50 1000 100 
Savory 98.2 ± 0.1 50 1000 50 
 
The association efficiency values were higher than the results for Ilex paraguariensis 
entrapment in calcium alginate nanoparticles coated with chitosan, (around 50%) since 
active compound was lost during immersion in chitosan (200). The good results for sage 
and savory association efficiency may be due to the huge affinity of chitosan and this two 
crude extracts. The results were also higher than a study reported for quercitrin 
encapsulation into nanoparticles, which was only 40% (152). However the high 
association efficiency reported in this study, was in accordance to other previously studies 
with the encapsulation of natural antioxidants extracted from Ilex paraguariensis into 
chitosan nanoparticles (193) and for the encapsulation antioxidant idebenone-loaded into 
chitosan nanoparticles (201).  
 
4.2.4. In vitro rosmarinic acid release from chitosan nanoparticles 
 
All the chitosan-based nanoparticles suspension and the PBS used as medium release 
were adjusted to the tear normal osmolarity (300 mOsm / L). This normal osmolarity is 
essential to maintain cellular volume, enzymatic activity, and cellular homeostasis (202). 
In this in vitro release study every effort was made in order to best fate the ocular 
physiological conditions to test the kinetic nanoparticles behavior in ocular surface. During 
the experiment a fast release was observed during the in vitro release assay which was in 
accordance with previous data (190). The different rosmarinic acid contents (in rosmarinic 
acid nanoparticles, sage and savory nanoparticles) were released in all the formulations 
freshly and lyophilized within 60 min with no significant differences (P > 0.05). An initial 
burst effect was observed in the first 30 min with approximately 80% in sage nanoparticles 
and almost 100% in rosmarinic acid and savory nanoparticles (Figure 4.4). The results 
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seem to demonstrate that a significant amount of rosmarinic acid or extracts were initially 
associated with nanoparticles on their surfaces by weak linkages to chitosan, which did 
not have the necessary strength to entrap all the compounds. This represents that 
chitosan nanoparticulate system could retain the primary structure of rosmarinic acid or 
extracts during encapsulation. The protection release happens only for few minutes due to 
the polymer network, which was in accordance with other studies, that encapsulate 
polyphenols from Ilex paraguariensis in chitosan nanoparticles prepared also by ionic 
gelation and a complete release of 100% were demonstrated in the first 15 min (193). In 
another study for quercetin encapsulation into other nanocarriers, the release within the 
first 20 min was also 95% (151). Nevertheless, this results were different from other works 
that demonstrated a complete release of polyphenols from chitosan nanoparticles within 4 
h (198). The efficient application of these nanocarriers will certainly depend of the drug 
purpose. Chitosan nanoparticles maintain their characteristics for this theoretical loadings, 
and this confers them valuable properties, such as protective and moisturizer, for the 
encapsulation of active agents for cosmetic or ocular applications, since a rapid released 
is intentional (193). However for other applications, like oral drug delivery a slower release 
should be optimized. 
 
Figure 4. 4. Rosmarinic acid in vitro release from rosmarinic acid, sage and savory 
chitosan-based nanoparticles. 
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4.2.5. Thermal behavior by differential scanning calorimetry analysis 
 
The DSC measurements provide quantitative and qualitative information about physical 
and chemical changes that involve endothermic or exothermic processes, or changes in 
heat capacity. Endothermic and exothermic peaks correspond to transitions that absorbs 
or release energy, respectively. DSC was performed to understand the behavior of 
rosmarinic acid, sage and savory loaded and unloaded chitosan nanoparticles and the 
thermograms were displayed in Table 4.3.  
 
Table 4. 3. Peak temperatures in the DSC thermograms collected from chitosan, 
rosmarinic acid, sage and savory, physical mixtures, and nanoparticles. 
    T (oC) 
    Onset Peak EndSet 
N
a
n
o
 
Chitosan 102 ± 0.55 122 ± 1.20 131 ± 0.12 
Rosmarinic acid 112 ± 0.61 130 ± 0.73 141 ± 0.24 
Sage 83 ± 0.27 108 ± 0.71 118 ± 0.93 
Savory 103 ± 1.11 124 ± 0.82 137 ± 0.44 
F
re
e
 Rosmarinic acid 134 ± 0.13 144 ± 0.23 149 ± 0.25 
Sage 140 ± 0.21 141 ± 0.14 145 ± 1.03 
Savory 141 ± 0.53 154 ± 0.51 158 ± 0.81 
P
h
y
s
ic
a
l 
m
ix
tu
re
 Chitosan-Rosmarinic acid 90 ± 0.38 122 ± 0.83 136 ± 0.14 
  147 ± 0.14 150 ± 0.70 154 ± 0.13 
Chitosan-Sage 94 ± 0.91 121 ± 0.10 134 ± 0.50 
  147 ± 0.67 151 ± 0.63 155 ± 0.84 
Chitosan-Savory 93 ± 0.70 121 ± 0.32 132 ± 0.32 
  145 ± 0.28 151 ± 0.64 154 ± 0.24 
 
Note: The results were given as mean of triplicate samples. 
 
The same chitosan-based nanoparticles thermal behavior was observed in all 
thermograms (Figure 4.5Ia, IIa and IIIa). In all chitosan curves, an endothermic peak near 
70°C can be ascribed to the loss of water as previously reported (203). The endotherm of 
rosmarinic acid, sage and savory nanoparticles showed different shift temperatures 
(Figure 4.5Id. IId and IIId, respectively). This may be accounted by the hydrophilic groups 
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incorporated due to rosmarinic acid that were in different amounts inside the extracts 
particles. Other previously studies also reported similar shifts in DSC plots of chitosan and 
chitosan nanoparticles (198, 204). It could also be seen that the peaks of the complexes 
were shifted from those of physical mixture. Peaks of physical mixture (Figure 4.5Ic, 
4.5IIc, 4.5IIIc) appeared to be combinations of each material but they were different from 
those of nanoparticles, probably because complexation of polyelectrolytes, in accordance 
with other similar works (205). Also, comparing endothermic peak of antioxidants loaded 
chitosan nanoparticles to the one obtained with unloaded nanoparticles, the former started 
at higher temperature, which was a possible evidence of the presence of antioxidants 
once its decomposition started at higher temperature when comparing to unloaded 
nanoparticles. The rosmarinic acid, sage and savory loaded sample showed the similar 
shift of chitosan nanoparticles, which confirms that there were no significant covalent 
interactions between antioxidants and chitosan after encapsulation and cross-linking 
(205). 
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Figure 4. 5. Thermogram of: I.(a). chitosan empty nanoparticles; (b). free rosmarinic acid; 
(c). rosmarinic acid and chitosan physical mixture (mixing ratio 1:1);  (d). rosmarinic acid 
encapsulated in chitosan nanoparticles (at a theoretical 40%  loading) (d). II.(a). chitosan 
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empty nanoparticles; (b). free sage; (c). sage and chitosan physical mixture (mixing ratio 
1:1); (d). sage encapsulated in chitosan nanoparticles (at a theoretical 50% loading). 
III.(a). chitosan empty nanoparticles; (b). free savory; (c). savory and chitosan physical 
mixture (mixing ratio 1:1); (d). savory encapsulated in chitosan nanoparticles (at a 
theoretical 50% loading). 
 
4.2.6. Spectroscopy by Fourier-transform infrared analysis 
 
Structural features, functional groups that represent backbone produce characteristic and 
reproducible absorptions in the spectrum, which can be analyzed by FTIR. With these 
series of experiments it was intended to monitorize the complexation of contrary charged 
polyelectrolytes at specific pH and stoichiometric relationship between the polyelectrolytes 
and antioxidants in nanocarriers. For this concern and to examine this relationship 
between components of nanoparticulate systems, preliminary concerns were taken over 
polyelectrolytes interactions and antioxidants entrapment. It is well established that the 
carboxyl group (–COO) of the anionic polymer may interact with the amino group ð-NH3 
of chitosan and form an ionic complex between the two compounds (205). Rosmarinic 
acid displays a typical vibrational absorption bands with the main bands located between 
1800 and 700 cm–1 (206). The three bands around 1605, 1520, and 1445 cm–1 were due 
to the presence of aromatic rings in the molecule indicating an aromatic ring stretching 
(206). Other evidences for phenolic groups were delivered through the bands at 1360 and 
1180 cm–1 resulting from O-H and C-O stretches (206). Therefore, the band at 1684 cm–1 
and the two shoulders recognized with this band result probably from the shifted bands 
due to the presence  of carboxylic acid groups and ester group 1725-1750 cm–1 (207).  
Figure 4.6 (I, II and III) showed that all the above characteristic peaks appear in the 
spectra of combined drugs loaded chitosan nanoparticles at the same wavenumber 
indicating no modification or interaction between the drug and carrier. This was in 
accordance to previous work (208). Nevertheless, some peaks clearly decreased in 
intensity, after the preparation of rosmarinic acid, sage and savory nanoparticles. 
Particularly evident were the phenolic group bands (1360 and 1180 cm–1) in rosmarinic 
acid nanoparticles and this is may be due to the highest amount of rosmarinic acid in 
these nanoparticles, comparing to the inside content of rosmarinic acid in extracts and into 
the nanoparticles. This effect was also reported by some authors that developed a new 
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FTIR method for the characterization of rosmarinic acid in Lavandula officinalis cultures 
(206). Nevertheless it must be underline that this characteristic bands decrease observed 
in the nanoparticles by FTIR analysis, and the decrease in antioxidant activity, may be 
due to the partial retention of antioxidant before their complete release (considering the 
theoretical loadings under studied). This was documented for other antioxidant 
nanoparticles studies, such as essential oils (197). Also no new peaks appeared in 
nanoencapsulation spectrum, and chitosan, rosmarinic acid, sage and savory were mixed 
together physically without any chemical reaction (152).  
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Figure 4. 6.  Spectrum of: I. (a). chitosan empty nanoparticles; (b). rosmarinic acid in a 
free form; (c). physical mixture between chitosan unloaded nanoparticles and rosmarinic 
acid (mixing ratio 1:1); (d). rosmarinic acid encapsulation into chitosan nanoparticles. 
II.(a). chitosan empty nanoparticles; (b). sage in a free form; (c). physical mixture between 
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chitosan unloaded nanoparticles and sage (mixing ratio 1:1); (d). sage encapsulation into 
chitosan nanoparticles. III.(a). chitosan empty nanoparticles; (b). savory in a free form; (c). 
physical mixture between chitosan unloaded nanoparticles and savory (mixing ratio 1:1); 
(d). savory encapsulation into chitosan nanoparticles. 
 
4.3. Conclusion 
 
In this study, chitosan nanoparticles incorporating rosmarinic acid, sage and savory were 
prepared and characterized in order to ensure their best size, efficient encapsulation, 
thermal stability, and in vitro release.  
Smooth, spherical and small sizing nanoparticles ca. 300 nm, were obtained. High 
association efficiency was attained for all the formulations, 51.2% for rosmarinic acid (with 
40% loading), 96.1 and 98.2%, for sage and savory nanoparticles, respectively (both with 
50% loading). No chemical interactions were found between antioxidants and chitosan, 
after encapsulation. The chitosan-based nanoparticles released rosmarinic acid in 1 h, 
which suggested a rapid released profile of the nanosystem, being adequate for ocular 
applications. The core of this work was to underline the potential application of sage and 
savory for pharmaceutical or biomedical formulations, considering the benefits of natural 
extracts containing rosmarinic acid. Bearing in mind that natural nanoparticles offer the 
most advanced treatment modality for crude extracts incorporation. This could be a 
fundamental alternative nanomedicine to enhanced antioxidant performance for OS 
conditions. 
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CHAPTER 5 – In vitro assessment of antioxidant 
activity of chitosan-based nanoparticles 
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5. Introduction 
 
The oxidative damage plays a causal role in aging and various degenerative diseases, 
such as heart disease, cataracts, cognitive dysfunction, cancer and ocular diseases (6). 
Free radicals and ROS in biological systems can be harmful, since they may induce lipid 
oxidation by attacking the cell membranes, modifying proteins or enzymes in tissues, 
carbohydrates and even DNA (6). Although organisms already possess their natural 
antioxidant defense, they seem to be inefficient against the cumulative and continuously 
attack from ROS. The supplementary delivery of antioxidants using in the conventional 
dosage forms is a challenge due to their in some cases poor solubility, poor permeability, 
instability and metabolism before reaching  the target (18). In this context, alternative 
carriers are being considered for pharmacokinetics and pharmacodynamics optimization 
of antioxidant molecules. For this application, chitosan has come to be particularly 
interesting for the association and delivery of these labile macromolecular compounds (4). 
This innovative drug carrier is expected to develop and improve stability and 
bioavailability, without compromising the safety performance of the antioxidants and target 
conditions (40). In this study the ability of chitosan-based nanoparticles to maintain the 
antioxidant activity of rosmarinic acid pure and in natural extracts was evaluated.  
 
5.1. Experimental 
 
5.1.1. Materials 
 
Materials were described previously in chapter 4. Briefly, the two selected plants sage and 
savory were provided by ERVITAL (Castro Daire, Portugal). The plants had been 
cultivated as organic products, and were supplied in their commercial form of dried leaves. 
The dried leaves were then kept in the dark at 20 ºC. Rosmarinic acid (purity 96.5%), 
methanol CHROMASOLV® (HPLC ≥ 99.9%) and formic acid (HPLC ≥ 98.0%) were 
purchased from Sigma-Aldrich (Missouri, USA). Chitosan low molecular weight (LMW) 
and TPP were also purchased from Sigma-Aldrich (Lisbon, Portugal). The degree of 
deacetylation for chitosan LMW was 85%, with a purity grade of 85%. Pure acetic acid 
was purchased from Pornalab (Lisbon, Portugal). Sodium hydroxide (NaOH) and 
  
92 
 
hydrochloric acid (HCl) were from Merck (Darmstadt, Germany). Ultra-pure water was 
obtained in the laboratory using a MilliporeTM water purification equipment 
(Massachusetts, USA).  
. 
5.1.2. Sample preparation 
 
Considering the two plants 1 g of each plant was crushed (using a lab mill) for 1 min, to 
obtain the corresponding powder. The extraction powder was performed as described in 
previously reports, via addition of 100 mL boiling water to 1 g of plant powder and after 5 
min, the extract was filtered through a 0.45 µm filter (190). This procedure was optimized 
to obtain the highest potential activity of these plants. After the crude plant sedimentation, 
samples were filtered and maintained at -80 °C, for lyophilization procedures (Heto Holten 
A/S Drywinner). Then, solutions of 1% (w/v) of lyophilized powder were dissolved in 
methanol for chromatographic analyses and in ultra-pure water for antioxidant activity 
tests. Before injections samples were filtered again through a 0.45 µm filter. 
 
5.1.3. Chitosan nanoparticles development and optimization 
 
Chitosan-based nanoparticles were developed and optimized based on previously studies 
and as described in previous chapters. The chitosan nanoparticles were obtained by 
inducing the gelation of a chitosan solution with TPP. For this purpose TPP was dissolved 
in purified water, and chitosan was dissolved in acetic acid aqueous solutions at various 
concentrations and pH adjusted to 5.8 with 1 M NaOH. The concentration of acetic acid 
was, in all cases, 1.75 times higher than that of chitosan, as previously described (188). 
After several assays considering the variation of concentrations and volumes, an optimal 
ratio between chitosan:TPP was achieved in chapter 4 (7:1). This optimal ratio was 
considering to achieve particles ranging (200-300 nm) using ZetaPALS (Brookheaven, 
New York, USA) and a charge as close as possible of 30 mV by laser Doppler 
anemometry, at 25°C. A final volume of 2.0 mL of TPP solution was added to 5 mL of the 
chitosan solution under magnetic stirring at room temperature, thus achieving a final 
concentration of 2 and 0.28 mg/mL of chitosan and TPP, respectively.  
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5.1.4. Encapsulation of sage, savory and rosmarinic acid into chitosan 
nanoparticles 
 
The 1% (w/v)  aqueous rosmarinic acid and aqueous extracts solutions were added to 
chitosan, previously dissolved in acetic acid, in different volumes in order to guarantee the 
best ratio between chitosan and the different compounds, as previously described in 
chapter 4 and documented (190). For this concern the encapsulation was tested in 
different theoretical loadings (5, 10, 15, 20, 30, 40 and 50%) fairly to the initial 
concentration of chitosan (2 mg/mL). All the tests were made for the 7 batches, 
considering the two plants and the pure rosmarinic acid. Some of the final batches were 
then lyophilized (Heto Holten A/S Drywinner) and maintained at -20 ºC for 1-2 months for 
further analysis.  
 
5.1.5. Antioxidant capacity assessment 
 
5.1.5.1. 2,2-azinobis (3-ethylbenzothiazoline-6-sulphonic acid)  method 
 
Determination of the antioxidant capacity was performed as  described in other research 
papers   (115). The ABTS•+ stock solution was prepared via addition, at 1:1 (v/v), of 7 mM 
ABTS (2,2-azinobis (3-ethylbenzothiazoline-6-sulphonic) acid) diammonium salt (Sigma-
Aldrich, St. Louis, MO, USA) to a solution of 2.45 mM potassium persulphate (Merck, 
Damstadt, Germany); the developing reaction took place in the dark, for 16 h. In order to 
obtain an absorbance of 0.700 ± 0.020 at 734 nm, measured with an UV 1203 
spectrophotometer (Shimadzu, Tokyo, Japan), the aforementioned stock solution was 
diluted in ultra-pure water as necessary. A 10 µL aliquot of the sample was assayed for 
percentage of inhibition (PI), to be between 20% and 80%,  to guarantee a linear 
response of the analytical method, after 6 min of reaction with 1 mL of diluted ABTS•+ 
solution. The total antioxidant capacity was expressed as percentage of inhibition (PI), 
according to the equation: 
𝑃𝐼 = (𝐴𝑏𝑠𝐴𝐵𝑇𝑆 • +  −  
𝐴𝑏𝑠 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑏𝑠𝐴𝐵𝑇𝑆 • +
) × 100 
  
94 
 
 where AbsABTS•+ denotes the initial absorbance of diluted ABTS•+, and Abs sample 
denotes the absorbance of the sample by 6 min of reaction. Triplicates of each sample 
were averaged to generate each datum point (which implies a total of six replicates per 
sample). The final result was expressed as equivalent concentration of ascorbic acid (in 
g/L), using a calibration curve. 
 
5.1.5.2. Oxygen radical absorbance capacity 
 
The oxygen radical absorbance capacity (ORAC) assay was employed to evaluate the 
antioxidant potential of chitosan-antioxidant nanoparticles as described in previously 
reports (209). All reaction mixtures were prepared in duplicate, and at least three 
independent measures were performed for each experiment. ORAC-fluorescein (FL) 
values were expressed in µmol trolox equivalent per mg hydrolyzed of antioxidant, as 
purposed elsewhere (210). 
 
5.1.6. Statistical analysis 
 
Statistical analysis was performed using IBM SPSS Statistics v 19.0.0 (Illinois, USA). The 
one-way analysis of variance (ANOVA) was used with Scheffé post hoc test comparison 
of groups with normal distribution, and Mann-Whitney test for groups with non-normal 
distribution. Differences were considered to be significant at a level of P < 0.05. 
 
5.2. Results and discussion 
 
5.2.1. Antioxidant activity measurement 
 
Rosmarinic acid is phenolic compound, with many beneficial functionalities and generally 
admitted as a free radical scavenger (125). Its high biological activity is particularly related 
to its two catechol moieties. Catechol is an important sub-structure for the potent 
antioxidant activity of phenolic antioxidants (125). The general antioxidant mechanism of 
  
95 
 
phenolic compounds is thought to be divided into two stages: radical catching stage and 
radical conclusion stage (126). For both methods the antioxidant activity was tested 
according to the antioxidant activity of rosmarinic acid, either in free solution or 
encapsulated, both in extracts or in a free form. For both methods no significant 
differences were found for antioxidant activity between the all nanoformulations, before 
and after lyophilization processes (P > 0.05), except for savory encapsulation. For these 
nanoparticles a decrease in the antioxidant activity was observed after lyophilization, 
especially evident in ORAC method. For the loading concentrations of 5 to 15%, no 
antioxidant activity was found by the ABTS or ORAC methods. This means that the 
antioxidant activity was clearly compromised for these low theoretical loadings. 
Considering the both extracts and rosmarinic acid nanoparticles, the highest antioxidant 
activity was correlated to the highest antioxidants concentrations (or higher loading value) 
(Table 5.1). Comparing rosmarinic acid, sage and savory in a free form, it can be easily 
observed that rosmarinic acid has the highest antioxidant activity, followed by sage that 
has the highest content of rosmarinic acid (10%) and then savory with only (5%) of 
rosmarinic acid content. By ABTS method, comparing the antioxidant activity before and 
after the encapsulation process, it was clear a decrease in the antioxidant activity after the 
encapsulation. This proofs that the antioxidant activity were decrease due to the partial 
entrapment effect of the compounds. Nonetheless the particles still demonstrated good 
antioxidant activity. This was in accordance to other previously reports that have showed 
the same good antioxidant effect of Trolox in chitosan nanoparticles (211). Other good 
results were obtained for the chitosan encapsulation of idebenone antioxidant (201). 
Furthermore and by ORAC, which is fluorimetric assay and a more sensitive one, it can be 
easily observed that after the encapsulation process the antioxidant activity was even 
lower, than the results achieved by ABTS (Table 5.1). These results were consistent with 
previously studies with the encapsulation of quercetin and rutin (212). This still may be 
due to the nanoparticles entrapment of rosmarinic acid, in other way because the 
antioxidant was not completely released. This partial retention means that the compounds 
will take more time to build up their specific activity. Nevertheless the nanosystems with 
this entrapment effect still have good antioxidant activity. Although even if the nanosystem 
antioxidant activity was lower than the unloaded compounds, it is well known that 
nanocarriers protects the antioxidants for degradation by biological and enzymatic fluids, 
increasing their bioavailability. The drug release can also be optimized to be even longer, 
prolonged and controlled in time considering the purpose application of this nanoparticles 
(187). This makes the nanoencapsulation advantageous and necessary. 
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Table 5. 1. Antioxidant activity measurements by ABTS and ORAC, considering the 50% 
loading (m/m) sage and savory nanoparticles; and 40% loading (m/m) of and rosmarinic 
acid nanoparticles for (n = 3). 
 
 
ABTS x ORAC y 
 
 
(eq [Asc. Ac.]g/L)/g extract (µmol/eq Trolox)/g extract 
 
 
Fresh  
Nanoparticles 
Lyophilized 
Nanoparticles 
Fresh 
Nanoparticles 
Lyophilized 
Nanoparticles 
N
a
n
o
 I
  
Rosmarinic 
acid 
0.0348 ± 0.0050 a 0.0554 ± 0.0139 a 4.8374 ± 0.1719 b 3.6520 ± 0.1770 b 
Sage 0.0537 ± 0.0015 c 0.0440 ± 0.0029 c 0.6227 ± 0.0901 d 0.4251 ± 0.0069 d 
Savory 0.0828 ± 0.0102 e 0.0378 ± 0.0015 f   1.5315 ± 0.2784 g 0.4526 ± 0.0087 h 
F
re
e
 I
I  
Rosmarinic 
acid 
0.0917 ± 0.0018 34.1218 ± 2.5733 
Sage 0.1621 ± 0.0470 19.5924 ± 1.9791 
Savory 0.1410 ± 0.0087 16.8117 ± 1.3605 
 
Note: The results were given as mean of triplicate samples, each with three measurements. The 
same letters, in the same line indicate that no significant differences were observed between the 
fresh and freeze-dried process (P > 0.05). The values are significantly different (P > 0.05) for the 
antioxidant methods (
x, y
) and for the encapsulation process (
I, II
). 
 
Considering the same loading concentrations of the rosmarinic acid and the extracts 
nanoparticles it was clear that rosmarinic acid in the extracts nanoparticles was in lower 
concentration than when was purely encapsulated. Rosmarinic acid nanoparticles (40% 
loading), with 50% efficiency means encapsulate, 0.4 mg/mL of rosmarinic acid. 
Nevertheless, sage or savory nanoparticles (50% loading), with almost 100% association 
efficiency (Table 4.2 – chapter 4), the nanosystem encapsulate 1 mg/mL of extract, but 
only 10 and 5% of rosmarinic acid (Table 4.2 – chapter 4), for sage and savory, 
respectively. It is also known and documented by our group (179), that these crude 
extracts (sage and savory) are complex natural matrixes with different antioxidant content 
(as Protocatechuic acid, coumaric acid, gallic acid, caffeic acid, ferulic acid, naringenin, 
quercetin, isorhamnetin, chlorogenic acid, prunin, isoorientin, quercitrin and rutin). 
Nevertheless when natural extracts were encapsulated, the pH value was to allow the 
great amount of rosmarinic acid interaction with chitosan solution, and then the success of 
the encapsulation. This means that some phenolic compounds were present in the 
extracts, but were not negatively charged at formation medium pH, may be lost in 
encapsulation procedure. However, other antioxidant compounds in extract nanoparticles 
that have a close pKa of rosmarinic acid were encapsulated adding a synergic antioxidant 
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activity. This justifies that with lower rosmarinic acid concentrations, the extracts have the 
same antioxidant activity, being good vehicles of rosmarinic acid and with good 
antioxidant synergic performance. Furthermore it was important to underline that 
rosmarinic acid-nanoparticles can encapsulate with only 50% of association efficiency, 
which means a huge waste of the compound.  This could represent that at this moment, 
for all the tests made for chitosan nanoparticles with sage or savory, they seem to be 
good vehicles for rosmarinic acid incorporation and represent a more economically 
process, than nanoparticles with rosmarinic acid pure. Another advantage could be added 
with the inclusion of biological activities of other natural compounds that were 
incorporated at this pH value in the nanoparticles. However, in vitro tests must be done in 
order to guarantee that all the biological activities of the extract and of rosmarinic acid 
were maintained. 
 
5.3. Conclusion 
 
In this study, chitosan nanoparticles incorporating rosmarinic acid, sage and savory were 
prepared and characterized in order to ensure the highest antioxidant activity 
performance.  
The best antioxidant activity results were obtained for rosmarinic nanoparticles by ORAC 
method after lyophilization, ca. 3.6520 ± 0.1770 µmol/eq Trolox. Nonethless, sage and 
savory showed to be good vehicles for rosmarinic acid regarding the antioxidant activity 
outline. After nanoparticles lyophilization the obtained values were: 0.4251 ± 0.0069 and 
0.4526 ± 0.0087 µmol/eq Trolox, for both sage and savory nanoparticles, respectively. 
Nevertheless, it is important to underline that the crude extracts have a lower 
concentration of rosmarinic acid, and the good antioxidant activity results suggested that 
other synergic compounds may be also encapsulated. Besides a lower antioxidant activity 
was observed in the nanoparticles comparing to the free compounds due to the partial 
entrapment effect of the compounds, chitosan-based nanoparticles still maintained the 
rosmarinic acid good antioxidant activity performance and also allowing its protection and 
best control its profile release. These results underline the pharmaceutical potential of 
chitosan-based nanosystems for antioxidants delivery. 
  
  
98 
 
 
  
  
99 
 
PART V 
 
 
“Science isn’t about why…it’s about why not?” 
 
Unknown 
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Abstract 
 
Introduction: In vitro assays are crucial to mimic biological conditions and predict 
nanoparticles cytotoxicity, mucoadhesion and the encapsulated bioactive permeability 
profiles. Neuroinflammation is a biological condition intimate related to the glaucoma 
pathophysiology, increasing the reactivity of microglia and the release of pro-inflammatory 
mediators. 
Objective: The goal of the study was to test the safety performance, mucoadhesiveness 
and permeability of rosmarinic acid encapsulated into the aforementioned nanoparticles 
towards ocular cell-based models, and predict their potential to prevent oxidative eye 
diseases. Nonetheless, it was also intend to evaluate the effect of rosmarinic acid in 
retinal pro-inflammatory control and infer if it may confer neuroprotection to the retina in 
an animal model of I-R. 
Methodology: Chitosan nanoparticles were evaluated considering mucoadhesiveness and 
their safety performance and cell permeability by in vitro tests using ARPE-19 and HCE-T 
monolayer cell lines. In vivo assays were performed injecting intravitreally rosmarinic acid 
in an I-R model, the rosmarinic acid neuroprotection was further evaluated by 
electroretinograms (ERG) and immunohistochemistry.  
Results: Nanoparticles previously characterized demonstrated to be safe without relevant 
cytotoxicity against ARPE-19 and HCE-T cell lines, with no irritancy to the eye. The 
permeability study in HCE monolayer cell line showed an apparent permeability coefficient 
Papp of 3.41 ± 0.99 x 10
-5 and 3.24 ± 0.79 x 10-5 cm/s for rosmarinic acid loaded chitosan 
nanoparticles and free in solution, respectively. In ARPE-19 monolayer cell line the Papp  
were 3.39 ± 0.18 x 10-5 and 3.60 ± 0.05 x 10-5 cm/s for rosmarinic acid loaded chitosan 
nanoparticles and free in solution, respectively. Considering the mucin particle method, 
nanoparticles indicate mucoadhesive proprieties. ERG and immunohistochemistry 
showed that at this concentration, by intravitreal injection, rosmarinic acid did not have a 
retina protective effect in I-R studied model. 
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Conclusion: The natural nanoparticles developed in this study demonstrated to be in vitro 
promising drug delivery systems for ocular application. Nonetheless, the in vivo results 
were not effective regarding retina neuroprotection, which may be due to the acute I-R 
model, which leads to severe pro-inflammatory damages that antioxidants are not able to 
revert with a single injection.  Despite, this antioxidants pharmacotherapy may be crucial 
to ocular diseases prophylaxis. 
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CHAPTER 6 - In vitro evaluation of cytotoxicity, 
mucoadhesion and ocular permeability of 
rosmarinic acid into chitosan-based nanoparticles 
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6. Introduction 
 
The ocular drug delivery is one of the major challenges in pharmaceutical sciences (213, 
214). Topical eye drop is the most convenient and comfortable route for ocular drug 
administration for patients. Nonetheless, it is well known that the delivery of drugs to 
targeted posterior ocular tissues is restricted by various precorneal, dynamic and static 
ocular barriers (3, 215). In the past two decades, ocular drug delivery research was 
focused on developing novel, safe and patient compliant formulations that may overcome 
these barriers and maintain higher drug levels in tissues. There are many described 
categories of ocular diseases, such as retinitis pigmentosa, glaucoma, cataracts, macular 
degeneration, retinoblastoma and diabetic retinopathy (216). However, the etiology of 
these degenerative diseases remains poorly explained, thus mainly associated to light-
mediated oxidative damage, PUFA content, environmental chemicals and the physical 
abrasion (217). All these factors contribute to OS that may be seen as the key factor for 
ocular conditions (218). OS is now associated to the disruption of blood-retinal barrier, 
apoptotic loss of retinal capillary cells, microvascular abnormalities, retinal 
neovascularization, oxidative modified DNA, as well as suppression of antioxidants 
systems (25). For this reason, the use of appropriate antioxidants may have potential on 
the metabolic and functional abnormalities in retinopathies (219, 220). The delivery of 
antioxidants using the conventional dosage forms is challenging due to their low 
permeability, high instability and the losses during metabolism before reaching systemic 
circulation (18). Nanotechnologies as ocular drug delivery systems are one of the most 
interesting and challenging endeavors, due to the eye critical environment (214). In the 
case of ophthalmic nano-drug delivery systems, it is crucial to evaluate an appropriate 
particle size and a narrow size range, ensuring low irritation, adequate bioavailability and 
compatibility with ocular tissues (221). Nanotechnologies together with the implementation 
of optimal, non-invasive and painless administration routes have been deeply studied, 
considering different biodegradable polymers, their core proprieties and mucosa 
interaction (3). Chitosan is a positively charged polysaccharide which binds to negatively 
charged corneal surface, with potential to improve precorneal residence and decrease 
clearance (222). However, for using chitosan as a base material to produce nanoparticles 
with application in biomedical sciences, it is essential to evaluate their bioavailability, 
cytotoxicity and capacity of transporting bioactive molecules. For this purpose, in vitro cell 
culture models may be considered as the most useful technique to better predict the 
permeability/absorption of bioactive compounds. Ocular cell-based models (e.g. HCE and 
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ARPE) have been used for numerous other purposes, such as studying passive and 
active transport of drugs and endogenous substances, cellular physiology, metabolism 
and protein expression, development of delivery systems for genes and antisense 
oligonucleotides, and cytotoxicity (223). Both cell lines have been deeply evaluated for 
drug permeation studies (224, 225).The main aim of this study was to evaluate the safety 
performance, mucoadhesiveness, permeability and applicability potential in ocular cell-
based models of chitosan nanoparticles encapsulating rosmarinic acid, sage and savory 
lyophilized extracts as rosmarinic carriers. 
 
6.1. Experimental 
 
6.1.1. Materials and cells 
 
Chitosan LMW (≈50 kDa) with deacetylation degree of 86%, and TPP were purchased 
from Sigma-Aldrich (Portugal). Stock solution of chitosan (1% w/v) were dissolved in 1% 
(v/v) acetic acid solution and deionized water followed by filtration using a Millipore #2 
paper filter and stored at 4 °C. TPP (0.1% w/v) were also dissolved in deionized water and 
stored in the same conditions. Two plants were selected as extract source namely sage 
and savory, both provided by ERVITAL (Castro Daire, Portugal). These plants had been 
cultivated as organic products, and were supplied in their commercial form of dried leaves. 
After the crude plant sedimentation, samples were filtered and maintained at -80°C, for 
lyophilization procedures (Heto Holten A/S Drywinner). Then, solutions of 1% (w/v) of 
lyophilized powder were dissolved in deionized water followed by filtration using a 
Millipore #2 paper filter and stored at -20 ºC, as previously described (190, 196).(190, 
196). ARPE-19 and HCE-T human cell lines were obtained from the American Type 
Culture Collection (ATCC) and used at passages 14-35 and 18-32, respectively. 
Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum (FBS), L-glutamine, non-
essential amino acids, and 100 U/mL penicillin and 100 mg/mL streptomycin, trypsin-
EDTA, Hank’s Balanced Salt Solution (HBSS), and wheat germ agglutinin (WGA) were 
purchased from Gibco (Invitrogen Corporation). Transwell® polycarbonate inserts (6 
wells, pore diameter of 3 μm polycarbonate, 4.67 cm2) were purchase from Corning 
(Madrid, Spain). 
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6.1.2. Preparation and characterization of antioxidant-containing chitosan 
nanoparticles 
 
Optimized conditions to obtain antioxidant-containing chitosan nanoparticles were 
previously documented and described in the above chapters (190, 196). Briefly, chitosan 
nanoparticles were obtained by inducing the gelation of a chitosan solution with TPP. For 
the study of the best ratio between chitosan:TPP, a volume of the TPP solution of 2 mL 
was added to 5 mL of the chitosan solution under magnetic stirring at room temperature, 
thus achieving a final concentration of 2 mg/mL and 0.28 of chitosan and TPP, 
respectively (7:1). The 1% (w/v) aqueous rosmarinic acid and aqueous extracts solutions 
were added to chitosan previously dissolved in acetic acid at a pH value adjusted to 5.8, 
in different volumes in order to guarantee the best ratio between chitosan and the different 
compounds, as previously documented (190). For this concern, the theoretical 
encapsulation was fixed in 40% for rosmarinic acid and 50% for sage and savory 
nanoparticles, fairly to the initial concentration of chitosan (2 mg/mL). Then, nanoparticles 
were lyophilized (Heto Holten A/S Drywinner) and kept at -20 ºC for 1-2 months 
 
6.1.3. Size and surface charge 
 
Size and polydispersity of freshly unloaded and loaded nanoparticles were determined by 
photon correlation spectroscopy using ZetaPALS (Brookheaven, New York, USA). A 
sample of 1.6 mL was gently homogenized, placed into analyzer chamber and measured. 
Collective 6 readings were performed three times on each sample at 25 ºC with a 
detection angle of 90º. The zeta potential was determined by laser Doppler anemometry, 
at 25 ºC. Triplicate samples were also analyzed, each sample being measured 6 times, 
and the arithmetic mean was adopted. 
 
6.1.4. Association efficiency 
 
Association efficiency (AE) and loading capacity (LC) was evaluated considering the 
amount of rosmarinic acid associated with the particles. For this purpose the particles 
were centrifuged (20.000 g for 45 min) and suspended in 7 mL of ultra-pure water. The AE 
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and LC were then calculated by the difference between the total rosmarinic acid used to 
prepare the particles, and the amount of residual rosmarinic acid in the supernatant. AE 
and LC of rosmarinic acid in rosmarinic acid nanoparticles, sage and savory nanoparticles 
were obtained according to the following equation:  
 
𝐴𝐸% =
Total amount of rosmarinic acid −  Free amount of rosmarinic acid in supernatant 
Total amount of rosmarinic acid
× 100 
 
𝐿𝐶% =
Total amount of rosmarinic acid −  Free amount of rosmarinic acid in supernatant 
Rosmarinic acid total weight
× 100 
 
6.1.5. Mucoadhesion proprieties evaluation by mucin interaction method 
 
An experiment was conducted to determine the chitosan nanoparticles mucoadhesion 
potential, considering the mucin-particle method. The nanoparticle-mucin interaction was 
determined measuring the amount of mucin that attaches the nanoparticles, and the 
success of their connection was evaluated by the variations in size and zeta potential. 
Particle size, polydispersity and zeta potential of rosmarinic acid-loaded nanoparticles 
were determined using ZetaPALS (Brookhaven, New York, USA), before and after 
incubation of nanoparticles in mucin aqueous solution (0.4 mg/mL, incubation conditions: 
37 ºC, moderate stirring, for 2 h). Mucin activity was stopped by cooling the particles 
suspension on ice for 45 min. The conditions applied in this experiment were adapted as 
previously described (226). Loaded nanoparticles before incubation with mucin were used 
as controls. The interaction of mucin in solution with nanoparticles was also assessed by 
measuring the transmittance of the dispersion, at 372 nm, measured with an UV 1203 
spectrophotometer (Shimadzu, Tokyo, Japan), before and after 45 min of incubation time, 
at three different pH values, namely 5.8, 5.5 and 7.4. This was performed in order to 
evaluate particle mucin interaction in ionic gelation, ocular inflammation and the 
homeostasis pH, respectively. Triplicate samples were analyzed, each sample was 
measured 6 times, and the arithmetic mean value was adopted. 
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6.1.6. Cell viability and cytotoxicity of nanoparticles 
 
The effect of antioxidant chitosan nanoparticles on cell viability was measured at selected 
concentrations using the methylthiazolyldiphenyl-tetrazolium bromide conversion (MTT) 
assay. Cells were seeded in 96-well at 2 x 105/well in 0.3 mL with standard medium, 
consisted of Dulbecco's Modified Eagle Medium (D-MEM) (1X) (Gibco BRL, Grand Island, 
NY), 10% Fetal Bovine Serum (Heat Inactivated) (Gibco BRL), 0.1 mg/mL streptomycin, 
and 1000 IU/mL penicillin (both from Gibco BRL) and incubated 24 h at 37 ºC in 5% CO2 
environment. The medium was then changed and the cells were treated with test samples 
for 4 and 24 h. Each treatment was tested in six individual wells. After time intervals (4 
and 24 h), the supernatant was removed and 20 µL of MTT solution (5 mg/mL in HBSS) 
was added to each well of 96-well plates and then incubated for 2 h at 37°C to allow the 
formation of formazan crystal. The medium was then removed, and blue formazan was 
eluted from cells by 150 µL of DMSO. The negative control used, was also DMSO. The 
plates were shaken on an orbital shaker to solubilize the crystals of formazan. The dark 
blue crystals were aspirated to another new 96-well plate and measured directly in the 
plate reader at 570 and 690 nm for background reduction.  
The effect of nanoparticles on cell membrane integrity was measured by the lactate 
dehydrogenase enzyme release (LDH) assays. Ocular cell lines were seeded in 96-well 
microplates at 2 x 105/well and incubated for 24 h at 37 ºC in 5% CO2 environment. The 
cultured cells were washed with HBSS (1×) (pre-warmed at 37 ºC). Test solution, and 
controls (DMEM and DMSO) were added in triplicate to the cell culture. Cells were 
incubated with medium at 37 ºC for 4 and 24 h. Afterwards, 100 μL of samples were 
withdrawn and centrifuged for 2 min at 5000 rpm to remove detached cells from the 
supernatant. The LDH content of 50 μL supernatant was measured at 490 nm (and 690 
nm for background deduction) with spectrophotometer using a commercial test kit 
(Takara, Shiga, Japan) after incubation for 30 min at room temperature in the dark. 
Cytotoxicity was measured by following the equation: 
 
𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 % =  
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 − 𝐿𝑜𝑤 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝐻𝑖𝑔ℎ 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐿𝑜𝑤 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 × 100 
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6.1.6.1. Cytotoxicity test using chorioallantoic membrane 
 
To evaluate the cytotoxicity and biocompatibility of extracts and rosmarinic acid-containing 
nanoparticles, Hen's Egg Tests (HETs) were performed on the chorioallantoic membrane 
(CAM) as previously described (227). HET-CAM test method was used for the detection of 
ocular corrosives and severe irritants, as defined by the U.S. Environmental Protection 
Agency (EPA 1996), the European Union (EU; EU 2001), and in the United Nations 
Globally Harmonized System (GHS) of Classification and Labelling of Chemicals (UN 
2003). Fertile hen’s eggs at 10 days of incubation at 37 °C, obtained from Guaraves 
Guarabira Aves Ltda, were used in the tests. Five eggs were used for each nanoparticles 
solution assay. After 10 days of incubation, the egg shell above the air space was 
removed. The exposed membrane was moistened with a drop of 0.9% physiological 
saline and the saline was removed, uncovering the chick embryo chorioallantoic 
membrane (CAM). An aliquot of 200 μL of nanoparticles solution was applied on the CAM. 
All assays were repeated five times. Signs of vasoconstriction, hemorrhage and 
coagulation for 5 min were observed evaluate the potential for irritation according to the 
method of HET-CAM. The time (in seconds) at which the indicated processes began were 
applied in Equation (228). The time (in seconds) at which the indicated processes began 
were applied in Equation (228): 
𝐻𝑒𝑡 − 𝐶𝑎𝑚 (𝐼𝑆) =
(301 − ℎ) × 5
300
 +  
(301 − 𝑣) × 7
300
+ 
(301 − 𝑐) × 9
300
  
 
After application of the formula above, it was possible to quantify the observed potential 
for irritation (irritation score-IS) and to obtain means and standard deviations for the 
analysis as follows: 0-0.9 no irritation, 1-4.9 slight irritation, 5-8.9 moderate irritation and 9-
21 severe irritation (228). All procedures with chicken eggs were followed by the 
regulations and procedures for handling of human or animal materials.  
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6.1.7. Permeability studies 
 
6.1.7.1. Cell monolayers culture 
 
Immortalization of human corneal epithelium (HCE) and retinal pigment epithelium 
(ARPE) cells have been described earlier. Polycarbonate Transwell® cell culture filters 
(Corning, 3 μm, 6 wells, USA) were used for permeability assays. Suspension of HCE and 
ARPE cells were seeded onto the filters at a concentration of 200.000 cells/cm2. The cells 
were grown at 37 °C in humidified air with 5% of CO2, in standard culture medium in 
apical chamber for 21 to 30 days until the cells were confluent. The culture DMEM 
medium was replaced every two days.  
 
6.1.7.2. Transepithelial electrical resistance 
 
Transepithelial electrical resistance (TEER) was measured at different phases of cell 
growth (Evom; World Precision Instruments, Sarasota, FL), as an indicator of epithelial 
differentiation and epithelial tightness. TEER data were corrected for low-background 
TEER by using a blank filter containing the possible coating materials and culture 
medium. At the end of each permeability experiment, TEER was measured to detect the 
condition of the cells.  
 
6.1.7.3. Permeation studies in cell monolayers 
 
The permeation study with different solutions was initiated by washing with HBSS (1x) 
liquid (without calcium and magnesium) both the basolateral and apical side one time and 
then adding 2.5 mL of HBSS to the basolateral side (receiver side) and 1.5 mL of HBSS to 
the apical side (donor side). At different time points, during 60 minutes, aliquots of 100 µL 
were withdrawn from the receiver chamber and replaced with an equal volume of blank 
medium. TEER was measure at each time and the plates were incubated with the sample 
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at 37 ºC to sum to the test times. Papp was calculated from the measurement of the flow 
rate of insulin from the donor to the acceptor chambers:  
P𝑎𝑝𝑝 (𝑐𝑚 𝑠) =  𝑑𝑄 𝑑𝑡⁄  (𝐴 × 𝐶0)⁄  
where, dQ is the total amount of permeated rosmarinic acid (mg), A is the diffusion area 
(cm2), C0 is the initial concentration of rosmarinic acid (mg/mL), and dt is the time of 
experiment in seconds (s). The coefficient dQ/dt represents the steady-state flux of 
rosmarinic acid across the monolayer. 
 
6.1.7.4. High performance liquid chromatography analysis 
The HPLC method was developed and validated, as previously described in chapter 3. 
Briefly, aliquots of 100 µL were injected at HPLC to quantify which quantity concentration 
permeates to the basolateral side of the plates. All HPLC runs were performed using a 
Waters Series 600 HPLC and results were acquired and processed with Empower® 
Software 2002 for data acquisition (Mildford MA, USA). HPLC analysis was conducted by 
using a Nova-Pack® RP C18 column (250 x 4.6 mm i.d., 5 µm particle size and 125 Å 
pore size) from Waters. Chromatographic analysis was performed in gradient mode. The 
mobile phase consisted of methanol: formic acid: water UP in the ratio 92.5:2.5:5 (v/v). 
Stationary phase was made with the same components in the ratio of 5:2.5:92.5, 
respectively. The phases were filtrated through 0.22 µm filter and degassed. Eluent was 
pumped at a flow rate of 0.75 mL/min, the injection volume was 20 μL and detection 
wavelength was 280 nm. 
 
6.1.8. Statistical analysis 
 
Statistical analysis was performed using IBM SPSS Statistics v 19.0.0 (Illinois, USA). The 
one-way analysis of variance (ANOVA) was used with Scheffé post hoc test comparison 
of groups with normal distribution, and Mann-Whitney test for groups with non-normal 
distribution. Differences were considered to be significant at a level of P < 0.05. 
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6.2. Results and discussion 
 
6.2.1. Particle size, polydispersity and zeta potential  
 
The particle size and mean size distribution are fundamental features that influence the in 
vivo distribution, biological fate, toxicity and the targeting ability of nanoparticles 
containing therapeutic drugs (191). It is also known that the highest value of zeta potential 
represents the greater electrostatic repulsive interactions among the particles. Zeta 
potential values of ± 30 mV indicates that the colloidal systems are stable in time and that 
amine groups of chitosan are on the surface (193). The developed nanoparticles ranged 
from 200-300 nm in size and zeta potential were around 20-30 mV (Table 6.1). It is 
described that for ultrafine particles the induction of ROS, OS, inflammation and 
vasculature are a risk (229). In this sense it can be considered that the particles of this 
study will have no such harmful effects. Moreover, the results are in agreement with 
similar nanoparticles containing rosmarinic acid we recently developed (230) and with 
other extracts, also encapsulated in chitosan nanoparticles (193). The results did not 
show significant differences (P > 0.05) in size between the rosmarinic acid and the two 
crude extracts, as previously described (190, 196). This may be due to the high rosmarinic 
acid content in extracts composition 10 and 5% in sage and savory, respectively (196). 
Thus the extracts under study are promising vehicles for rosmarinic acid nano-
incorporation, as previously documented (190, 196). The size obtained is also in 
agreement with ocular drug delivery demands, as particles with size ≤ 200 nm were 
observed to reach the retina, vitreous and trabecular meshwork (231) and have more 
vitreal half-life compared to huge nanoparticles (232). The obtained nanoparticles also 
showed values of polydispersity between 0.1 and 0.2 corresponding to a narrow 
distribution and monodispersed particles. These results are in accordance to other works 
using similar antioxidant nanoparticles (194).  
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Table 6. 1. Average hydrodynamic diameter (Z), polydispersity index (PdI) and zeta 
potential of chitosan nanoparticles loaded rosmarinic acid, sage and savory.  
Nano 
Z-average 
(nm) 
PdI 
Zeta potential  
(mV) 
Association  
efficiency 
(%) 
Loading 
capacity  
(%) 
RA 280.0 ± 16.0 a 0.201 ± 0.091 b 30.1 ± 1.8 c 60.2 ± 1.3 d 5.3 ± 0.4 f 
Sage 302.4 ± 18.2 a 0.288 ± 0.074 b 27.5 ± 0.9 c 96.8 ± 0.2 e 8.1 ± 0.6 g 
Savory 298.3 ± 20.8 a 0.214 ± 0.085 b 28.2 ± 2.2 c 98.0 ± 0.3 e 7.8 ± 0.2 g 
 
Note:
 
Values were means of triplicate samples ± standard deviation; 
a,b,c,d,e,f,g  
means within the 
same column, labelled with the same letter, were not statistically different from each other (P > 
0.05). 
 
6.2.2. Association efficiency and loading capacity 
 
Chitosan can interact with the negatively charged TPP, forming inter- and intra-molecular 
cross-linkages, yielding ionically cross-linked chitosan nanoparticles in acidic media (pKa 
6.5) (36). It is also known that the inter- and intra-molecular linkages created between 
TPP and the positively charged amine groups of chitosan were responsible for the 
success of the gelation process (188). Among the different sources of rosmarinic acid 
encapsulated into chitosan nanoparticles, it was observed different loading capacity 
between free drug and extracts (Table 6.1). This may be correlated to the lower initial 
amount in rosmarinic acid used to prepare nanocomplexes, as previously described for 
insulin encapsulation into chitosan-alginate ionotropic nanoparticles (233). The results 
were in line with previous data for ionic gelation chitosan nanoparticles (234, 235). Higher 
association efficiency was found for rosmarinic acid entrapment in extracts of sage and 
savory (with no significant differences observed between them (P > 0.05), than in pure 
rosmarinic acid entrapment in chitosan nanoparticles. The results were on the row with 
other chitosan idebenone and ilex paraguensis encapsulation (193, 201). Other studies 
showed similar association efficiency for other phenolic compound, such as cathechin 
(198) and epigallocatechin gallate (199). The results also exhibited higher association 
efficiency than the obtained for quercetin encapsulation in PLA nanoparticles (i.e. 40%) 
(152). Nevertheless, higher association efficiency for rosmarinic acid nanoparticles were 
previous described in solid-lipid-nanoparticles (230). Nevertheless, higher association 
efficiency for rosmarinic acid nanoparticles were previous described in solid-lipid-
  
115 
 
nanoparticles (230). Therefore, the association efficiency was highly dependent on the 
nanosystem used, as well as from the loading and rosmarinic acid amount utilized into the 
nanoparticles.  
 
6.2.3. Mucoadhesion proprieties evaluation by mucin interaction method 
 
Ocular mucosa may affect the stability chitosan nanoparticles in the presence of mucus 
components (2). Mucus consists in a heterogeneous tridimensional network, being 
basically composed of a mucin fibers network, creating an endless system of canals in 
which particles can diffuse and/or be retained (236, 237). Chitosan is a mucoadhesive 
polymer that may increase residence time and intimate contact of the delivery vehicle with 
the mucosa, consequently increasing the drug bioavailability, such proprieties were well 
documented in literature (168). The chitosan adhesion mechanism is mainly associated to 
the electrostatic interactions established between protonated amine groups of 
mucoadhesive chitosan and negatively charged groups of mucin (238). In this study, the 
nanoparticle-mucin interaction was determined measuring the amount of mucin that 
attaches the nanoparticles (239). The degree of adsorption of nanoparticles/mucin 
particles can be determined by the variations in size (240), zeta potential (241) or 
electrophoretic mobility (242) of formed complexes with mucosal fluids, in particular with 
mucin. Size can influence the diffusion of drug carriers through the mucin mesh that 
composes mucus fluids, being the optimal range between 200 and 500 nm to enhance 
diffusion (243). Higher or smaller diameters may decrease transport through the mucus 
layer. This is in contrast to the prevailing belief, demonstrate that large nanoparticles, can 
rapidly penetrate physiological human mucus, and that large nanoparticles can be used 
for mucosal drug delivery (243). For this purpose, rosmarinic acid containing nanoparticles 
were evaluated, since chitosan was the only responsible for the mucoadhesion results 
and rosmarinic acid was the principle active of all the formulations used. As depicted in 
Table 6.2, the rosmarinic acid nanoparticles obtained in this study were in optimal range 
mentioned, for the three pHs used. The influence of pH values was intended to 
demonstrate that the particles were mucoadhesive in different conditions, at the normal 
ionic gelation pH (5.8), at an inflammation pH (5.0) and in homeostasis pH (7.4). The 
increased size after mucin incubation suggests that nanoparticles-mucin interaction were 
forming microaggregates, and decrease in zeta potential values was probably due to the 
electrostatic interaction between positive charged of chitosan and anionic mucin (241). 
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Strong ability of those nanoparticles to interact with mucin through electrostatic forces 
were observed, highlighting their potential as mucoadhesive carriers (226). Other study 
demonstrated the effect of low, medium and high molar mass chitosan in coated poly-
caprolactone (PCL) nanoparticles (238). The results were according to mucoadhesive 
nanoparticles made of thiolated quaternary chitosan crosslinked with hyaluronan (244). 
 
Table 6. 2. Average hydrodynamic diameter (Z), polydispersity index (PdI) and zeta 
potential of chitosan nanoparticles loaded rosmarinic acid before and after mucin 
interaction (n = 3). 
Nanoparticles pH Z-average (nm) PdI Zeta potential (mV) 
Rosmarinic acid 5.8 236.0 ± 7.1a 0.719 ± 0.036 40.1 ± 0.8 c 
Rosmarinic acid + Mucin 5.0 488.2 ± 30.5 b 0.619 ± 0.049 22.5 ± 0.9 d 
Rosmarinic acid + Mucin 7.4 414.1 ± 32.3 b 0.511 ± 0.014 23.1 ± 0.6 d 
 
Note:
 
Values were means of triplicate samples ± standard deviation; 
a, b, c, d 
means within the same 
column, labelled with the same letter, were not statistically different from each other (P > 0.05). 
 
6.2.4. Cell viability studies 
 
In order to evaluate any potential cytotoxicity of rosmarinic acid, sage and savory on 
ARPE-19 and HCE-T cell lines, pure rosmarinic acid and extracts-loaded chitosan 
nanoparticles were tested for 4 and 24 h. The effect of nanoparticles on membrane 
integrity was measured by the LDH enzyme release assay and the effect on cell viability 
was measured using the MTT conversion assay. In vitro cytotoxicity results were 
presented in (Figure 6.1). Results showed that after 4 h the cytotoxicity was below 10% 
for the tested concentration range, for both cells lines. Moreover, there were no significant 
differences (P > 0.05) between the 4 and 24 h (testing time) considering all formulations 
and different cell lines.  
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Note: NR, R - rosmarinic acid loaded and unloaded chitosan nanoparticles, respectively; NSL, SL 
– Salvia officinalis loaded and unloaded chitosan nanoparticles, respectively; NSG, SG – Satureja 
montana loaded and unloaded chitosan nanoparticles, respectively. 
 
Figure 6. 1. Effect of rosmarinic acid, sage and savory-loaded chitosan nanoparticles on 
cell cytotoxicity of ARPE (A, C and E) and HCE (B, D and F) cell lines after 4 h (black bar) 
and 24 h (white bar) of incubation. DMEM+cells and DMSO were used as controls. The 
formulation concentration used was displayed in the tables, relatively to rosmarinic acid 
(A, B), sage (C, D) and savory (E, F) (results were the mean of 6 replicates, bars 
represent standard deviation). 
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Results of cell viability for rosmarinic acid, sage and savory loaded chitosan nanoparticles 
obtained from the MTT test were shown in Figure 6.2. These were in a good correlation 
with those from the LDH assay. Antioxidant/chitosan nanoparticles presented a good 
profile in terms of cell viability of ARPE-19 and HCE-T cells. The results showed that 
these nanoparticles were not toxic for the cells at concentrations below 1 mg/mL. The 
results were in line with chitosan cell safety performance regarding its use as drug 
delivery systems and data show that it was completely safe with no-toxicity effect upon 
cell lines since chitosan can interact with cell membranes and be uptake with no 
cytotoxicity and cell collateral damages. The results were in line with previous studies on 
the use of chitosan in drug delivery systems, (40) regarding its non-toxicity, good cell 
membrane interaction and cellular uptake with no collateral damages. Moreover, other 
studies demonstrated that chitosan nanoparticles besides being non-toxic, may have 
protective effects on cell lines (245-247).  
 
 
 
 
 
 
 
 
 
 
 
 
  
119 
 
 
Note: NR, R - rosmarinic acid loaded and unloaded chitosan nanoparticles, respectively; NSL, SL 
– Salvia officinalis loaded and unloaded chitosan nanoparticles, respectively; NSG, SG – Satureja 
montana loaded and unloaded chitosan nanoparticles, respectively. 
 
Figure 6. 2. Effect of rosmarinic acid, sage and savory-loaded chitosan nanoparticles on 
viability of ARPE (A, C and E) and HCE (B, D and F) cell lines after 4 h (black bar) and 24 
h (white bar) of incubation. DMEM+cells and DMSO were used as controls. The 
formulation concentration used was displayed in the tables, relatively to rosmarinic acid 
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(A, B), sage (C, D) and savory (E, F) (results were the mean of 6 replicates, bars 
represent standard deviation). 
 
The cellular models have been established as promising tools for the investigation of 
pathological ocular conditions, and the toxicological screening of compounds as 
alternative to in vivo toxicity tests. Animal based experiments are important for 
pharmacological and toxicological studies while cell models are relevant to mechanistic 
researches (165). Several animal models including rabbits, pigs, rats and monkeys have 
been exploited for studies of ocular drug pharmacokinetics and bioavailability. The ethical 
controversy associated to these biological trials implies the need to develop cell cultures 
that mimic the action of drugs on the organism. It is now known that the development and 
validation of in vitro tests to replace animal experimentation is among the priorities of the 
7th European Community framework program (162, 165). Several studies have been 
conducted to evaluate the feasibility of using HET-CAM as a complete replacement for the 
in vivo rabbit ocular test (Draize test). This test has several advantages, such as avoiding 
the ethical concerns, allow high simplicity, rapid, sensitive and easily performance. It is 
also an economic method to simulate in vivo ocular reactions (248). Animal experiments 
regulation allows protocols that use chick embryos without needing authorization from 
animal experimentation committees (248). The HET-CAM test has been proposed as a 
model for a living membrane because it has a functional vasculature, in other words, the 
acute effects induced by a test substance on the small blood vessels and proteins of this 
soft tissue membrane are similar to those of the rabbit eye test, while offering the 
advantages of being a non-animal test, more rapidly and universally acceptable. For that 
reason, HET-CAM cytotoxicity test was intended to evaluate the development of irritation 
symptoms. Cytotoxicity of rosmarinic acid, sage and savory-loaded chitosan nanoparticles 
was then evaluated for hemorrhage, coagulation (intra- and extravascular protein 
denaturation) and vasoconstriction, when the test substances were added to the 
membrane and left in contact for 5 min (Table 6.3). The particles were shown to be non-
irritating (IS = 0.0) because they did not prompt vasoconstriction, haemorrhage or 
coagulation in the HET-CAM cells within 5 min of contact. These results were in 
agreement with the MTT and LDH assays made before, and with those obtained 
elsewhere for chitosan, chitosan nanoparticles and other nanosystems (227, 249-251). 
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Table 6. 3. Cytotoxicity of rosmarinic acid, sage and savory-loaded chitosan nanoparticles 
for development of irritation symptoms such as vasoconstriction, hemorrhage and 
coagulation.  
Nanoparticles 
Assays Sage Savory Rosmarinic acid SLS 1% 
Vasoconstriction n. o. n. o. n. o. 7 ± 0.6 
Hemorrhage n. o. n. o. n. o. 49 ± 2.0 
Coagulation n. o. n. o. n. o. 68 ± 3.0 
Irritation 
Potential 
0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 18 ± 0.5 
 
Note: Positive control - sodium lauryl sulfate 1% (SLS). n.o. signs not observed. Non-irritating: 0-
0.9; slightly irritating: 1-4.9; Irritating: 5-8.9 and severely irritating: 9-21. 
 
6.2.5. Permeability assays 
 
Only about 1-5% of a topically applied drug dose often reaches the anterior segment of 
the eye (118). Therefore, the subsequent diffusion of drugs to the posterior segment will 
often be low. Moreover eye drops in solution are eliminated from the precorneal area 
within 90 seconds and absorbed systemically through the highly vascular conjunctival 
stroma and nasolachrymal ducts (252). This means that drugs topically administered have 
low probability of reaching the posterior segment in significant amounts (due to corneal 
and conjunctival epithelium, then aqueous humor, and lens physical barriers) (132).  
Undoubtedly, the permeation of a molecule is determined by the delicate balance of 
numerous parameters that are clearly interrelated. In modern pharmacological discovery 
stage, the study of biological activity and drug physical-chemical profile are crucial. Some 
of these core properties are the aqueous solubility, lipophilicity and membrane 
permeability, which will influence the transport, cellular uptake and distribution of 
chemicals in biological systems (253). 
In the ocular system, the drug absorption from the surface of the eye can be summarized 
in either corneal or noncorneal (254). Mostly drugs are passive diffused across the cornea 
and this diffusion transport is influenced by solubility, molecular weight, partition 
coefficient and drug ionization degree (253). In structure, the corneal epithelium is the 
main limiting barrier for hydrophilic drugs that penetrate through the paracellular pathway, 
but in another way, hydrophilic compounds may have the diffusion eased in cornea 
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hydrophilic stroma, which also is the most tightness structure of cornea and represents 
85-90% of cornea total mass (162). In the opposite case, the lipophilic compounds are 
able to permeate through the cornea epithelium via transcellular route, nonetheless, they 
will deal with a huge difficulty to cross the stroma (27). Having this in mind, chitosan 
mucoadhesive carriers that increases the retention time in ocular surface may be, in the 
future, a crucial solution in topical administration. 
In this study, after morphological characterization, mucoadhesion, and viability assays, the 
rosmarinic acid transport study was conducted to track the effect of chitosan nanoparticles 
on the in vitro permeability. The transport of rosmarinic acid (loaded chitosan-based 
nanoparticles and free in solution) was tracked through the different ocular cell models 
(e.g. ARPE and HCE), following by the measurement of rosmarinic acid transport across 
the cells. For these permeability experiments, initial TEER values were ≈ 300 Ωcm2, for 
both cell lines, at 21 days of post-seeding (90-100% confluence) on the Transwell®. The 
results demonstrated similar Papp after 1 h, for both rosmarinic acid (loaded chitosan-
based nanoparticles and free in solution) and for both cell lines, with no significant 
differences (P > 0.05) between wither loaded and free solution or cells. HCE cell line 
permeability study showed a Papp of 3.41 ± 0.99 x 10
-5 and 3.24 ± 0.79 x 10-5 cm/s for 
rosmarinic acid loaded chitosan-based nanoparticles and free in solution, respectively 
(Figure 6.3). In ARPE-19 cell study the Papp  was 3.39 ± 0.18 x 10
-5 and 3.60 ± 0.05 x 10-5 
cm/s for rosmarinic acid loaded chitosan-based nanoparticles and free in solution, 
respectively (Figure 6.4). Papp was calculated considering only the apical to basolateral 
direction. No significant differences between formulations neither between cell lines (P > 
0.05) were observed. Regarding TEER results it has been reported ARPE-19 TEER 
values of 30, 100 and higher than 200 Ωcm2 (223). Thus, the great disparity in the TEER 
values found in the literature was probably due to differences in post seeding time and 
percentage of confluence of ARPE-19 cell lines. Regarding the HCE-T cell line, TEER 
values obtained were expectable and similar to those reported by Nagai et al. (ca. 400 
Ωcm2) (255). The TEER values under studied guarantee that the established monolayers 
were considered to be tight enough for permeability experiments (162). In the same way 
as TEER values, Papp values can also depend on various factors such as passage 
number, age of the cells, the media and growth conditions used and even the own TEER 
values (256). For this reason, this technique was more precise when a comparative 
manner with all the compounds assessed in the same assay and under the same 
conditions. The Papp  values may allow the permeability compounds rating into poorly, 
moderately, and highly permeable (Papp < 1 x 10
-6, 1-10 x 10-6, and >10 x 10-6 cm/s, 
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respectively) (257, 258). Considering this, and the rosmarinic acid Papp values (>10 x 10
-6 
cm/s) it can be predicted that this phenolic acid was highly permeable in ocular cell lines. 
In fact, the low molecular weight (i.e. 360.31) of this compound was in the range of “non-
restricted membrane diffusion” (259). Also, its hydrophilic character and consequent 
passive diffusion trough the paracellular route was predicable. The increase of rosmarinic 
acid permeability during the time in HCE-T and ARPE-19 cell lines was deeply related 
with the decrease of tight junction stickiness, tracked by the deacrease of TEER values 
found for the cell culture during the time of the experiment, promoting the paracelular 
transport of rosmarinic acid (Figure 6.3 and 6.4). It is already known that as the tight 
junctions open, the TEER values of cell monolayers are significantly reduced, due to ion 
passages through the paracellular route (260). It was expectable that chitosan enhanced 
rosmarinic acid cell permeability, due to its ability to open epithelium tight junctions. In 
addition, the chitosan is also commonly explored for improving precorneal residence of 
nanoparticles because it is positively charged which hence it binding to negatively 
charged corneal surface and thereby improves precorneal residence and decreases 
clearance (261). Nevertheless, chitosan permeation effect was not observed in this study, 
since no significant differences were detected in permeation between rosmarinic acid 
loaded chitosan nanoparticles or free in solution. One important fact that may be on the 
base of the absence of enhancement effect of chitosan nanoparticles was the natural 
rapid release profile of these particles described previously (190, 196). Since that in the 
first 15-20 min over 50 to 60% was released at physiological pH, which was the ideal 
profile when it is not needed to prolong the drug release for several hours, as in the case 
of ophthalmic solutions. This may be one of the reasons that from this time on, no 
significant differences could be found between nanoformulation and the free compound. 
These solutions must ensure the best compromise between efficiency and minimum 
residence time possible in order to not cause discomfort to the patient. The permeability 
values were higher than other previous reports considering rosmarinic acid in Prunella 
vulgaris and ursolic acid in Salvia officinalis extracts across Caco-2 cell monolayers (262). 
Moreover, the results were also in the line with those reported in other study, which 
showed rosmarinic acid intestinal absorption efficiency and evidences of transport mainly 
via paracelluar diffusion (263). Furthermore, it was described that rosmarinic acid 
appeared to be unsusceptible to hydrolysis by mucosa esterase in Caco-2 cells and 
further metabolized and degraded into m-coumaric and hydroxylated phenylpropionic 
acids by gut microflora, which were then efficiently absorbed and distributed by the 
monocarboxylic acid transporter (MCT) within the body (263). Notwithstanding and 
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besides no enhancement permeability effect was observed in chitosan encapsulation of 
rosmarinic acid, it should be underline the chitosan mucoadhesiveness proprieties that are 
crucial to overcome the drug lost by blinking process that happens in the first 90 s (252). 
In this sense it is vital the particles adherence and protection of the drug delivery in the 
first brief minutes, as chitosan particles ensure in this study.  
 
 
Figure 6. 3. Cumulative transport and TEER cell monolayer measurements of rosmarinic 
acid loaded chitosan-based nanoparticles and free in solution across HCE-T model cells 
(Values were means of 6 replicates, bars represent standard deviation).  
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Figure 6. 4. Cumulative transport and TEER cell monolayer measurements of rosmarinic 
acid loaded chitosan-based nanoparticles and free in solution across ARPE-19 model 
cells (Values were means of 6 replicates, bars represent standard deviation). 
 
6.3. Conclusion 
 
In this study, was reported an extensive in vitro study for chitosan nanoparticles 
encapsulating rosmarinic acid, in a pure form, and also in two different natural extracts 
(e.g. sage and savory). Results demonstrated mucoadhesive nanoparticles ranging 200-
300 nm with a surface charge between 20-30 mV and without relevant cytotoxicity against 
ocular cell lines (e.g. ARPE and HCE). Rosmarinic acid showed to be a compound highly 
permeable (loaded and unloaded chitosan nanoparticles), regarding both studied cell lines 
above (3.2 x 10-5 cm/s) after 60 min. In this study it was proposed, for the first time, 
chitosan formulations as biodegradable mucoadhesive nanocarriers for delivery of 
rosmarinic acid, sage and savory natural antioxidants that in newer future may represent a 
suitable alternative to current invasive clinical methods. Nonetheless a better correlation 
with in vivo data should be deeply explored, in order to deeply understand the real 
potential of these systems in ocular diseases prevention and treatment. 
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CHAPTER 7 - Therapeutical potential evaluation 
in ischemia-reperfusion animal model of chitosan 
based-nanoparticles 
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7. Introduction 
 
The ocular endogenous antioxidants act constantly like safeguard against oxidative ocular 
pathologies. Nonetheless, the constant eye insults of ROS such as UV light, visible light, 
ionizing radiation, chemotherapeutics, and environmental toxins contribute inevitable to 
some oxidative damage in ocular tissues (264). These long-term affronts lead to a 
considerable risk for pathological consequences of OS, such as glaucoma. 
Glaucoma was deeply defined by an elevation of intraocular pressure (IOP), but 
nowadays it is considered as a neurodegenerative disease, characterized by 
degeneration of the optic nerve and loss of retinal ganglion cell (RGC) (265). The 
increased levels of proinflammatory cytokines in aqueous humor (266) and retina (267) of 
glaucoma patients also suggest disease intimate relationship with neuroinflammation. 
Rodent models are common chosen models for glaucoma study, namely I-R model. The I-
R model simulates the retinal Ischemia, which may be defined as an inefficient blood 
supply to the tissue, resulting in hypoxia and failure of tissue nutrient demands (268). The 
ischemia clinical impairment in some ocular diseases like glaucoma is evident, being a 
common cause of visual impairment and blindness (269). The I-R model is characterized 
by an elevation of IOP above systolic pressure, which allows the control of the magnitude 
and duration of ischemia, as well as the duration of reperfusion, which are very important 
parameters concerning RGCs death (169). Even though it does not directly track the exact 
pathophysiology that occurs in human glaucoma, it induces a specific insult to RGCs, 
which is fundamental (169). Since it is very difficult to study the pathophysiology of 
glaucoma in human patients, animal models seem central in order to understand the 
underlying mechanism of disease and to develop new therapies. Therefore and 
considering the ethical concerns about in vivo tests, in this work it was aimed to 
investigate the rosmarinic acid effect on the retina inflammatory control in an I-R injury 
model. Rosmarinic acid is a powerfull antioxidant, with anti-inflammatory, anti-proliferative, 
and anti-angiogenic activities associated (270). Rosmarinic acid is described to inhibited 
all angiogenic processes including proliferation, migration and tube formation of 
endothelial cells, which is mediated by suppression of induced VEGF (271). Its anti-
proliferative effect suggests that proliferative vascular diseases including tumor, arthritis 
as well as retinopathy might be targets for the pharmacological application of rosmarinic 
acid. 
 
 
  
130 
 
7.1. Experimental 
 
7.1.1. Animals and drug administration 
 
All procedures involving animals were in accordance with the Association for Research in 
Vision and Ophthalmology (ARVO) statement for vision and ophthalmic research, and 
were approved by the Institutional Ethics Committee (Comissão de Ética da Faculdade de 
Medicina da Universidade de Coimbra) - Approval ID: FMUC/12/09. Male Wistar rats aged 
8 weeks were housed under controlled environment (21.8 ± 0.1 ºC of temperature and, 
67.6 ± 1.6% of relative humidity, 12 h-light/dark cycle) with free access to food and water. 
After intravitreal and I-R the 2 animals were maintained at 22 ± 1 ºC on a 12 h light/12 h 
dark cycle, with still access to water and food ad libitum for the best performance of ERG. 
One male Wistar rat was also used for saline intraviteral and isquemia control, the same 
conditions were maintained for the 3 animals. In the study rosmarinic acid was injected 
intravitrously in both left eyes, 2 h before I-R injury, at the reported therapeutic dosage 
(e.g. 50 µM) (270), the right eyes in both animal were used as control with only the 
injection of rosmarinic acid at the same concentration. 
 
7.1.2. Intravitreal administration of rosmarinic acid 
 
Animals were randomly selected for the treatment with rosmarinic acid. Intravitreal 
injection of 5 μL was performed using a 10 μL Hamilton syringe, in both left eyes 2 h 
before the induction of retinal I-R.  
In each animal the eyes were considered for different proposes, in order to decrease the 
use of animals, in this sense: 
i) Right eyes: Intravitreal injection of 5 μL of rosmarinic acid without I-R; 
ii) Left eyes: Intravitreal injection of 5 μL of rosmarinic acid followed by retinal I-R; 
 
7.1.3. Electroretinogram recordings 
 
ERG were performed as described previously (272). ERG recorded 24 h before treatment 
(intravitreal injection), which represents the Baseline ERG, and 24 h after treatment. The 
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animals were anesthetized by intramuscular injection of ketamine (50 mg/kg) and xylazine 
(10 mg/kg) and fully dilated pupil with topical tropicamide (1%) under red light, for weak 
illumination. Body temperature was maintained with a heating pad set to 37 °C during the 
procedure. Using a Ganzfeld stimulator, a series of flashes of white light ranging, 0095 to 
9.49 cd-s/m2 were applied under scotopic and photopic conditions. ERG was recorded 
with a corneal electrode gold wire, a reference at the head, and a ground electrode tail. A 
width of 1-300 Hz band and a sampling rate of 3.4 kHz (0.65 kHz to flicker test) were used 
to acquire (Roland Consult GmbH, Brandenburg, Germany). OFF-line digital filters were 
applied to the -wave (high cut-off frequency of 50 Hz) and oscillatory potentials (lower 
cut-off frequency of 60 Hz ERG to scotopic and photopic ERG to 55 Hz) with the software 
RETIport (Roland Consult GmbH, Brandenburg, Germany). 
 
7.1.4. Retinal ischemia-reperfusion injury 
 
Retinal I-R was induced in left eyes by elevating the IOP to 80 mmHg for 60 min, after 
intravitreal injection of rosmarinic acid. Animals were anesthetized with 2.5% isoflurane 
(IsoFlo, Abbott Laboratories) in 1 L/min O2 with a vaporizer throughout the procedure of 
ischemia, and were placed on a heating plate to maintain their body temperature. After 
topical anesthesia with application of oxybuprocaine (4 mg/mL, Anestocil, Edol) and 
pupillary dilation with topical application of tropicamide (10 mg/mL, Tropicil Top, Edol), the 
anterior chamber of the one eye, for I-R injury, was cannulated with a 30-gauge needle 
connected to reservoir infusing sterile saline solution. The IOP was raised by elevating the 
reservoir to a height of 1.8 m. Retinal ischemia was confirmed by whitening of the iris and 
loss of the red reflex. IOP was also measured with the Tonolab and it was increased to 80 
± 1 mmHg. In order to avoid corneal opacity, viscoelastic solution (2% Methocel, Dávi II – 
Farmacêutica S.A.) was applied to both eyes. After 60 min of ischemia the needle was 
withdrawn and reperfusion was established. Fusidic acid ointment (10 mg/g, Fucithalmic, 
Leo Pharmaceutical) was applied in the end of the experiment. Animals were sacrificed 24 
h after ischemia. 
 
7.1.5. Preparation of frozen retinal sections 
 
Animals were anesthetized with an intraperitoneal injection of a solution of ketamine (90 
mg/kg; Imalgene 1000) and xylazine (10 mg/kg; Ronpum 2%). The animals were then 
transcardially perfused with phosphate-buffered saline (PBS, in mM: 137 NaCl, 2.7 KCl, 
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Na2HPO4, 1.8 KH2PO4; pH 7.4) followed by 4% (w/v) paraformaldehyde (PFA). The eyes 
were further enucleated and post-fixed in 4% PFA for 1 h. The cornea and the lens were 
carefully dissected out and the eyecup was fixed for an additional 1 h in 4% PFA. After 
washing in PBS, the tissue was cryopreserved in 15% sucrose in PBS for 1 h followed by 
30% sucrose in PBS for 1 h. The eyecups were embedded in tissue-freezing medium 
(Optimal Cutting Temperature, OCT; Shandon Cryomatrix, Thermo Scientific) with 30% of 
sucrose in PBS (1:1), and stored at -80 º C. The tissue was sectioned on a cryostat (Leica 
CM3050 S) into 10 μm thickness sections and mounted on Superfrost Plus glass slides 
(Menzel-Glaser, Thermo Scientific). Glass slides were dried overnight and then stored at -
20 º C. 
 
7.1.6. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) assay 
 
Cell death was performed with a TUNEL assay kit with fluorescein detection following the 
instructions provided by the manufacture (Promega). Sections were washed twice in PBS 
and then permeabilized with proteinase K (20 μg/mL) for 10 min. After washing twice in 
PBS, the sections were incubated with equilibration buffer (200 mM potassium cacodylate, 
25 mM Tris-HCl, 0.2 mM DTT, 0.25 mg/mL BSA and 2.5 mM cobalt chloride) for 10 min. 
Sections were further incubated with the recombinant TdT enzyme and with nucleotide 
mix containing dUTP conjugated to fluorescein at 37 ºC for 1 h. The reaction was stopped 
by immersing the slides in saline-citrate (SSC) buffer (175 g/L NaCl, 88.1 g/L sodium 
citrate) for 15 min at room temperature. Samples were washed three times in PBS 5 min, 
followed by incubation with the nuclear dye DAPI (diluted 1:2000). Sections were washed 
in PBS and mounted with fluorescent mounting medium (Dako, USA). 
 
7.1.7. Immunohistochemistry 
 
The glass slides were defrosted at room temperature overnight. The sections were fixed 
with ice-cold acetone at -20 º C for 10 min, and then rehydrated in PBS twice until OCT. 
The tissue was surrounded with a hydrophobic pen and it was permeabilized with 0.25% 
Triton X-100 in PBS for 30 min. The sections were blocked in 10% Normal Goat Serum 
plus 1% bovine serum albumin (BSA) in PBS for 30 min at room temperature in a 
humidified environment. After washing with PBS, the sections were incubated overnight 
with primary antibody prepared in 1% BSA in PBS at 4 ºC, in a humidified environment. 
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Then, the sections were rinsed in PBS followed by incubation with the corresponding 
secondary antibodies prepared in 1% BSA in PBS for 1 h at room temperature, in the 
dark. The sections were washed with PBS and then incubated with the nuclear dye 4',6-
diamidino-2-phenylindole (DAPI), diluted 1:2000. The tissue was washed in PBS and 
mounted with fluorescent mounting medium (Dako, USA). 
 
7.1.8. Image analysis 
 
The samples were examined in a Zeiss LSM 710 confocal on an Axio Observer Z1 
microscope using an EC Plan-Neofluar 40x/1.30 Oil DIC M27 objective. Images 
(1024x1024 formats) were collected using 405, 488 and 561 nm laser lines for excitation. 
Z-stacks images were acquired and merged using the maximum intensity projection mode 
of the Zeiss software (Zen 2009, Zeiss). For the analysis of microglial reactivity, 4 images 
per section were acquired (4 sections each eye). It was observed for microglial reactivity, 
the number of cells immunoreactive to both Iba1 (Ionized calcium binding adaptor 
molecule 1) and OX-6 (Iba1+ OX-6+). The survival of RGCs was assessed by 
immunoreactive to Brn3a (Brn3a+) cells in a Leica DM IRE2 fluorescence microscope 
using the 40x/0.70 HC PL APO objective. For each eye, 4 sections were analyzed and the 
observation of Brn3a+ cells taking into account in the entire retinal section. Representative 
images were acquired with a Zeiss LSM 710 confocal microscope, as described 
previously. The cell death was assessed by visualizing of TUNEL+ cells in a Leica DM 
IRE2 fluorescence microscope using the 40x/0.70 HC PL APO objective. For each eye, 4 
sections were analyzed and the TUNEL+ cells were observed in the entire retinal section. 
Representative images were acquired with a Zeiss LSM 710 confocal microscope, as 
described previously. 
 
 
7.2. Results and discussion 
 
7.2.1. Differential effects of rosmarinic acid on electroretinograms  
 
It was assessed the potential changes in light responses of rats induced by a single 
intravitreal administration of rosmarinic acid. The ERG was chosen to measure responses 
of the global population retina, which tend to be dominated by specific group of retinal 
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layers technique, allowing pathophysiological interpretation (273). Rosmarinic acid 
potential effect on retinal physiology, scotopic and photopic was evaluated. ERG were 
recorded in animals administered with rosmarinic acid (50 µM, single administration), 24 h 
before (Baseline ERG), and 24 h after rosmarinic acid intravitreal injection (Figure 7.1). 
Waveforms were elicited by flash light stimuli with intensities ranging from 0.0095 to 9.49 
cd-s/m2. The results showed an evident decrease in retina signaling. However it is difficult 
to evaluate the effect of application of rosmarinic acid, without distinguishing the nefarious 
effect of intravitreal injection itself and the insult of I-R injury. It may be complicated to 
study and distinguish individual and combined effects through a single injection of 
rosmarinic acid and in such small numbers of animals. In this sense, more studies should 
be considered. 
  
 
 
 
 
 
 
Figure 7. 1. Electroretinogram of mixture response of both rods and cones cell 
populations either in photopic or scotopic conditions (α and β – waves) recordings of 
rosmarinic acid administration effect. Left eye:  representative traces of individual ERG 
recorded 24 h before treatment injection (Baseline ERG – blue line) and 24 h after 
intravitreal injection in I-R model (red line); Right eye: representative traces of individual 
ERG recorded 24 h before treatment injection (Baseline ERG – blue line) and 24 h after 
intravitreal injection (red line).  
 
In a mixture response of both rods and cones cell populations either in photopic or 
scotopic conditions the α-wave (photoreceptors) undergoes in a very high decrease, being 
reduced to a small negative peak and there was an almost complete loss of β-wave 
(Muller/bipolar) (Figure 7.1). Since even without I-R injury the single intravitreal injection of 
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rosmarinic acid highly decreased the retina cell populations, when compared to baseline 
ERG, it can be assumed that by intravitreal injection, with or without I-R injury the effect of 
rosmarinic acid, at the tested concentration was not benefic to retina. The results were 
different from that of antioxidant ergothioneine that seem have a neuroprotective effect in 
the retina. (274). Evidences also support the fact that epigallocatechin gallate was a 
powerful antioxidant when injected into the eye, ERG data showed a significant protection 
effect of retinal photoreceptors (275). From the present results it is clear that future 
studies should evaluate multiple injections of rosmarinic acid in different concentrations, 
and other rosmarinic acid administrations routes addressed to other animal models.  
 
7.2.2. Effect of rosmarinic acid on retinal ischemia-reperfusion injury rat model 
- Microglial reactivity 
 
Microglia reactivity was assessed by immunohistochemistry using Iba 1 and OX-6 
antibodies. Iba 1 can be used as a marker of microglia/macrophages and is recognized as 
microglia/macrophage-specific calcium-binding protein (276). OX-6 is an antibody 
knowing the major histocompatibility complex (MHC) class II antigen, which is only 
expressed by activated microglia/macrophage (277). Retinal sections reveal the 
positioning of cells Iba1+ at the level of internal layers of retina inner nuclear layer (INL), 
inner plexiform layer (IPL) and ganglion cell layer (GCL). In this work, the right eyes (from 
the two animal studied) were considered the control condition, since all eyes were injected 
with the drugs (except in saline-injected animals). In the animals eyes it was not observed 
substantial microglia reactivity (cells immunoreactive to OX-6). Interestingly, there was no 
visualized difference in microglial cells with only intravitreal injection of rosmarinic acid or 
between intravitreal injection after treated I-R retinas (Figure 7.2). One possible 
explanation could be the fact that intravitreal injection, even if of saline, can somehow 
induce changes in the retinal environment and induce microglia reactivity. Recently, it was 
reported ocular hypertension induces upregulation of OX-6 and microglia reactivity in the 
retinas (278).  
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Figure 7. 2. Rosmarinic acid effect on activated microglia induced by I-R injury at 24 h of 
reperfusion retinal. Retinal sections were stained with antibodies against Iba1 (green) and 
OX-6 (red). Nuclei were stained with DAPI (blue). Representative images were depicted 
in: Activated microglia/macrophages (Iba 1 - OX-6 immunoreactive cells), comparing with 
saline ischemial. 
 
Other important fact that may explain the inconclusive results upon rosmarinic acid 
administration is that OX-6 (MHC II antigen presenting cells) was reported not to be 
expressed 24 h after ischemia, but after 3 and 7 days (279). One important aspect to 
consider is that the markers used to identify microglia are also present in macrophages. 
Since there is no known cell-surface marker to distinguish central nervous system resident 
from blood-borne macrophages, it becomes difficult to discern the resident microglia from 
monocytes that enter the central nervous system from the bloodstream and subsequently 
adopt microglial-cell morphology (280). The neuroinflammatory response, either resident 
microglia or infiltrating monocytes, becomes a critical issue in determining, not only the 
nature of the response and characteristics of the injury, but also the effectiveness of 
modulating their response. 
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7.2.3. Effect of rosmarinic acid on cell death and retinal ganglion cell loss 
 
Cell death by apoptosis was assessed by TUNEL assay and the loss of RGCs was 
assessed by immunohistochemistry with an antibody that recognizes the transcription 
factor Brn3a that in the retina is expressed only in RGCs and can be used to identify these 
cells (Figure 7.3) (281). Regarding these results it was not observed any beneficial effect 
of rosmarinic acid administration after I-R injury in comparing with saline-treated retinas 
(Figure 7.3). This may indicate that rosmarinic acid after intravitreal injection at this value 
concentration, caused cell death. Rosmarinic acid per se also induced Brn3a+ cells loss 
after single intravitreal injection (Figure 7.3). Previously reports described that rosmarinic 
acid inhibited retinal neovascularization in an oxygen-induced retinopathy, a mouse model 
retinopathy of prematurity, as well as VEGF-induced tube formation of retinal endothelial 
cells (270). The authors also demonstrated that rosmarinic acid was not toxic to mice 
retina in concentrations five times higher the therapeutically effective concentration to 
retinal neovascularization (250 µM). Nonetheless, it must be taking into account the 
animal model clinical differences that may compromise the success of the results, 
regarding even the same compound. Some studies also reported the effect of caffeine on 
microglia neuroinflammation and cell death controlling pro-inflammatory mediators (282). 
Nonetheless this beneficial effect may be difficult to achieve for the majority of 
compounds. It is well known that cell death can be the result of inflammatory process of 
the exaggerated microglial activation, which is a consequence difficult to revert, and it 
becomes difficult to distinguish the influence of the inflammation and nefarious intravitreal 
drugs administrations.  
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Figure 7. 3. Rosmarinic acid administration did not altered the cell death induced by I-R 
injury at 24 h of reperfusion. Cell death was assayed with TUNEL assay. Nuclei were 
stained with DAPI (blue). Representative images were depicted in: TUNEL+ cells (green) 
comparing with saline intravitreal and ischemial. 
 
7.3. Conclusion 
 
Intravitreal administration of rosmarinic acid did not show significant modulation of the pro-
inflammatory response in the retina induced by I-R injury. Nevertheless, only one single 
injection of rosmarinic acid was studied, in a small number of animals which may not be 
sufficient for deep conclusions about this topic. The study respected the ethical concerns 
about in vivo tests and the 3 R's policy - reduce, reuse, recycle. Since the results were not 
promissing no more animals were sacrified. Moreover, other administration routes of 
rosmarinic acid, multiple injections, at different concentration, regarding long-term 
supervision, in different retinal neuroinflammatory animal models, at a more 
representative population of animal models should be considered in the future. Besides 
these and all the bioactive potential in different animal models, it must be underlined the 
potential effect of chitosan-based nanoparticles in the topical administration of rosmarinic 
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acid. Nanoparticles may increase the residence time in ocular surface, protecting 
rosmarinic acid form the surrounding physiological environment and improving rosmarinic 
acid bioavailability, being non-toxic and biodegradable drug delivery systems. More 
studies should be then developed in order to realize this chitosan-based nanoparticles 
effect in the rosmarinic acid enhancement performance on ocular pharmacological 
studies.   
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PART VI 
 
 
“Everything seems impossible until it’s done” 
Nelson Mandela 
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CHAPTER 8 - General conclusions 
 
 
  
  
144 
 
 
 
  
  
145 
 
8. Conclusions 
 
In this work, a bold attempt was made to achieve a new topical, mucoadhesive, natural, 
safe and non-invasive prophylaxis for degenerative eye diseases. For this purpose 
rosmarinic acid was encapsulated in chitosan based systems, using the commercial form 
and in natural extracts in which it is the major compound.  
The studied nanoparticles aiming for a new rosmarinic acid-nanodelivery system, and 
remarkable results in terms of both their physical-chemical features as well as their 
behaviour in the conducted in vitro studies with ocular cell lines (e.g. HCE-T and ARPE-
19) were demontrated. Regarding particle size, nanoparticles presented sizes comprised 
within the range of 200-300 nm and with homogeneous distributions, demonstrating great 
potential for ocular administration. Through SEM and TEM it was possible to confirm 
these results and also to assess the nanoparticles morphology. The nanoparticles 
presented spherical and uniform shape, with a smooth surface.  
Zeta potential values ranged from approximately 20 to 30 mV, justified by the presence of 
the positively-charged of chitosan amino groups, which help stabilizing nanoparticles in 
suspension during the storage time. Particle size and zeta potential were not significantly 
affected by neither the encapsulation of the commercial rosmarinic acid or by the natural 
extracts encapsulation.  
 
 Other successful proof of chitosan nanoparticles was the high association efficiency, 
(about 51.2%) for rosmarinic acid nanoparticles and even higher for sage and savory 
nanoparticles (e.g. 96.1 and 98.2%, respectively). Rosmarinic acid encapsulation in the 
different systems was further confirmed by FTIR spectroscopy studies, which identified 
the characteristic transmittance peak of the drug in rosmarinic acid and extracts-loaded 
chitosan nanoparticles. DSC demonstrated the carriers thermal stability and also that 
there were no significant covalent interactions between antioxidants and chitosan after 
encapsulation. 
The antioxidant activity performance was confirmed by ABTS and ORAC methods. The 
antioxidant activity for the nanosystems was lower than that achieved for the unloaded 
compounds due to partial retention, which means that the compounds will take more time 
to build up their specific activity. Nevertheless the nanosystems with this entrapment 
effect still have good antioxidant activity, higher than 0.0348 eq [Asc. Ac.]g/L/g extract and 
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0.4251 µmol/eq Trolox/g extract. Even considering this decrease in the nanosystem 
antioxidant activity, it is well known that the systems protect the antioxidants from 
degradation by biological and enzymatic fluids, increasing their bioavailability and efficacy. 
Nonetheless regarding the encapsulation of the natural extracts, other antioxidant 
compounds in extract nanoparticles that have a close pKa of rosmarinic acid may be 
encapsulated adding a synergic antioxidant activity. This justifies that with lower 
rosmarinic acid concentrations, the extracts have the same antioxidant activity of 
rosmarinic acid nanoparticles. Associated to this synergic effect was the combination of 
other biological activities of those natural compounds that were incorporated at this pH 
value in the nanoparticles.  
Additionally, in vitro release studies showed a fast release for all the formulations freshly 
and lyophilized within 60 min, which was adequate for ocular applications, since a rapid 
released was intentional on the effect. Regarding the mucin particle method the 
nanoparticles showed mucoadhesive proprieties. This is one of the most crucial 
advantages of these nanosystems, for ocular drug delivery. This propriety will help to 
overpass the topical drug loss issue, due to the ocular blinking mechanism. The 
developed chitosan-based nanocarriers were also not toxic to the HCE-T and ARPE-19 
monolayer cell lines by MTT and LDH assays. The HET-CAM test also corroborates with 
the cytotoxicity tests and showed that the particles were not irritant to the eye. 
Permeability tests showed that in HCE monolayer cell line the rosmarinic acid Papp was 
3.41 ± 0.99 x 10-5 and 3.24 ± 0.79 x 10-5 cm/s for rosmarinic acid loaded chitosan 
nanoparticles and free in solution, respectively. In ARPE-19 monolayer cell line the Papp 
was 3.39 ± 0.18 x 10-5 and 3.60 ± 0.05 x 10-5 cm/s for rosmarinic acid loaded chitosan 
nanoparticles and free in solution, respectively.  
Besides pharmacokinetics and toxicological relevance of chitosan-based nanoparticles 
were guaranteed by in vitro model systems, the study of the effective biologic potential of 
rosmarinic acid required a minimum amount of in vivo experiments using an I-R animal 
model. The therapeutic efficacy and safety in vivo were performed in rats by intravitreal 
injection and the effects were monitored by immunohistochemistry and ERG assays. The 
purposed of the study was to evaluate if the intravitreal administration of rosmarinic acid 
modulate the pro-inflammatory response in the retina induced by I-R injury. In the study 
only one single injection of rosmarinic acid was considered, in a minimum number of 
animals which was clearly not sufficient to have conclusive results. Nonetheless it must be 
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underlined the topical purpose of these nanoparticles and the potential effect suggested 
and reported in this thesis of chitosan-based nanoparticles in the topical administration of 
rosmarinic acid. 
Concluding, the attained results suggest that the devised formulations show a huge 
potential for rosmarinic acid ocular drug delivery, in chitosan nanoparticles and that sage 
and savory were good vehicles for rosmarinic acid. These natural extracts are a more 
natural and cheaper way to rosmarinic acid drug delivery, adding to the final formulation 
more biological compounds with a synergic effect. This study casts light on the improved 
therapeutic utilization of the rosmarinic acid loaded in chitosan-based nanoparticles for the 
novel development of pharmaceutically acceptable nanoparticles. The development of 
these antioxidant-nanoparticles provided a further insight on ocular application, benefiting 
from the advantages of the eye for drug delivery and, additionally, offering new potential 
applications of chitosan as drug carrier and of natural antioxidants for ocular diseases 
prevention. 
At least, it should be underline that no subject was completely explored and there is 
always room for improvement. Further and more extensively studies should be conducted 
for nanotechnology approaches of this kind to become a reality in the clinical practice of 
rosmarinic acid drug delivery to degenerative eye diseases prophylaxis.  
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CHAPTER 9 - Future prospects 
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9. Future prospects 
 
For future work, regarding nanoparticles development, other mucoadhesive systems 
should be considered, optimized and characterized. Encapsulate antioxidant compounds 
into different chitosan-based nanoparticles, namely chitosan matrix, alginate/chitosan and 
chitosan-coated solid lipid nanoparticles and optimize nanoparticulate systems after deep 
physical-chemical characterization; 
Additionally, a more comprehensive study should be directed to the targeting efficacy and 
internalisation of the devised nanoparticles. Taking into consideration cellular uptake, 
nanoparticles can be further functionalised with a hydrophilic polymer providing 
stealthness, aiming to both increase their blood circulation time and to promote cellular 
internalisation. 
The cellular uptake and internalisation of antioxidants through the use of nanoparticles 
could also be assessed resourcing to additional techniques such as fluorescence 
microscopy or flow cytometry. 
Evaluate the mucoadhesion, permeability, absorption and stability of nanoparticles on the 
ocular surface by in vitro cell cultures using the HCE-T, ARPE and conjunctival cell line 
(IOBA-NHC), through confocal laser scanning microscopy (CLSM) and flux cytometry, and 
to measure time of action and bioavailability of antioxidant-containing chitosan 
nanoparticles (162, 165). 
To study the actual effects of the antioxidant power in the elimination of free radicals and 
decreased vascularity in the retina, as well as, to evaluate the toxicity, bioavailability and 
effectiveness, by using the immortalized human ARPE-19 cells, with subsequent study of 
the monolayers (162, 166, 167). 
Measure the therapeutic effects of antioxidant-containing chitosan nanoparticles after 
topical administration in vivo by monitoring retina morphology and biological parameters 
both before and during appearance of the symptomatology, in distinguish animal model. 
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